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Abstract 
 
Kidney transplantation is the gold standard treatment for end-stage renal disease. 
Renal ischemia-reperfusion injury is an unavoidable consequence of the 
transplantation procedure and is responsible for delayed graft function and poorer 
long-term outcomes.  
 
Pharmacological inhibition of heat shock protein 90 is a preconditioning strategy that 
has previously been shown to reduce renal ischemia-reperfusion injury. However, the 
clinical application of heat shock protein 90 inhibitors is limited by their toxicity 
profile and the exact mechanisms of protection conferred are unknown.  
 
The aims of this thesis were to establish mechanisms of protection offered by these 
drugs and investigate a less toxic analogue that has the potential to be safely 
translated into human studies. AT13387 is a novel small molecule heat shock protein 
90 inhibitor with a low toxicity profile, which is being evaluated in phase II studies 
in oncology and therefore has excellent translational potential in the context of 
transplantation. 
 
Heat shock protein 90 inhibition up-regulates protective heat shock proteins 
(especially heat shock protein 70) and potentially down-regulates NF-ҡB activity by 
disruption of the IҡB kinase complex. Toll-like receptor 4 is a further regulator of 
NF-ҡB activity and studies have suggested that Toll-like receptor 4 plays a dominant 
role in mediating kidney damage following ischemia-reperfusion injury.  
 
 
  iv 
To explore potential molecular mechanisms of protection, human embryonic kidney 
cells were pre-treated with AT13387 and exposed to endotoxin-free hyaluronan to 
stimulate sterile Toll-like receptor 4-specific NF-ҡB activation. AT13387-treatment 
resulted in breakdown of IҡB kinase, which abolished Toll-like receptor 4-mediated 
NF-ҡB activation by hyaluronan. Inhibition of autophagy prevented IҡB kinase-α 
degradation by heat shock protein 90 inhibition and resulted in regain of NF-ҡB 
activity by hyaluronan. In subsequent investigations, AT13387 decreased pro-
inflammatory cytokine release following hyaluronan stimulation and increased cell 
viability in an in vitro model of oxidative stress.  
 
In mice, AT13387 induced heat shock protein 70 expression in the kidney. AT13387 
pre-treatment then significantly reduced kidney injury following renal ischemia-
reperfusion injury. In contrast, in severe combined immunodeficient mice, AT13387 
no longer reduced kidney injury from renal ischemia-reperfusion injury. This 
emphasises the potential importance of the adaptive immune system in the protective 
effect of this agent. This resonates with reports of heat shock protein 70 up-
regulation in the context of heat preconditioning, which leads to renal protection 
from renal ischemia-reperfusion injury that is lymphocyte-dependent. 
 
Secondary lung injury is an additional consequence of renal ischemia-reperfusion 
injury. In further experiments, pre-treatment with AT13387 again did not reduce 
kidney injury following renal ischemia-reperfusion injury in severe combined 
immunodeficient mice. However, AT13387 did reduce secondary lung injury. This 
lung protective effect may have been related to heat shock protein 70 up-regulation 
in the lungs by AT13387.  
 
A rationale for enhancing recovery, following renal ischemia-reperfusion injury, by 
inhibiting heat shock protein 90 was then sought. This investigation was undertaken 
 
  v 
in order to broaden the range of the available therapies to a wider group of patients 
including renal transplant recipients. AT13387 pre-treatment of the recipient mice 
preceded an isograft renal transplantation with a kidney harvested from a treatment 
naive mouse and cold stored for 4 hours. Although a significant reduction in tubular 
necrosis was not demonstrated following AT13387 treatment, the feasibility of the 
treatment strategy was demonstrated and interestingly lung injury secondary to 
transplantation was reduced.  
 
This thesis therefore highlights AT13387 as a new agent with the potential of 
reducing kidney injury and secondary lung injury following renal ischemia-
reperfusion injury. The findings also demonstrate that the mechanisms of protection 
offered by this drug may involve the adaptive immune system. In addition to the 
induction of heat shock protein 70 expression in the kidney and repression of Toll-
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Chapter 1: Introduction 
 
1.1 End-stage renal disease 
 
End-stage renal disease (ESRD) is defined as an irreversible decline in kidney 
function that is severe enough to be fatal in the absence of renal replacement therapy 
(either dialysis or kidney transplantation) [1]. In 2011 the incidence rate of ESRD in 
the USA was 357 per million population [2], a figure that has risen rapidly and  is 
unlikely to reach steady state for another 20 years [3]. 
 
1.2 Kidney transplantation 
 
During 2013 the incidence of renal replacement therapy in the UK was 109 per 
million population and by the end of the year there were 56,940 adult patients 
receiving renal replacement therapy [4, 5]. Renal transplantation is currently the best 
available treatment for ESRD as it not only offers freedom from dialysis, it also 
improves survival, provides better quality of life and is more cost effective [6-9]. 
Patients who are eligible for a renal transplant but do not have a living donor 
available must wait for a suitable kidney to be offered from a deceased donor. There 
were 5881 patients active on the UK kidney transplant waiting list at the end of 
2013/2014 and 3233 renal transplants were performed. The UK median waiting time 
for a renal transplant is over three years [10]. Over the past forty years transplanted 
kidneys have come primarily from donation after brain death (DBD) donors [11]. 
Since current donor organ supply falls short of demand, efforts have been made to 
increase the donor pool using kidneys from donation after circulatory death (DCD) 
donors. Increases in overall renal transplant number in the last 10 years have been 
due largely to increases in the use of DCD donors. During 2013/14 in the UK, renal 
transplantation from DCD donors accounted for 38% of all deceased donor kidney 
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transplants compared to 7% in 2003/4 [10, 12]. As a result of this increase in DCD 
donors, and a rise in living donors, the gap between organ supply and demand has 
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Figure 1.1 The number of renal transplants from each transplant source and the total number on the transplant list at the end of each year in 
the UK 
Source: UK Transplant Registry; http://www.organdonation.nhs.uk/statistics/transplant_activity_report/.  
Abbreviations: DCD – donation after circulatory death, DBD – donation after brain death. 
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1.3 DCD transplantation 
 
Controlled DCD occurs after death that follows the planned withdrawal of life-
sustaining treatments that are felt to be of no overall benefit to a critically ill person 
who does not fulfill the criteria of brain stem death. This is typically performed in 
patients on intensive care units who are considered to have suffered a non-
recoverable brain injury. Uncontrolled DCD takes place after an unexpected cardiac 
arrest from which an individual cannot or should not be resuscitated. This usually 
occurs when a patient sustains an out of hospital cardiac arrest or there is 
unsuccessful resuscitation, typically in an emergency department. It is associated 
with even greater ischemic insult to kidneys than controlled DCD. Whilst 
uncontrolled DCD represents a further potential source of organs, this type of 
donation is still very rare and until the last year there were no active programs using 
this source of organs in the UK.  
 
Before controlled DCD takes place, assent is obtained from the donor’s family for 
life-sustaining treatments, including ventilation, to be withdrawn. In UK practice, 
pre-mortem procedures such as vascular cannulation and heparin administration are 
prohibited in DCD donors but these maneuvers can be utilised in the United States 
[13]. After treatment withdrawal, an “agonal” phase with increasing hypotension and 
hypoxia occurs for a variable time period before circulatory arrest. There is then a 5-
minute mandatory standoff period prior to confirmation of death. Following 
verification of death, the donor is transferred to the operating theatre and a rapid 
laparotomy is carried out, followed by in situ perfusion with cold preservation fluid 
and organ recovery [14].  
 
In all kidney grafts, the technical process of organ recovery and cold storage, leads to 
an unavoidable degree of ischemia. The process of DCD organ recovery exposes the 
kidney to an additional period of warm ischemia during both the agonal phase after 
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withdrawal of treatment and following circulatory arrest. The subsequent period of 
cold ischemia, particularly if extended, exacerbates the detrimental effects of warm 
ischemia, leading to a significantly increased risk of delayed graft function (DGF) 
following transplantation [15]. It should be noted, that while IRI is a major factor in 
DGF, it is not considered the principle contributor to early graft loss, which is mainly 
caused by technical factors or primary non-function. In a Cambridge series of 801 
patients who received a kidney-only transplant from a deceased donor, early graft 
loss within 30 days of transplantation occurred in 50 patients (6.2%). The underlying 
reasons for early graft loss included primary non-function (20; 2.5%), arterial or 
venous thrombosis (18; 2.2%), haemorrhage (6; 0.7%) and acute rejection (3; 0.4%) 
[16].  
 
DGF is usually defined as a need for dialysis during the first week following 
transplantation, and in the UK occurs in 49% of DCD kidneys compared to 24% of 
DBD kidneys [15]. Short-term, DGF leads to a requirement for dialysis, prolonged 
hospitalisation and increased costs [17]. It may also mask features of acute rejection 
[18]. Longer term, DGF is associated with poorer graft survival including a 41% 
increased risk of graft loss after 3 years of follow-up [19]. Although it is now 
recognised that in contrast to DBD kidneys, DGF has no impact on DCD kidney 
graft survival [20]. Indeed, for first time recipients of kidneys from controlled DCD 
donors, graft survival and function are equivalent to kidneys from DBD donors [15, 
21]. However, in DCD transplantation, a cold ischemic time of more than 12 hours 
compared to less than 12 hours is associated with 1.5 times risk of graft failure after 
three years follow up, and importantly only 18% of DCD transplants achieve a cold 
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1.4 Ischemia-reperfusion injury 
 
Ischemia-reperfusion injury (IRI) is a highly complex and multi-factorial event that 
involves multiple cell types and numerous biological processes such as cell death, 
micro-vascular dysfunction, altered transcription and immune activation [22]. IRI is 
an unavoidable consequence of the transplantation procedure and is responsible for 
DGF in approximately 25% of kidneys obtained and transplanted from donors with 
brain stem death and up to 50% of kidneys from donors after cardiac death [23].  
 
Strategies to protect donor kidneys from ischemic injury are lacking and are urgently 
needed to improve both early and late graft function. In this setting, effective 
treatments could even lead to expansion of the donor pool by improving the outcome 
for kidneys severely damaged by ischemia. There is currently no active 
pharmacological agent used at the time of organ donation to reduce renal IRI, 
therefore the use of an agent in this clinical setting would be unique. 
 
1.5 Acute ischemic kidney injury 
 
The incidence of acute kidney injury is also increasing and represents a significant 
global health concern [24]. One of the commonest causes for acute kidney injury is 
renal ischemia, which may result from multiple and often interrelated causes such as 
hypoperfusion, blood loss and surgery [25]. Apart from supportive renal replacement 
therapy, no other therapies exist for patients with acute kidney injury. The best 
treatments presently offered are avoidance of further kidney damage through careful 
resuscitation, effective treatment of sepsis and avoidance of nephrotoxic medications 
[26]. In addition, despite anticipated complications, effective preventative strategies 
prior to predictable renal insults (e.g. elective cardiac surgery) are currently 
unavailable for patients at high risk of developing post-operative acute kidney injury. 
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1.6 Preconditioning 
 
The concept of treating an organ in order to protect it, prior to a known impending 
injury is termed preconditioning and was first described in the heart by Murry et al. 
in 1986 [27]. Since then many different physical and pharmacological 
preconditioning strategies have been explored in organ transplantation and in the 
context of renal IRI. One of the most recent strategies described involves the 
pharmacological induction of heat shock proteins (Hsps).  
 
1.7 Other therapies 
 
Although a number of preconditioning drugs have shown promise in preclinical 
trials, clinical efficacy has proven harder to demonstrate in phase I/II trials [22]. To 
date at least 445 studies on IRI have been registered in ClinicalTrials.gov [28]. 
Despite this level of investigation, relatively few pharmacological therapies have 
been tested in randomised controlled trials (RCT) in renal transplantation and there is 
currently no active pharmacological agent used during transplantation to reduce the 
impact of IRI. The trials performed during the past 25 years are briefly summarised 
(Table 1.1) [28-41]. An example of a drug that may reduce IRI that is already in 
clinical use for another condition is heme arginate. It is used in patients to treat 
porphyria but also leads to up-regulation of heme-oxygenase-1 and reduces renal IRI 
in aged mice [42]. Since there is patient safety data already available for heme 
arginate, it has rapidly been translated into a RCT in recipients of deceased donor 
kidneys (ClinicalTrials.gov Identifier: NCT01430156).
 
Chapter 1 - Introduction  13 
 
Author/Year Trial Design Participants N Method of drug 
administration 
Agent/mechanism Outcome measure Follow up Results 
Schneeberger 











radical scavenger  
Early graft function  
Graft survival  
Rejection rate 
4 years No difference in early graft 
function, significantly better 
graft survival due to less 
rejection at 4 years 







116 Recipient IV infusion prior 




radical scavenger  
Creatinine clearance at 48 h and 
day 6 
6 days No difference 






Any recipient 30 Recipient IV infusion prior 




Plasma creatinine at 7 days 7 days No difference 







140 Recipient IV infusion for 48 
h starting at induction 
Pentoxifylline/Anti-
inflammatory 
DGF 1 month No difference 
Haug et al. 
(1993) [34] 






at high risk of 
DGF 
18 Recipient IV infusion 1-3 h 







2 years Significantly less DGF, less 
primary non-function, better 
graft survival (78% vs. 56% 
at 2 years).  








262 Recipient IV injection 3 h 
before transplant and daily 




Acute rejection rate 
DGF 
1 year survival 
1 year No difference in any 
outcome 
Hladunewich et 







with acute renal 
allograft failure 
43 Recipient IV injection 
within 5 h of transplant and 
twice daily for 6 days 
Insulin-like growth 
factor/Growth factor 
Day 7 inulin clearance 
Need for dialysis 
Nadir serum creatinine 
6 weeks No difference in any 
outcome 




Any recipient 26 Recipient IV infusion for 48 





renal blood flow 
Day 1 creatinine and ultrasound 
measured renal vascular 
resistance 
1 day No difference in any 
outcome 













Graft survival  
Varied 4 
weeks to 4 
years 
Relative risk for DGF 0.55, 
95% CI 0.42 to 0.73. No 
difference in graft loss, 
mortality or requirement for 
haemodialysis. 
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at high risk of 
DGF 
104 Recipient IV injection 
before transplant, at 12 h, 7 
and 14 days post op 
High dose epoetin 
beta/Increase tissue 
oxygen delivery  
eGFR at 1 month 
DGF  
3 month graft survival 
3 months No difference in any 
outcome 
Trials yet to report 













Annexin V protein 
DGF 
eGFR at 12 months 
Graft survival at 12 months 
Acute rejection rate 
 
1 year  
NCT01794663 Multi-centre phase 




high risk of DGF 
Aim 
278 
One off IV dose to recipient 







Acute rejection rate 
Graft survival 6 months 
Primary non-function rate 

















Speed of graft warming 
Daily creatinine decrease first 
week 
Doppler graft blood flow 
One year graft survival 
One year graft biopsy 
morphology 
 
1 year  
NCT00802347 Multi-centre, 






donor kidneys  
Aim 
374 
Not specified QPI-1002/ 
Synthetic SiRNA 













Single dose perfused to the 
donor kidney via the renal 
artery during cold perfusion 






Renal function and histology at 
12 months 
Acute rejection 










 IV dose to recipient before 





Heme-oxygenase-1 induction  
Renal function for 5 days post 
transplant 
Renal biopsy on day 5  
Urinary biomarkers 
5-days  
Table 1.1 Summary of previous and on going clinical trials of pharmacological agents to prevent IRI in renal transplant recipients.  
DGF is defined as need for dialysis within the first week unless otherwise stated. Abbreviations: eGFR - estimated glomerular filtration rate. 
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1.8 The potential for synergy of treatments and 
emerging therapies 
 
It is important to note that the clinical trials performed for pharmacological agents in 
renal transplantation have been based on one specific treatment strategy, which may 
have led to the failure of therapies to achieve the desired effect despite inherent 
efficacy. This could be due to the dosing regimen used or the timing or route of drug 
delivery [22]. Furthermore, each agent that has been tested in a clinical trial thus far 
has been thought to inhibit IRI through one specific mechanism. The complexity of 
IRI may mean that use of a single agent, may not be sufficient in mitigating IRI and 
future studies may benefit from a therapeutic approach involving a combination of 
drug treatments [41]. However, given that off-target effects of various agents may be 
underappreciated, combining regimens could potentially lead to serious adverse 
events. 
 
Targeting of new IRI pathways that orchestrate injury may also be important [43]. 
This could include the development of new therapeutic strategies that interfere with 
regulated cell death and in turn inflammation [44]. It could also involve the 
investigation of other existing treatments like cyclosporine A, which is a drug that is 
widely accepted in kidney transplantation due to its immunosuppressive properties 
but may have additional influence over regulated cell death. Cyclosporine A inhibits 
mitochondrial permeability transition, which is a process that induces necrotic cell 
death. Indeed, it has been considered that this potential of cyclosporine A may have 
already led to a reduction in regulated necrosis, less inflammation and improved graft 
survival in kidney transplantation [45]. Mitochondrial oxidative damage also occurs 
early in renal IRI, and may initiate an inflammatory response, therefore another 
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1.9 Heat shock proteins 
 
Hsps are abundant intracellular proteins that are phylogenetically highly conserved. 
They occur in constitutive or inducible forms [47]. There are several Hsp families 
each with specific properties that have been well established. Hsps are subdivided 
into their respective families according to their molecular weight in kilodaltons [48]. 
With increasing knowledge, the number of Hsps has greatly expanded resulting in 
more members being added to the various Hsp families. To enable better 
classification of Hsps, Kampinga et al. (2009) have devised guidelines for the 
nomenclature of Hsps based on assignments made by the HUGO Gene Nomenclature 
Committee and used in the National Center of Biotechnology Information Entrez 
Gene database for the heat shock genes [49]. 
 
The various functions of Hsps include; chaperoning of client proteins, regulation of 
protein complex formation, protein trafficking, refolding of denatured proteins, 
mitochondrial protein folding and assembly, targeting of misfolded proteins for 
proteasomal degradation, preventing unfolded protein aggregation and inhibiting 
apoptosis. To fulfill these diverse roles each Hsp family has unique structural 
features and domains, but the multi-faceted nature of Hsps is increasingly being 
recognised and various new roles are being appreciated as the level of understanding 
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Mammalian 
Hsp family 
Principal location Summary of structural features and 
domains 
Main established functions 
Hsp90 Cytosol Homodimer with two cytosolic 
isoforms α and β, dimerization occurs 
at C-terminal and nucleotide 
exchange at N-terminal 
Chaperone for a multitude of 
client proteins and regulator of 
protein complex formation 
Hsp70  Cytosol/nucleus/
mitochondria 
Consists of a N-terminal (ATPase 
domain) and a C-terminal substrate 
binding domain connected by a short 
flexible linker 
Protein trafficking and 
degradation  
Refolding of denatured 
proteins during stress 
Anti-apoptotic properties 
Hsp60 Mitochondria Arranged as two stacked heptameric 
rings with three domains (apical, 
intermediate and equatorial) 
Mitochondrial protein folding 
and assembly 
Hsp40 Cytosol/nucleus J-domain that stimulates the ATPase 
activity of Hsp70 and C-terminal that 
loads polypeptides to Hsp70 
Regulates activity of Hsp70 
Binds non-native protein  
Processes pro-collagen 
Hsp27  Cytosol Conserved C-terminal and highly 
variable N-terminal (WDPF domain) 
Prevents unfolded protein 
aggregation 
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1.9.1 Heat shock response 
 
The heat shock response was first discovered in 1962 in Drosophila by Ferrucio 
Ritossa [51] and encompasses the up-regulation of Hsps that are well recognised for 
cytoprotective activity in a multitude of injury-repair states [52]. A wide range of 
stressors, including heat, infection, hydrostatic pressure, oxidative stress, chemical 
insults and ultraviolet radiation induce the heat shock response [53, 54] and crucially 
this confers protection from subsequent insults [55].  
 
Owing to the generality of this phenomenon, Hsps are often called stress proteins 
[56]. Furthermore, they have been described as “cellular mechanics” [57] and are 
commonly referred to as molecular chaperones; since they have been found to play a 
fundamental role in the correct folding of newly synthesised proteins, the re-folding 
of proteins that are denatured by various stressors and post-translational translocation 
of proteins to their sites of action [58]. They are also capable of activating cell 
signalling pathways [59] and inhibiting caspase-dependent apoptosis [60].  
 
Hsps, therefore, are strongly associated with cellular protection and up-regulation in 
the clinical setting promises significant benefits. This cellular capability fits well 
with the clinical concept of preconditioning. Hsps are thus prime therapeutic 
candidates to be used in the context of predictable injury [61]. Indeed, Hsps, and 
especially Hsp70, have been extensively studied in this context. Nevertheless, despite 
extensive experimental investigation, reliable manipulation of Hsp responses for 
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1.9.2 Hsp regulation 
 
Heat shock transcription factor 1 (HSF1) is the main regulator of heat shock genes 
across species [62]. It is found normally in the cytoplasm in an inactive form, bound 
to a multi-chaperone complex that includes Hsp90 [63]. In order to achieve 
transcriptional activation, HSF1 must dissociate from this complex, form a 
homotrimer, move to the nucleus and become hyperphosphorylated [64]. Hsp90 is 
the primary regulator of HSF1 with binding of Hsp90 to HSF1 maintaining HSF1 in 
its inactive, compacted form in the cell. In the presence of cellular stress, there is an 
increased concentration of unfolded proteins [65]. These compete with the Hsp90 
multi-chaperone complex allowing free HSF1 to dissociate and be transported to the 
nucleus where it binds to specific promoter regions with resulting Hsp transcription 
[63] (Figure 1.1). 
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Figure 1.2 HSF1 regulation by Hsp90 
In its inactive form HSF1 binds to a multi-chaperone complex with Hsp90 in the cell cytoplasm. There is dissociation of the Hsp90 multi-chaperone 
complex by competition from a stress-induced increase in the concentration of unfolded proteins. As a result, HSF1 is released, moves to the nucleus 
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1.10 Hsp90 
 
The Hsp90 molecular chaperone family is expressed in almost all organisms and 
under normal conditions Hsp90 accounts for 1-2% of all cellular proteins [66]. As a 
result, Hsp90 is one of the most plentiful cytoplasmic proteins in the unstressed cell 
[67]. When a cell is exposed to physiological stressors including heat, hypoxia, 
acidosis and heavy metals, basal levels can be increased up to 10 times [68, 69].  
 
Hsp90 is a ubiquitous homodimeric molecular chaperone [70] with two cytosolic 
isoforms termed α and β [71]. Dimerisation occurs when the isoforms form 
homodimers with the highly conserved C-terminal site of Hsp90 [67].  
 
Hsp90 congregates with other molecular chaperones to form a large protein complex, 
known as a multi-chaperone complex. This chaperone complex has diverse functions 
including the prevention of aggregation of unfolded proteins under stressful 
conditions and regulation of the folding and maturation of a number of signal 
transduction molecules and receptors [72]. Hsp90 interacts with numerous client 
proteins in this complex including co-chaperones (such as Hsp70), signal 
transducers, activators of transcription and potentially IҡB kinase (IKK) [73].  
However, as an ATP-binding protein [67], Hsp90 is dependent on its intrinsic 
ATPase activity to be able to fulfil this chaperone purpose [74]. 
 
Being a member of the GHKL family of ATPases, Hsp90 exhibits a distinctive N-
terminal nucleotide-binding pocket [75]. ATP hydrolysis and ADP/ATP nucleotide 
exchange in the N-terminal domain induce a conformational change of the protein 
[67] and are essential for Hsp90 chaperone function [70]. 
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Evidence for a central role of Hsp90 in the regulation of HSF1 includes the 
observation that Hsp90 inhibitors can activate all steps of the stress protein response. 
Indeed, activation of HSF1 occurs uniformly in response to all Hsp90 inhibitors 
currently under clinical evaluation [76]. In this sense, HSF1 is an unusual Hsp90 
client protein: other Hsp90-associated proteins become destabilised and degraded by 
proteolysis on Hsp90 dissociation, while HSF1 is activated leading to Hsp induction 
[77].  
 
1.11 Hsp90 inhibitors 
 
The discovery of geldanamycin marked the initial report of a group of drugs termed 
the benzoquinone ansamycins. Geldanamycin was first isolated from streptomyces 
hygroscopicus and was identified as having antiprotozoal activity. Herbimycin A was 
subsequently discovered and was the first of these compounds to be identified as an 
agent capable of short circuiting the Hsp response [78].  
 
The anti-tumour potential of the benzoquinone ansamycins was soon recognised as 
first herbimycin [79] and then geldanamycin [80] were shown to inhibit the 
malignant transformation of fibroblasts by the v-Src oncogene. It was further noted 
that benzoquinone ansamycins prevented the formation of a stable complex between 
Hsp90 and Src, resulting in Src degradation by the ubiquitin-proteosome pathway 
[81]. Since this discovery various other oncogenic proteins including HER2, EGFR, 
mutant ER, HIF1α, Raf-1, AKT and mutant p53 have been identified as requiring 
functioning Hsp90 in order to exert their effects [82]. 
 
While geldanamycin, herbimycin and then radicicol were the first natural Hsp90 
inhibitors discovered, their instability and hepatotoxicity limited any clinical 
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potential [76]. The geldanamycin analogue 17-allylamino-17-
demethoxygeldanamycin (17-AAG) was better tolerated and the first of these 
compounds to be assessed in a clinical trial. A side-chain modification of 17-AAG 
resulted in the water-soluble geldanamycin analogue, 17-dimethylamino-ethylamino-
17-demethoxygeldanamycin (17-DMAG) (Figure 1.3). Since then numerous other 
smaller molecule Hsp90 inhibitors have been discovered representing some of the 
most actively pursued cancer drug treatments by the pharmaceutical industry, with at 
least 17 agents having entered clinical trials [83].  
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Figure 1.3 Structure of Hsp90 inhibitors 
The upper structure is geldanamycin, the middle structure is 17-AAG, and the lower structure is 17-
DMAG, which has a side chain modification that makes it water-soluble. 
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Although cancer treatment has formed the focus of research on Hsp90 inhibitors, 
therapeutic application has been demonstrated in a number of other disease states 
[56]. These include renal IRI [84, 85], autoimmune encephalomyelitis [86], sepsis-
induced lung injury [70], endotoxin-induced uveitis [87], rheumatoid arthritis [88] 
and atherosclerosis [73]. In addition, Hsp90 inhibitors are capable of blocking the 
activity of pro-inflammatory mediators, inhibiting Hsp90-dependent immune 
pathways [89], attenuating oxidative stress [90], reducing viral replication [91] and 
treating fungal infection [92]. Moreover, Hsp90 inhibition has therapeutic potential 
in the treatment of neurodegenerative diseases including Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease and motor neurone disease - through 
prevention of the aggregation and toxicity of misfolded proteins such as amyloid β, 
tau, α-synuclein, mutant huntingtin and mutant superoxide dismutase-1 [93]. 
 
1.11.1 Routes of administration and dosing regimens 
 
In the pursuit of Hsp90 inhibitors that are safe for clinical use, a major limitation of 
17-AAG is its poor solubility in water. To improve solubility, DMSO in egg 
phospholipid and cremophor-based formulations were initially developed but 
required anti-allergenic premedication as well as specialised giving sets for 
intravenous administration. To overcome these problems, injectable isotonic 
suspensions, oil-in-water nanoemulsions and newer albumin-bound forms of 17-
AAG have emerged to improve solubility and deliver higher concentrations of drug 
to target sites. 17-DMAG being water-soluble is easier to administer and can be 
given both intravenously and orally [83].  
 
In a recent phase II study investigating 17-AAG, 11 patients with metastatic, or 
locally advanced irresectable breast cancer, were given dosing regimens of 220 
mg/m2 IV over 2 h on 5 separate days during a 21-day chemotherapy cycle. Five of 
the study group developed grade 3/4 toxicities, which were primarily hepatic and 
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pulmonary [94]. In phase I studies of 17-DMAG in patients with advanced solid 
tumours, the recommended doses for future phase II investigations were found to be 
16 mg/m2 x 5 days and 25 mg/m2 x 3 days every 3 weeks administered by hour long 
intravenous infusion. Similar to 17-AAG, the most common grade 3/4 toxicities 
encountered with 17-DMAG were hepatic (14%) and pulmonary (9%) [95]. The 
doses that lead to these significant side effects are high and often at the maximum 
tolerated level. However, the dose required to give cellular protection is predicted 
lower and thus associated with less toxicity. For example, doses of 1 mg/kg of 
geldanamycin, 17-AAG and 17-DMAG have previously conferred renal protection in 
a mouse model of IRI [84]. 
 
1.11.2 Toxicity profile of Hsp90 inhibitors 
 
Hsp90 is exploited by cancer cells to sustain oncoproteins including many mutated 
kinases and transcription factors that are over-expressed in cancer. Hsp90 also 
buffers cellular stress induced by malignant cells aiding their survival and 
propagation [76]. Use of Hsp90 inhibitors in the treatment of malignancy therefore 
does not lead to cancer cell death by cytotoxicity but by targeting and inhibiting 
these disease-dependent mechanisms e.g. by destabilising oncogenic kinases that are 
essential for tumour growth [96]. 
 
Newer Hsp90 inhibition agents, some of which have good oral bioavailability, lack 
the hepatotoxic profile of first-generation Hsp90 inhibitors possibly due to an altered 
quinone moiety and rate of superoxide formation [97]. This allows for repeated 
administration at higher concentrations. Nevertheless, the Hsp90 chaperone function 
extends to maintaining normal cellular homeostasis and concerns exist regarding the 
inhibition of specific Hsp90-dependent cellular mechanisms, at least on a long-term 
basis, which could be the case with certain chemotherapy regimens [76].  
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Since the treatment philosophy in organ preconditioning is different to that of cancer 
therapy, the implications of blocking normal homeostatic functions of Hsp90 are less 
important when considered in relation to IRI reduction. In this context, an Hsp90 
inhibitor is administered on a once only basis at a dose sufficient to up-regulate 
Hsp70 expression. A two- to three-fold increase in renal Hsp70 in mice given 1 
mg/kg of geldanamycin, 17-AAG and 17-DMAG into the peritoneum has previously 
been demonstrated. Hsp70 expression was maximal at 6 h in mice treated with 17-
DMAG, which was significantly earlier than in geldanamycin (8 h) or 17-AAG (16 
h) treated groups, perhaps reflecting improved bioavailability as a result of water 
solubility. No toxic effects were observed over a 2-week period following treatment 
[84].  
 
Administering the currently available Hsp90 inhibitors at a lower once only dose is 
unlikely to significantly block the normal homeostatic functions of Hsp90 or lead to 
the level of toxicity observed in chemotherapy regimens. However, preconditioning 
agents should ideally not have any harmful side effects, particularly in a DCD setting 
when the donor is still alive. Therefore a major challenge going forward is to develop 
less toxic Hsp90 inhibitors that could be safely utilised in human subjects in the 
setting of renal transplantation.  
 
1.11.3 Isoform-selective Hsp90 inhibitors 
 
In addition to the two cytosolic isoforms of Hsp90 termed α and β, two other human 
isoforms of Hsp90 exist: tumour necrosis factor receptor-associated protein (Trap-1), 
which is localised to the mitochondria, and glucose-regulated protein, Grp94, which 
resides in the endoplasmic reticulum. Recently, it has been suggested that the side-
effects of Hsp90 inhibitors like geldanamycin, 17-AAG and 17-DMAG may be due 
to pan-inhibition of Hsp90 and that development of isoform-selectivity may be a 
means of reducing toxicity. Interestingly, there is also known to be a number of pro-
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inflammatory mediators that are Grp94-dependent clients, including Toll-like 
receptor 4 (TLR4) [98]. This opens up the possibility that Hsp90 inhibitors may exert 
a protective effect through Grp94 inhibition. It also highlights the need for newer and 




AT13387 (Astex Pharmaceuticals) is a novel small molecule Hsp90 inhibitor with 
activity at nanomolar concentrations and low toxicity profile in phase II studies in 
oncology [99, 100] (Figure 1.4). In previous studies, pharmacological inhibition of 
Hsp90 by radicicol, geldanamycin and geldanamycin analogues has been shown to 
be highly protective in experimental renal IRI in mice [84, 85]. However, given that 
a drug designed to reduce IRI in renal transplantation has an absolute requirement for 
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Figure 1.4 Structure of AT13387 
The structure of AT13387 is unrelated to geldanamycin. Astex Pharmaceuticals developed AT13387 
by screening fragments against Hsp90 and optimising hits into leads with inhibitory activities in the 
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1.12 The role of Hsps in modulating IRI in the kidney 
 
Hsps are crucial regulators of ischemic injury in the kidney. This is affirmed by 
Zhang et al. (2008) who used micro-array analysis to compare gene expression in rat 
kidneys subjected to IRI. Of the 30,000 genes analysed, Hsp70 gene product up-
regulation was greatest (43-fold), followed by Hsp27 (12-fold) and hemeoxygenase-
1 (10-fold) [102].  
 
Increasing evidence supports a role for Hsps during the recovery from renal 
ischemia, especially in the tasks of cellular rescue from apoptotic cell death and 
cytoskeletal restoration [61]. Pioneering work by Perdrizet et al. (1993) 
demonstrated that total body hyperthermia, followed by recovery, caused enhanced 
Hsp72 production and protected renal allografts from cold and warm ischemia [103, 
104]. Since then Hsp induction has been shown to be associated with improved 
kidney viability and function post IRI in a variety of experimental models [52, 84, 
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Table 1.3 Protection in renal transplantation-relevant models associated with Hsp up-regulation 
Abbreviations: SA - sodium arsenite, EPO - erythropoietin, VD3 - 1,25-dihydroxyvitamin D3, GGA – 
geranylgeranylacetone, HBA - Hsp90 binding agent (Hsp90 inhibitor), RHP - repetitive hypoxic 
preconditioning, HO-1 – hemeoxygenase-1 
Author Year Species Stimulus Model Protein Ref 
Perdrizet 1993 Swine Heat Allograft Hsp72 [104] 
Redaelli 2001 Rat Heat Isograft Hsp72/HO-1 [107] 
Yang 2001 Rat SA IRI Hsp70 [111] 
Yang 2001 Rat Cyclosporin  IRI Hsp70 [112] 
Redaelli 2002 Rat Heat Isograft Hsp72/HO-1 [106] 
Park 2002 Mice Ureteral obstruction IRI Hsp25 [116] 
Yang 2003 Rat EPO IRI Hsp70 [115] 
Wagner 2003 Rat Heat Isograft HO-1 [105] 
Kim 2005 Rat VD3 IRI Hsp70 [114] 
Suzuki 2005 Rat GGA IRI Hsp70 [108] 
Jo 2006 Rat Heat IRI Hsp70 [52] 
Fuller 2007 Rat Glutamine Isograft Hsp70 [109] 
Harrison 2008 Mice HBA IRI Hsp70 [84] 
Zhang 2009 Rat Glutamine IRI Hsp70 [110] 
Stacchiotti 2010 Rat Stannous Chloride IRI HO-1 [117] 
Yeh 2010 Rat RHP IRI Hsp70 [113] 
Sonoda 2010 Mice Radicicol IRI Hsp70 [85] 
Wang 2011 Mice GGA IRI Hsp70 [118] 
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1.13 Mechanisms of protection offered by Hsp90 
inhibition  
 
Why Hsp90 inhibition leads to cellular protection in renal IRI is unclear but is likely 
a consequence of two main effects. NF-ҡB controls cell survival, immune responses 
and pro-inflammatory transcription [119, 120]. Firstly, Hsp90 inhibition may be 
protective by inhibiting the pro-inflammatory effects of NF-ҡB via disruption of the 
IKK complex with Hsp90 [73]. Secondly it may lead to release of HSF1 from its 
repressive multi-chaperone complex with Hsp90, resulting in subsequent up-
regulation of anti-inflammatory Hsps, especially Hsp70 [121]. 
 
1.13.1 The inhibition of pro-inflammatory transcription 
factors 
 
In the kidney, IRI induces inflammatory mediators such as adhesion molecules, 
cytokines, and chemokines [122]. These mediators are thought to instigate an 
inflammatory cascade leading to leukocyte recruitment and microcirculatory 
compromise with ensuing renal dysfunction.  
 
As many of these mediators have ҡB-binding regions, their transcriptional regulation 
is thought to be under the control of NF-ҡB [123, 124]. Therefore, NF-ҡB, which is 
likely to be regulated by Hsp70 and 90 via the IKK complex [125], may be a 
potential therapeutic target in ischemic renal injury [52] and specifically through the 
use of Hsp90 inhibitors.  
 
Hsp90 inhibitors prevent nucleotide binding to Hsp90, resulting in client protein 
destabilisation, deactivation and degradation [126]. IҡB is an inhibitory protein that 
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masks the nuclear localisation signal sequence of NF-ҡB [70]. Therefore, activation 
of NF-ҡB requires phosphorylation and dissociation from IҡB by IKK [127]. 
Although numerous upstream pathways, such as tumour necrosis factor-alpha 
(TNFα) and TLR4, can lead to NF-κB activation, IKK is a common point of 
convergence [128], and activation of NF-κB occurs almost ubiquitously via IKK-
mediated degradation of IκB [129] 
 
IKK is composed of two protein kinase subunits IKKα, IKKβ as well as the 
regulatory subunit NEMO [127]. Hsp90 may be needed to stabilise the IKK complex 
[130] and the use of Hsp90 inhibitors could cause the dissociation of the IKK 
complex and prevention of NF-ҡB activation (Figure 1.5) [125]. 
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Figure 1.5 Repression of TLR4-mediated NF-ҡB activation by Hsp90 inhibition 
Hsp90 inhibition may block TLR4-mediated NF-ҡB activation by disruption of the IKK complex. The inhibitory action of IҡB on p50/p65 is 
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Indeed, geldanamycin has inhibited TNFα-mediated IKK and NF-κB activation in a 
number of in vitro models [131-135]. Pittet et al. (2005) also demonstrated this 
effectively when observing that heat treatment or sodium arsenite stress induced 
dissociation of Hsp90 from the IKK complex rendering the IKK complex detergent 
insoluble. Simultaneously, it was observed that the NF-ҡB system became impassive 
to cytokine stimulation [136].  
 
This potential of Hsp90 inhibitors is highly attractive from a translation perspective 
since it offers a pharmacological strategy to temporarily dampen NF-ҡB. This is in 
contrast to ablative strategies targeting IKK that reduce NF-ҡB mediated 
inflammation but also prevent subsequent NF-ҡB mediated protection from 
apoptosis [137].  
 
1.13.2 The up-regulation of anti-inflammatory proteins  
 
Hsp90 inhibitor blockade of the Hsp90 ATP-binding site leads to both degradation of 
client proteins via a ubiquitin–proteasome-dependent pathway and up-regulation of 
other Hsps, particularly Hsp70 [121] (Figure 1.6).  
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Figure 1.6 Hsp70 induction by Hsp90 inhibition  
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During an investigation of lung preconditioning, Pittet et al. (2002) showed that 
treatment of rats with two intraperitoneal doses of the Hsp90 inhibitor geldanamycin 
induced renal Hsp70 [138]. Harrison et al. (2008) also observed this effect and went 
on to show that use of Hsp90 inhibitors protected primary renal tubular epithelial 
cells from oxidative stress in vitro and conferred functional and morphological 
protection in a mouse model of kidney IRI [84].  
 
1.14 Cellular and molecular mechanisms of 
protection by Hsp70  
 
The Hsp70 family is capable of protecting cells from lethal heat and other insults 
[139]. Since Hsp70 prevents protein aggregation and facilitates the refolding of 
denatured proteins, up-regulating Hsp70 as a preconditioning strategy has been 
shown to be cytoprotective in a number of organs including the kidney and heart 
[118, 140-145].  
 
The protective properties of Hsp70 in renal IRI are not fully understood and further 
putative modes of protection include correction of protein conformation, cytoskeletal 
stabilisation, anti-inflammatory effects, requirement in autophagy, anti-apoptotic 
properties, influence over macrophage phenotype and stimulation of regulatory T 
cells (Tregs) (Figure 1.7). 
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Figure 1.7 Mechanisms of Hsp70 mediated protection from renal IRI 
Hsp70 induction in IRI may correct cytoskeletal destabilisation, reduce aggregation of unfolded 
proteins, promote cell survival through autophagy and prevention of apoptosis, and resolve 
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1.14.1 Correction of protein conformation 
 
Variations in protein location and abnormal protein folding occur in many kidney 
diseases and are central components of ischemic injury [50]. Hsps exhibit complex 
protective mechanisms, that can prevent the formation of nonspecific protein 
aggregates and assist proteins in the acquisition of their native structures [146]. 
Following cellular injury, Hsps refold damaged proteins, mark irreparably damaged 
proteins for removal, limit the accumulation of misfolded proteins and aid 
appropriate folding of nascent proteins [50]. Hsp70 is one of the most highly 
conserved of these molecular chaperones and its functions encompass regulation of 
protein transport, prevention of abnormal protein aggregation and resolubilisation of 
misfolded proteins [61]. Specifically in the injured kidney, Hsps also have a role in 
the management of protein assembly and stabilisation of multi-protein complexes as 
well as translocation of proteins to their appropriate intracellular locations [50]. 
 
1.14.2 Intracellular protection and cytoskeletal 
stabilisation 
 
Hsps protect cell structure and facilitate survival under conditions that would 
normally be lethal. Following kidney injury, Hsps may be capable of reducing 
mitochondrial load, conserving ATP levels, repairing DNA damage, maintaining 
tight junction integrity and preventing calcium redistribution within the cell [50]. The 
actin cytoskeleton is also an integral component of the architecture of cells but 
cellular stresses can lead to major defects [146]. For instance, following renal IRI, 
renal tubular cells rapidly lose their polarity and the cytoskeleton becomes grossly 
disrupted. In experimental renal IRI models, Hsps (and in particular Hsp70) play a 
pivotal role in restoring renal tubular cell cellular polarity and repairing essential 
proteins that are involved in stabilising cytoskeletal structures [61].  
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1.14.3 Anti-inflammatory effects 
 
It is now recognised that inflammation is perhaps the most critical 
pathophysiological process involved in the propagation of renal IRI [25]. The exact 
mechanism by which Hsp70 reduces inflammation remains uncertain but it has been 
postulated that it may result from IҡB stabilisation or prevention of NF-ҡB p65 
translocation [147-151].  
 
Jo et al. (2006) who investigated the effect of heat preconditioning in a rat kidney 
IRI model endorse this theory of protection. In this study, heat preconditioning 
protected the kidney, induced Hsp70 and suppressed IRI induced NF-ҡB activation 
[52]. The administration of quercetin, a widely known but non-specific inhibitor of 
Hsp70 [152], decreased Hsp70 expression markedly with associated loss of the 
functional protection from IRI conferred by heat preconditioning. Quercetin 
treatment was also associated with a reversal of NF-ҡB suppression [52].  
 
Additionally, Ran et al. (2004) demonstrated Hsp70 binding to the coiled-coil 
domain of NEMO, which prevented the oligomerisation of NEMO and arrangement 
of the active IKK complex [150]. Weiss et al. (2007) observed that Hsp70 disturbed 
the role of the IKK complex, impairing IҡB phosphorylation and degradation and 
preventing translocation of NF-ҡB [151]. Another possibility is that Hsp70 leads to 
ubiquitinisation and proteasomal degradation of certain pro-inflammatory Hsp90 
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1.14.4 Requirement in autophagy 
 
Autophagy is a catabolic process that degrades cytoplasmic components through the 
action of lysosomes. Autophagy is induced under stress and plays an adaptive role in 
cell survival. Up-regulation of autophagy in renal tubular cells ameliorates both IRI 
and cisplatin induced acute kidney injury [154]. Hsp70 is required for autophagy due 
to many forms of stress [155]. In an immune context, Hsp70 is also associated with 
autophagy, leading to a preferential uploading of Hsp70 peptides in MHC class II 
molecules of stressed cells. Tregs then target the conserved Hsp70 peptides that may 
then be presented in these conditions leading to the repression of inflammation [153]. 
 
1.14.5 Anti-apoptotic effects 
 
Ischemic injury leads to both necrosis and apoptosis of renal tubular cells, which 
results in the release of damage associated molecular pattern molecules (DAMPs), 
which are endogenous ligands released from stressed or damaged cells, and 
propagation of inflammation [156]. A stressed but not critically injured renal tubular 
cell may undergo apoptosis and cell death or alternatively the cell can survive and 
recover function [61]. Another possibility is that the stressed cell may become 
senescent [157]. This is in contrast to lethally injured cells that inevitably succumb to 
apoptosis or necrosis and therefore cannot be salvaged [45]. As a consequence, it is 
the outcome of these stressed but viable cells that would seem the most amenable to 
cytoprotective interventions [61]. Distinct from necrosis, which is a passive energy-
independent mode of cell death, apoptosis is programmed cell death resulting from 
the engagement of pathways that eventually result in the activation of caspase 
proteases [45, 158]. Caspase activation is generally considered to be a `point of no 
return' in this cell death pathway [159].  
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Hsps interact with important proteins involved in apoptotic pathways and this has 
crucial consequences for cell survival, proliferation and apoptosis following IRI 
[160]. For instance in renal IRI, Hsp70 limits apoptosis by controlling the activity of 
the kinases Akt and glycogen synthase kinase 3β that regulate the activity of the pro-
apoptotic protein Bax. This prevents Bax translocation to the mitochondria and 
activation of caspase 3 [118]. As a result, renal epithelial cells might be rescued from 
apoptotic cell death following Hsp induction [61]. It is therefore of interest that 
cortical Hsp70 levels following renal IRI inversely correlate with apoptosis, tubular 
injury and renal dysfunction [118].  
 
1.14.6 Influence on the phenotype of mononuclear 
phagocytes 
 
Mononuclear phagocytes are pivotally involved at various stages of renal IRI and 
depending on the phenotype they exhibit and the time point following injury, they 
can be viewed as either injurious (M1 macrophages) or reparative (M2 
macrophages). Hsps appear capable of promoting an anti-inflammatory phenotype in 
monocytes, which leads to release of anti-inflammatory cytokines such as 
interleukin-10 (IL-10) and suppression of harmful cytokines including interferon-γ 
(INF-γ) [153]. Hsps may also influence macrophage phenotype with transcriptomic 
profiling during the differentiation and polarisation of human macrophages showing 
distinct patterns of Hsp expression. For example, upon activation to a M1 phenotype 
a significant up-regulation of members of the Hsp70 family (HspA2 and HspA8) and 
Hsp90 family (Hsp90AA1) are observed, which suggests their influence over the 
effector stage of macrophage activation. While in M2 macrophages other members 
of the Hsp70 (HspA13), Hsp40 (DNAJB5) and Hsp27 (HspBAP1) families are 
significantly up-regulated [161].  
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In experimental renal IRI models, preconditioning with heat protects rat kidneys 
from ischemic damage by inducing Hsp70 and suppressing NF-ҡB activation. Heat 
preconditioning also reduces chemokine (C-C motif) ligand 2 (CCL2) expression, 
which is necessary to attract monocytes to the site of injury [52]. Furthermore, Hsp70 
induction by either geranylgeranylacetone or repetitive hypoxic preconditioning 
reduces macrophage infiltration, protects kidney function, attenuates tubular damage 
and reduces renal tubular cell apoptosis following renal IRI [108, 113]. The causality 
of Hsp70 in these observations has been asserted in subsequent investigations that 
showed reversal of this effect following the addition of the Hsp70 inhibitor, quercetin 
[108]. However, despite being widely known, quercetin is a non-specific inhibitor of 
Hsp70 [152] and further investigation of Hsp70 in this context is needed. 
 
1.15 Pharmacological modulation of Hsp70 
expression  
 
Hsp70 is one of the most frequently studied Hsps because of its potential anti-
inflammatory properties and attractiveness as a therapeutic target due to its wide 
tissue distribution and ability to interact with a multitude of other molecules [153]. 
Even though Hsp70 is highly inducible, it may not be clinically desirable to generate 
Hsp70 by a classical heat shock response involving cellular stressors. In addition, 
physical preconditioning approaches often involve an additional thermal or ischemic 
injury with potential associated negative consequences. An example is renal ischemic 
preconditioning, which is thought to confer some of its proposed protection from 
renal IRI by induction of Hsps, but unfortunately depends on time consuming and 
often surgeon dependent intra-operative manoeuvers to be implemented in a clinical 
environment. Local ischemic preconditioning is also not directly applicable to the 
treatment of the various medical causes of acute kidney injury, such as 
hypoperfusion and sepsis. In light of this, approaches to induce Hsp70 without the 
need for preceding cellular stresses have been sought. As such, recent research in this 
area has begun to focus on pharmacological induction of Hsp70 for potential 
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therapeutic gain. In the setting of renal IRI, protective Hsp70 overexpression 
strategies have included the use of reagents such as geranylgeranylacetone [118], 
glutamine [110], radicicol [85], geldanamycin and geldanamycin analogues [84].  
 
To date these treatments have been used only in murine models of IRI. The main 
barrier to the translation of these treatments to clinical use is the lack of mechanistic 
understanding of how Hsp70 induction results in kidney protection. There is also 
further uncertainty regarding non-specific mechanisms of protection offered by the 
various pharmacological therapies used thus far. If these issues could be clarified, 
then Hsp70-inducing drugs could be developed further or newer, more highly 
specific and less toxic medications could be designed. 
 
1.16 The role of immunity and TLR4 
 
TLRs are a family of trans-membrane proteins, named after the Drosophila protein 
Toll with which they share structural homology [162]. TLRs are highly conserved 
germline-encoded pattern recognition receptors [163] that are central to immune 
responses [156] including NF-ҡB regulation [164]. 
 
It is now appreciated that TLRs not only represent the major pattern recognition 
receptors across species but that they also recognise specific endogenous DAMPs 
that have been transformed from their native state or gathered in non-physiological 
sites or abnormal amounts during tissue injury [165].  
 
Ischemic injury is thought to lead to necrosis and apoptosis of renal tubular cells 
leading to production of DAMPs [156]. These are recognised by local TLRs and 
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promote inflammation through the production of cytokines and chemokines, and 
enrolment of immune cells that propagate the initial injury [156].  
 
TLRs may be expressed by kidney tubular epithelial cells and mesangial cells in 
response to insults such as IRI [166]. Kim et al. (2005) demonstrated that rat kidneys 
subjected to IRI showed enhanced TLR mRNA and protein expression [167] and 
there is growing experimental evidence emerging to suggest that engagement of 
TLRs by endogenous ligands may be a key trigger of inflammation following 
ischemia in the kidney [168].  
 
1.16.1 TLR4 and renal IRI 
 
As shown by in situ hybridisation, TLR4 is constitutively expressed at the RNA level 
on renal epithelium and this expression is enhanced upon IRI [169]. In mice 
subjected to renal ischemia, TLR4 expression is especially amplified at sites most 
susceptible to IRI, such as in the proximal renal tubules at the cortical-medullary 
junction [168]. This expression is independent of pathogen invasion and TLR4 
appears to recognise endogenous molecules that are exposed during cellular injury 
and extracellular matrix remodelling [166]. To date, a number of proposed 
endogenous ligands for TLR2 and TLR4 have been found in ischemic renal tissue, 
including high mobility group box 1 (HMGB1) protein, hyaluronan, biglycan [168] 
and Hsp70 [167].  
 
In vivo experiments have confirmed reduced organ injury in kidney IRI in transgenic 
mice missing TLR4 or the TLR4-related scaffolding protein MyD88 [170, 171]. 
Results of experiments by Pulskens et al. (2008) also show lower levels of 
chemokines and inflammatory cells, less renal injury and more preserved renal 
function following IRI in TLR4-/- mice as compared to wild types [170].  Wu et al. 
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(2007) used chimeric mice to show that TLR4 expressed specifically on tubular 
epithelium is an important modulator of ischemic injury [168], while Chen et al. 
(2011) extended this role of TLR4 into the endothelium of the kidney and 
demonstrated that leucocytes release IL-6 when TLR4 receptors are stimulated by 
HMGB1 release from injured cells [172]. In a rat model, Liu et al. (2010) showed 
that inhibition of TLR4 by the drug Eritoran, a structural analogue of the lipid A 
portion of lipopolysaccharide (LPS), attenuated inflammatory signalling cascades in 
renal IRI [173].  
 
Similarly, in the case of TLR2, Leemans et al. (2005) [174] and Shigeoka et al. 
(2007) [175] both demonstrated that parenchymal cell deficiency of this receptor 
dramatically limited kidney injury following IRI, and diminished the associated renal 
inflammation. In further studies, Rusai et al. (2010) found that a double genetic 
deletion of TLR2 and TLR4 conferred only similar protection to single deletions of 
TLR2 or TLR4 [176]. 
 
This collective body of research suggests that TLR4 signalling plays a dominant role 
in mediating kidney damage following IRI [168, 172], with at least three major cell 
types (epithelia, endothelia and leukocytes) being identified as expressing TLR4 at 
various times during ischemic kidney injury [172]. Moreover, it has been 
demonstrated that for the classical response to ischemia to occur there is an absolute 
necessity for TLR4 in these cells [168, 172, 177].  
 
This experimental research also appears to translate to the clinical situation, as a 
recent study in humans confirmed the role of the donor TLR4 and HMGB1 
interaction in kidney transplant IRI [178]. This is in keeping with previous 
suggestions that kidneys from deceased donors may experience an increased 
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ischemic injury in response to danger signals provided by the recipient’s innate 
immune system [179].  
 
1.17 Hsp90 inhibitors and immune regulation 
 
Although IRI typically occurs in a sterile environment, activation of innate and 
adaptive immune responses occurs and contributes to injury, including activation of 
pattern recognition receptors such as TLRs [22]. A number of key signalling proteins 
that are Hsp90 clients play important roles in the cellular activation of both innate 
and adaptive immune responses. Therefore, a rationale exists for targeting Hsp90-
dependent pathways in immune-mediated diseases [89]. 
 
In rats, 17-AAG has been shown to halt the development of LPS induced 
autoimmune uveitis by inhibiting activation of multiple signalling molecules that 
mediate the TLR4-induced pro-inflammatory cytokine response in retinal cells [87]. 
 
Likewise, Dello Russo et al. (2006) demonstrated that 17-AAG blocked pro-
inflammatory TLR4 activation in vitro and dramatically decreased disease incidence 
and severity in an experimental model of autoimmune encephalitis [86]. More 
recently, Yun et al. (2011) used a synthetic Hsp90 inhibitor, EC144, to prevent LPS-
mediated TLR4 signalling in RAW 264.7 cells through inhibition of ERK1/2, 
MEK1/2, JNK, and p38 MAPK but not NF-ҡB [89].   
 
The above evidence suggests that inhibiting Hsp90 function may be applicable to 
treatment of autoimmune diseases, but whether TLR4 signalling can be similarly 
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targeted in IRI remains uncertain and to date the interaction between Hsp and TLRs 
(a controversial area in the literature) is yet to be fully delineated.  
 
1.17.1 Interaction of Hsp and TLRs 
 
Members of the heat shock protein family, including Hsp60, 70, 72, 90 and gp96, are 
capable of inducing production of pro-inflammatory cytokines via CD14/TLR2 and 
CD14/TLR4 receptor complex-mediated signal transduction pathways [180]. Ohashi 
et al. (2000) found that the pro-inflammatory signalling of human Hsp60 was 
dependent on a functional TLR4 [181]; whereas Vabulas et al. (2002) defined Hsp70 
as an endogenous stimulus for the Toll/IL-1 receptor signal pathway that engages 
TLR2 and TLR4 [182]. 
 
In an experimental study investigating cardiac IRI, it was shown that extracellular 
Hsp70 plays a role in IRI by TLR4-dependent mechanisms and that recombinant 
Hsp70 induced NF-ҡB activation as well as the expression of TNFα, IL1β and IL-6 
[183]. In the context of renal IRI, Kim et al. (2005) suggested that enhanced TLR 
mRNA and protein expression in a rat model of IRI was due to endogenous TLR 
ligand levels of Hsp70 within tubular cells [167]. 
 
The mechanism by which Hsp produce cellular activation through TLR2- and TLR4-
dependent mechanisms is not well understood, and there is continuing debate 
regarding the importance of interactions between Hsps and TLRs [171].  
 
It has been argued that early investigations identifying Hsps as TLR-ligands were the 
result of contamination with pathogenic ligands, since the reported cytokine effects 
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of Hsps in vitro were similar to pathogen-associated molecular pattern molecules, 
such as LPS from Gram-negative bacteria [162]. Since then, a number of in vitro 
techniques have evolved to nullify the risk of LPS contamination including protein 
expression in eukaryotic hosts, chaperone treatment with polymyxin B, neutralising 
monoclonal antibodies and acyloxyacyl hydrolase. Other techniques include the use 
of various controls, including chaperone antibodies, mutants of the chaperone and 
LPS itself. If the latter is used, transcriptional micro-array analysis is effective at 
determining differences in response. Finally, purity can also be tested with a limulus 
assay, mass spectrometry and SDS-PAGE [184].  
 
There is also research that highlights other trans-membrane receptors such as CD91 
and LOX-1 as the principle Hsp70 receptor. This evidence may call into question the 
importance of Hsp and TLR interaction. On the other hand, the implication of Hsp70 
signalling through multiple germline-encoded immune receptors may serve to further 
underline the potential importance of Hsp70 in immune-regulation [185].  
 
Either way, in vivo Hsp and TLR interactions that have been well described cannot 
be explained by contamination. Therefore, another argument against Hsp and TLR 
interaction has evolved and suggests that molecules bound to, or chaperoned by, 
Hsps can activate TLRs, rather than the Hsp molecules themselves [186].  
 
Despite these arguments, it has been shown that dying cells often undergo the stress 
protein response, leading to lysis and release of Hsp into the extracellular space 
[187]. This is thought to be able to activate not only inflammatory but also immune 
responses [188]. Conversely, Hsp60 has been reported as being translocated to the 
surface of apoptosing cells as a recognition element for phagocytotic clearance, 
thereby attenuating an inflammatory response [189]. In addition, HSF1 has been 
identified as a transcriptional repressor with a role in the counter-regulation of 
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cytokine gene transcription [190]. As a result the pro-immune effects of extracellular 
Hsp have been described as being countered by the intracellular stress protein 
response in what is now known as a dichotomy of effects, which is best depicted in 
the case of Hsp70 [188].  
 
1.17.2 Extracellular Hsp70 and potential pro-
inflammatory effects 
 
Hsp70, like Hsp90, has immune regulation properties with both pro- and anti-
inflammatory effects [191] and large clinical studies investigating cardiac ischemia 
have provided inconsistent reports of protective [192, 193] or detrimental [194] 
effects of this chaperone. 
 
Hsp70 residing in its cytosolic compartment appears to have the ability to decrease 
pro-inflammatory signalling cascades, thereby down-regulating inflammatory 
responses. In contrast, extracellular Hsp70 is thought to exhibit powerful immune-
stimulatory effects and has therefore been acknowledged as a “chaperokine” [191].  
 
The overall action of Hsp70 on the inflammatory equilibrium is reliant on the cellular 
compartment in which Hsp70 displays its predominant effect, which depends mainly 
on the extent of the tissue injury [185]. 
 
In general systemic stress, there is reliance on NF-ҡB, in addition to up-regulation of 
intracellular Hsp70 in inflammatory cells [195-197]. In this scenario, pro-
inflammatory messages via innate immune receptors can be overcome by the 
intracellular down-regulating action of Hsp70 on NF-ҡB signalling, thereby reducing 
the undesirable effects of systemic inflammation [185]. On the contrary, the response 
 
Chapter 1 - Introduction  51 
could be pro-inflammatory when in the absence of cytosolic stress, there is a lack of 
intracellular Hsp70 up-regulation and absence of its down-regulatory effect on NF-
ҡB [185].  
 
This hypothesis is in agreement with the “danger theory” described by Matzinger 
[198], in which DAMPS such as Hsp are released from damaged cells providing the 
immune system with a “danger” signal. The response to that hazard is initiated by 
antigen-presenting cells that identify Hsp via TLRs resulting in up-regulation of NF-
ҡB and activation of pro-inflammatory cytokines [199].  
 
In summary, the novel functions of Hsp70 could depend on its location with 
intracellular Hsp70 attenuating inflammatory cascades, while Hsp70 released into the 
extracellular space specifically binds to TLR2 and 4 and produces immune-
regulatory effects, including up-regulation of adhesion molecules, co-stimulatory 
molecule expression, and cytokine and chemokine release [188]. It is predicted that 
in Hsp90 inhibition intracellular up-regulation of Hsp70 predominates and exerts a 
protective effect through an as yet unknown mechanism. This theory requires 
confirmation and a recent review has highlighted that studies aimed at more 
accurately characterising the molecular pathways activated by Hsp70 are required to 




There is increasing recognition that processes of repair can become maladaptive in 
renal IRI. These mechanisms, which include cell-cycle arrest, cellular senescence, 
pro-fibrogenic cytokine production and activation of pericytes and interstitial 
myofibroblasts, trigger the onset of progressive fibrotic kidney disease, a process that 
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mirrors the development of accelerated kidney ageing [200] This ties in with the 
concept of “inflammaging”, which is a chronic low grade inflammatory process 
underlying human aging [201]. In diseases with a strong inflammatory component, 
such as renal IRI, the identification of mechanisms that control age-related 
inflammation is felt to be important. A particular mechanism of interest is cellular 
senescence, which can cause chronic inflammation through the senescence-
associated secretory phenotype [202]. In terms of the involvement of Hsps in this 
process, higher levels of intracellular Hsp70 and Hsp90 occur with age and in 
patients with inflammation, compared to control subjects [203]. Serum 
concentrations of Hsp70 also decrease with normal aging; with higher levels of 
Hsp70 associated with inflammation and frailty in elderly patients. As such, it has 
been hypothesised that Hsp70 in the serum is of benefit during acute short-lived 
elevation, but is related to negative clinical conditions when chronically elevated 
[204].  
 
1.19 Hsp90 and maintenance of vascular tone 
 
Ramirez et al. (2004) showed that Hsp90α and Hsp90β cytsolic isoforms are 
expressed along the nephron in rats [205]. Ramirez et al. (2008) then went on to 
demonstrate that inhibition of Hsp90 with radicicol in rats reduced renal blood flow 
and glomerular filtration rate. Since the effect was associated with a reduction in 
nitric oxide synthesis and increased endothelial nitric oxide synthase 
phosphorylation, it was suggested that Hsp90 might be a regulator of vascular tone 
within the kidney [206].  
 
Quantification of total renal blood flow as a measure of effective blood flow can be 
misleading in renal IRI due to the possibility of ischemic injury being localised to 
specific areas of microvasculature within the kidney [25]. Nevertheless, the potential 
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role of Hsp90 in maintaining vascular tone in the kidney could have important 
implications for use of Hsp90 inhibitors in renal IRI.  
 
Indeed, Barrera-Chimal et al. (2014) from the same group have recently identified in 
renal IRI that endothelial nitric oxide synthase-Hsp90 uncoupling occurs and reduces 
nitric oxide levels. They were then able to restore endothelial nitric oxide synthase-
Hsp90 coupling by intra-renal Hsp90α or Hsp90β transfection prior to renal IRI, 
which subsequently reduced morphological kidney injury. Although no significant 
improvement in kidney function was demonstrated, these observations again 
implicate Hsp90 in regulating the nitric oxide/endothelial nitric oxide synthase 
pathway and renal vascular tone [207]. As such, a degree of caution may need 
exercised when inhibiting Hsp90 in renal IRI.  
 
1.20 Lymphocytes and renal IRI 
 
Renal IRI is a highly complex form of tissue injury involving many biological 
processes, including acute inflammation, cell death, microvascular dysfunction, and 
immune activation together with multiple myeloid and lymphoid cell types that may 
play a role in both the initiation and the resolution of tissue injury [22, 208]. 
Although the complex pathophysiology of renal IRI represents a challenge, it also 
offers an opportunity to manipulate these cellular responses in order to limit injury 
and facilitate subsequent repair. 
 
In addition to activating innate immune receptors, renal IRI elicits a profound 
adaptive immune response. T and B lymphocytes are the major effector cells of the 
adaptive immune system with T cells involved in cell mediated immunity and B cells 
the humoral response [209]. Evidence suggests that T and B lymphocytes may 
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amplify kidney injury in renal IRI, in contrast there is also data to suggest that 
lymphocytes could play a protective role depending on the cell type involved and the 
stage of injury [210]. 
 
Burne et al. (2001) demonstrated in a murine renal IRI model, that nu/nu mice 
(lacking CD4+ and CD8+ T cells) show significantly less kidney injury compared to 
wild-type mice, with reconstitution of CD4+ T cells but not CD8+ T cells restoring 
kidney injury to the level of wild-type mice [211]. In the early phase of renal IRI 
(<24 h) antigen specific activation may play an important role in the propagation of 
kidney injury by CD4+ T cells following renal IRI [212]. In terms of B-cells, renal 
IRI studies using RAG-1-/- mice (lacking B and T cells) have shown both renal 
protection [213] and a similar kidney injury to wild-type controls [214, 215].  
Compared to wild types, renal IRI studies using mu MT mice (lacking B cells alone) 
are also inconsistent with some suggesting less severe injury [216] and others a more 
severe kidney injury [217].  
 
1.20.1 Tregs and renal IRI 
 
CD25 + Foxp3 + Tregs are a pivotal subtype of T-lymphocytes that display potent 
immunosuppressive properties and can regulate both immunological function and 
inflammatory injury. In contrast to the possible harmful effects of CD4+/CD8+ 
lymphocytes, Tregs appear to have a protective role in IRI [22], and specifically 
during the repair phase of renal IRI [218]. Treg immunodepletion using an anti-
CD25 antibody worsens renal IRI [219], and increasing Treg recruitment to the 
kidney ameliorates renal IRI [220]. The fact that Tregs both inhibit the innate 
immune injury of renal IRI [221] and are involved in renal repair following renal IRI 
[218] highlights their potential utility for therapy in patients with ischemic kidney 
injury. 
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1.20.2 Hsp70 interaction with Tregs in renal IRI 
 
Various preconditioning strategies, including transient ischemia or heat 
preconditioning, have been used to induce renoprotection from subsequent renal IRI, 
and it is highly pertinent that previous studies have demonstrated a role for both 
Tregs and Hsp70 in mediating the protective effect of preconditioning [52, 222]. It is 
also of interest that Hsp90 inhibition, which leads to Hsp70 induction, has recently 
been identified as promoting Treg-dependent suppression of autoimmunity [223]. 
 
In a very recent publication, Kim et al. (2014) [224] examined the role of Hsp70 in 
the protection from renal IRI afforded by heat preconditioning comprising the 
heating of mice to 41°C for 15 min, 24 h before the induction of bilateral renal IRI. 
The level of kidney injury was determined 24 h after surgery. They then presented 
data supporting the concept that Hsp70, expressed by CD11c + dendritic cells, plays 
an important role in Treg-mediated protection from renal IRI. 
 
Heat preconditioning of mice provided significant protection from the adverse effects 
of renal IRI, as previously observed by their group [52], with heat-preconditioned 
mice exhibiting reduced serum creatinine and less tubular injury. Treg 
immunodepletion induced by the administration of an anti-CD25 antibody prior to 
the induction of renal IRI significantly abrogated the protective effect of heat 
preconditioning. The restoration of the protective effect of heat preconditioning by 
adoptive transfer of Tregs to anti-CD25-treated mice strongly suggested an important 
mechanistic role for Tregs, and experiments were therefore undertaken to explore the 
specific effect of heat preconditioning on Tregs. 
 
Heat preconditioning increased the number of splenic CD4 + CD25 + Tregs and 
reduced the proliferative response of cultured splenic mononuclear cells to a 
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mitogenic stimulus. Although Hsp70 expression was noted in spleen, kidney, liver, 
and lung under basal conditions, Hsp70 expression was increased by heat 
preconditioning, with CD11c + Hsp70 + dendritic cells evident in the spleen by 
immunohistochemistry and flow cytometry. Also, in vitro treatment of cultured 
splenocytes with the Hsp70 inducer geranylgeranylacetone increased Hsp70 
expression and the proportion of CD4 + cells expressing CD25 [224]. 
 
Increased numbers of CD4 + CD25 + Tregs were detected by flow cytometry in 
enzyme-dissociated kidneys following renal IRI compared with sham kidneys, 
indicating localisation of Tregs to the injured kidney. Heat preconditioning 
significantly expanded the intra-renal CD4 + CD25 + Treg population following 
renal IRI in comparison with control injured kidneys, with increased expression of 
Foxp3 mRNA also evident [224].  
 
In order to probe the role of Hsp70 in heat preconditioning, Kim and colleagues 
[224] administered the Hsp70 inhibitor quercetin to mice 3 hours before heat 
preconditioning. Quercetin decreased Hsp70 expression in splenocytes, reduced the 
expansion of splenic Tregs, and blocked the protective effect of heat preconditioning 
in renal IRI. Furthermore, the adoptive transfer of Tregs to quercetin-treated mice 
restored the protective effects of heat preconditioning. These data suggest that the 
protective effect of heat preconditioning might be mediated through an interaction 
between Hsp70 and Tregs. However, because of the lack of specificity of Hsp70 
inhibition by quercetin and the possible up-regulation of other anti-inflammatory 
Hsps by heat preconditioning, Kim et al. (2014) [224] undertook further experiments 
using T cell-deficient nude mice and the adoptive transfer of cells derived from 
Hsp70 knockout mice. 
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As previously demonstrated by Burne et al. (2001) [211], Kim et al. (2014) [224] 
found that nude mice exhibited reduced injury following renal IRI, with the adoptive 
transfer of T cells purified from control mice reconstituting injury and significantly 
increasing serum creatinine. In contrast, the transfer of T cells from heat-
preconditioned wild-type mice to nude mice did not increase injury. Importantly, 
nude mice given T cells from heat-preconditioned Hsp70 knockout mice before renal 
IRI exhibited increased creatinine and partial reconstitution of injury.  
 
The totality of these data from Kim et al. (2014) [224], suggests that heat 
preconditioning induces renoprotection that is Treg dependent and associated with 
increased numbers of both splenic and infiltrating renal Tregs. It is suggested that 
splenic Treg expansion may result from CD11c + Hsp70 + dendritic cells. The 
administration of Hsp70 inhibitors and inducers as well as adoptive transfer of T 
cells from heat-preconditioned Hsp70 knockout mice suggest that Hsp70 is important 
for the generation of injury-limiting Tregs. The study therefore reinforces the 
capacity of both Tregs and Hsp70 induction to modulate renal IRI, and, since Hsp70 
is amenable to pharmacological up-regulation, the findings speculatively suggest 
translational potential for preventing renal IRI (Figure 1.8).  
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Figure 1.8 Putative pathway of Hsp-regulation of Hsp70, Treg expansion and suppression of 
renal IRI 
Schematic diagram illustrating the potential beneficial effects on renal IRI of Hsp70 up-regulation 
induced by either heat preconditioning or pharmacological agents. Induction of Hsp70 expression 
in splenic CD11c+ cells induces expansion of Tregs that ameliorate renal injury, as reported by 
Kim et al. (2014) [224]. Tregs may also be induced by adenosine 2A receptor (A2AR) agonists. In 
addition, Hsp70 induction in renal parenchymal cells, such as tubular epithelial cells, may exert a 
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The study by Kim et al. (2014) also raises a number of questions, and, as ever, there 
are several caveats to the work. For example, the molecular mechanism underlying 
the protective effect of Tregs induced by heat preconditioning is unclear, but 
previous work suggests that IL-10 is an important Treg effector molecule in renal IRI 
[221]. As such, the role of IL-10-producing Treg type 1 cells should be formally 
examined. It should also be noted that anti-inflammatory Tregs that protect from 
renal IRI may also be induced by treatment with an adenosine 2A receptor agonist 
[225], and it would be of interest to determine whether concurrent Hsp70 induction 
and treatment with an A2AR agonist or other agents could augment protection.  
 
Increased Hsp70 expression by splenic CD11c + dendritic cells was noted, and it is 
suggested that these are key to Treg induction. Heat preconditioning also induced 
renal Hsp70 expression, and it is possible that Hsp70 up-regulation in renal immune 
cells may also play a role in renal protection. The importance of systemic Hsp70 
induction over Hsp70 up-regulation in renal parenchymal cells, renal tubular cells or 
resident leucocytes could be addressed in a renal transplantation experiment 
involving systemic Hsp70 induction in the recipient of a non-treated and injured 
kidney.  
 
Also, Hsp70 present within T cells may physically interact with Foxp3 and directly 
support survival and proliferation of Tregs and their immunosuppressive function 
[226] such that CD11c + dendritic cells may not be required. In this regard, it would 
be interesting to investigate the degree of dependence on CD11c + dendritic cells by 
ablating CD11c + dendritic cells before pharmacological Hsp70 induction and 
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1.21 Translational perspective 
 
1.21.1 Preconditioning and prevention of IRI  
 
Despite great improvements in outcome following kidney transplantation, the 
incidence of graft failure remains high. In the UK, all-cause graft survival after 3 
years is 83% for recipients of DCD kidneys and 85% for recipients of DBD kidneys 
[15]. The shortage of organs for transplantation has led researchers to look for new 
techniques to expand the donor pool resulting in the increasing use of grafts from 
expanded criteria and DCD donors [18]. Respectively, these kidneys have worse 
outcome because of either pre-existent pathology, which renders them more 
susceptible to IRI, or more prolonged warm ischemic injury during organ recovery.  
 
Transplantation necessitates inflicting an ischemic injury on an organ, but the 
planned nature of this insult presents an opportunity to act to reduce the magnitude of 
this injury. There is currently no therapeutic means of treating kidneys destined for 
transplantation in order to improve post-transplantation function, a process termed 
pharmacological preconditioning. The use of an agent in this clinical setting would 
therefore be unique. Preconditioning strategies also have the potential to improve the 
function of substandard organs so that they become suitable for transplantation, thus 
expanding the donor pool [17].  
 
Debate surrounds the potential benefit of pharmacological strategies over physical 
preconditioning manoeuvres. In the latter, cellular protection is achieved by repeated 
temporary interruption of blood flow to an organ or distant site [227]. A pilot study 
has recently demonstrated a reduction in acute kidney injury after heart surgery 
following remote ischemic preconditioning of the leg [228]. In transplantation, organ 
physical preconditioning has been studied almost exclusively in liver and on the 
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whole, results have been disappointing [229]. Pharmacological preconditioning also 
has advantages over a physical preconditioning strategy as an ischemic injury with 
associated negative consequences is avoided and time-consuming, surgeon-
dependent intraoperative manoeuvres are not required.  
 
Developing a pharmacological strategy to reduce IRI, the main contributor to DGF 
after DCD kidney transplantation is therefore highly desirable. The ultimate aim of 
pharmacological preconditioning is to improve the function of transplanted organs by 
administering a single dose of an agent to an organ donor prior to organ retrieval. 
This would prime protective cellular mechanisms in anticipation of the injurious 
nature of ischemia and reperfusion. In addition, it may be beneficial to treat the organ 
ex vivo with a drug delivered by machine perfusion prior to the implant procedure. 
However, this may only be applicable to normothermic perfusion strategies since the 
activity of certain agents may be decreased at the lower temperatures used for 
hypothermic machine perfusion [230]. 
 
Although a number of alternative preconditioning drugs have shown promise in 
preclinical trials, clinical efficacy has proven harder to demonstrate in phase I/II 
trials [22]. Preconditioning strategies typically involve direct treatment to the organ 
donor and/or organ, aiming to reduce injury prior to the onset of ischemia. These 
other strategies are frequently aimed at treating the organ recipient, which may be 
more feasible but could also be too late 
 
Donor pre-treatment clearly has much potential because it would allow prevention 
and treatment of IRI at the earliest stage. However, there are ethical, logistical and 
organ-specific issues that need resolved before these strategies can be implemented 
in a clinical environment. These issues revolve around legislation, consent of 
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donor/recipient and the fear that some preconditioning agents may be beneficial to 
one organ but not to others [231].  
 
To date using the older Hsp90 inhibitors, geldanamycin and related analogues (17-
AAG and 17-DMAG), up-regulation of Hsps together with protection against 
oxidative injury (in cell culture) and IRI in mice has been demonstrated [84].  Hsp90 
inhibition has additionally been shown to induce Hsp70 up-regulation in the liver, 
lung and heart of mice [84]. Hsp90 inhibitors therefore have potential benefits for all 
organs retrieved in the multi-organ donor setting. These donors carry huge 
socioeconomic value and improving early function and longevity of transplanted 
organs in this setting is a high priority area. This could represent a particular 
advantage of Hsp90 inhibitors over other agents.  
 
Pharmacological preconditioning occurring in the context of renal transplantation 
merits particular consideration, as transplantation presents possibilities to promote 
anti-inflammatory recipient Tregs as well as induce cytoprotective Hsps in the donor 
kidney before harvesting the organ. However, it is noteworthy that the commonly 
used immunosuppressive drug mycophenolate mofetil worsens experimental IRI of 
native kidneys via effects on lymphocytes and renal Treg recruitment [232], though it 
is unclear whether this is of clinical relevance. Also, the up-regulation of the renal 
heat-shock response is associated with increased tubular major histocompatibility 
complex class II expression and immunogenicity [233]. This association may result 
from the increased action of HSF1 that underlies both endogenous and 
pharmacologically induced Hsp70 up-regulation. The specificity of both 
pharmacological inhibitors and inducers of Hsps is a further issue with some drugs; 
for instance, geldanamycin and its analogs induce both Hsp70 and Hsp27 [84], 
though this may not be problematic if all the induced Hsps exert a protective action. 
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Renal IRI is not unique to transplant surgery though, and occurs in variety of 
different clinical settings including shock, sepsis, exposure to nephrotoxic 
medications, vascular surgery and cardiothoracic surgery. This leads to an acute 
ischemic kidney injury, which not only causes potentially life-threatening renal 
failure, but additionally ignites a pro-inflammatory cascade through the release of 
inflammatory mediators that lead to a systemic response eventually resulting in 
remote organ injury and multi-organ failure [234].  
 
Defining a method of inducing protective Hsp expression in transplantation could 
lead to a reduction of renal IRI in these other allied surgical disciplines as well as 
opening up avenues of investigation for treatment of non-surgical causes of acute 
ischemic kidney injury. Preconditioning strategies could be administered before the 
ischemic insult and are thus of use in patients at risk of renal ischemia or acute 
kidney injury. For instance, high risk patients (e.g. pre-existing CKD, diabetes, 
extensive vascular disease etc.) awaiting toxic drug or radiological contrast exposure 
may also benefit from such preventative measures [61]. Despite this there may be 
difficulty deciding who should receive such treatments but the development of 
various predictive models of outcome following diverse interventions may well be 
able to stratify patients according to the risk of developing acute kidney injury in the 
future.  
 
1.21.2 Enhancing recovery following IRI 
 
Despite evidence that Hsp70 induction after renal IRI can mediate kidney protection 
[118], current research in this area has focused almost exclusively on preconditioning 
and to a lesser extent on deploying protective Hsp expression strategies in the 
recovery from renal IRI. Further investigation of recovery therapy might increase the 
capacity of these treatments to help patients that have already suffered acute 
ischemic kidney injury in a native or transplanted kidney. Moreover, treatment of the 
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transplant recipient may be more translationally feasible due to the ongoing ethical 
and logistical barriers to pre-treatment of donors [231].  
 
It is anticipated that a greater emphasis on recovery phase therapy may evolve from 
further understanding of how Hsp70 induction may interact with specific cell types 
in renal IRI. For instance, confirmation that Hsp70 induction influences circulating 
or infiltrating immune and inflammatory cells, either involved in the propagation or 
recovery from IRI would provide stronger evidence that treatment in the recovery 
stage could also be of benefit. For example, it has been shown that Hsp70 up-
regulation by geranylgeranylacetone administered after renal IRI is still protective 
[118], but it is unknown whether this results from the induction of protective cells 
such as anti-inflammatory Tregs, or by more direct beneficial effects on renal 
parenchymal cells, such as tubular cells.  
 
Following transplantation the recipient’s circulation continues to carry infiltrating 
inflammatory cells to the kidney. These circulating inflammatory cells are possible 
treatment targets due to their ability to either sustain or resolve tissue inflammation 
[208]. Hsp70 induction may occur in immune cells remote from the kidney following 
heat shock and plays an important role in mediating protective Treg responses in 
renal IRI [224]. Consequently, it is predicted that an Hsp70 inducing candidate drug 
could also modulate infiltrating inflammatory cells or the immune activity of Tregs 
through a similar systemic effect. There is thus potential for using Hsp70 inducing 
treatments in recipients prior to transplantation or even after the kidney has been 
implanted.  
 
These effects have not been unequivocally confirmed as yet and Hsp inducing agents 
may still have their major impact on renal tubular cells or renal resident leukocytes. 
As such, Hsp70 induction within the kidney parenchyma itself would be of prime 
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importance with circulating or infiltrating inflammatory cell populations not 
representing the key target.  In this case, researchers will need to induce protective 
levels of Hsp70 within renal tubular cells or renal resident inflammatory cells at the 
earliest possible stage. The focus will therefore remain on preconditioning the 
kidney, which may slow translational progress in this field particularly in the context 
of transplantation. 
 
Prior to translation to human disease, there is undoubtedly scope for much future 
work in this area to determine key cellular and molecular mediators together with an 
exploration of pharmacological agents that may be used to harness and manipulate 
the endogenous protection of Tregs and Hsps in an experimental setting. Indeed, this 
area of research has started to bear fruit in other conditions, such as chronic 
inflammatory diseases with recent evidence from human trials in arthritis suggesting 
that exogenous administration of Hsp peptides may exert anti-inflammatory effects 
via actions on T cells and Tregs [235]. In these studies, Hsp40 and Hsp60 peptides 
have been shown to modulate T cell responses by inhibiting the division of CD4+ 
and CD8+ T cells, and promote the production of anti-inflammatory cytokines 
including IL-10, IL-6 and transforming growth factor-β [153, 235, 236]. This 
suggests that Hsps may have an important role in preventing or arresting 
inflammation in renal IRI and thus protecting renal function. It also hints at distinct 
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1.22 Summary 
 
Pharmacological induction of Hsp expression is an emerging preconditioning 
strategy aimed at reducing IRI following organ transplantation and other ischemic 
injuries. The possibility of applying pharmacological agents to induce Hsp70 and 
prevent renal IRI has significant potential to benefit patients undergoing renal 
transplantation or at high risk of acute ischemic kidney injury.  
 
Hsp90 inhibitors lead to up-regulation of Hsp expression (especially Hsp70) and 
potentially block NF-ҡB activation by disruption of the IKK complex. The 
importance of TLR4 signalling in mediating kidney damage following IRI is now 
clear. Hsp90 inhibition is an attractive strategy to reduce TLR4-mediated IRI but as 
yet remains unproven.  
 
Prior to converting these therapies into a clinical context, an increased mechanistic 
knowledge of the protection offered by Hsp70 is also required. From a translational 
standpoint, an enhanced understanding of the inflammatory and immune cell types 
involved could also broaden the scope of these therapies to wider group of patients, 
including renal transplant recipients.  
 
Hsp70 induction is protective from renal IRI and it has recently been reported in the 
context of heat preconditioning that the protective effect of Hsp70 up-regulation in 
renal IRI is lymphocyte-dependent [118, 224]. Consequently, it is predicted that an 
Hsp70 inducing candidate drug such as AT13387, could also reduce renal IRI by 
modulating lymphocyte behaviour. There is thus therapeutic potential for using 
AT13387 in a recipient prior to transplantation in order to systemically up-regulate 
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Chapter 1 - Introduction  68 
1.23 Hypotheses 
 
1.23.1 In vitro  
 
1. AT13387 represses TLR4-mediated NF-ҡB activation resulting in reduced 
pro-inflammatory cytokine release. 
 
2.  AT13387 enables cellular survival following oxidative stress. 
 
1.23.2 In vivo 
 
1. AT13387 leads to induction of renal Hsp70 in mice. 
 
2. AT13387 pre-treatment results in functional and morphological protection 
from renal IRI.   
 
3. The protection afforded from renal IRI by AT13387 is lymphocyte-
dependent.  
 
4. Recipient treatment with AT13387 reduces renal IRI in transplantation. 
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Chapter 2: Materials and methods 
 
2.1 Cell culture 
 
Cell lines included Human embryonic kidney cells (HEK293) (European Collection 
of Cell Cultures, Porton Down, UK, Catalogue No: 85120602), stably transfected 
HEK293 expressing TLR4 (HEK293-TLR4, Catalogue No: IML-204) and stably co-
transfected HEK293 expressing both TLR4 and a secreted alkaline phosphatase 
(SEAP) reporter under the transcriptional control of NF-ҡB (HEK293-TLR4-NF-ҡB, 
Catalogue No: IML-104MD2CD14) (Imgenex, San Diego, USA). Cells were 
maintained in Dulbecco’s modified eagle’s medium (Gibco, Paisley, UK) 
supplemented with 10% foetal bovine serum, penicillin (50 U/ml), streptomycin (50 
μg/ml) and non-essential amino acids (5%). The selection agent for HEK293-TLR4 
cells was 10 μg/ml blasticidin (Invivogen, San Diego, CA) and for HEK293-TLR4-
NF-ҡB cells were 10 μg/ml blasticidin, 2 μg/ml puromycin, 200 μg/ml zeocin and 




Male FVB/n mice aged 6-8 weeks and weighing 20-25 g, were used from in-house 
colonies. Male Balb/c mice and male Balb/c severe combined immunodeficient 
(SCID) mice aged 6–8 weeks and weighing 20–25 g, were obtained from Harlan 
Laboratories, Blackthorn, UK. For renal transplantation experiments, slightly older 
male BALB/c mice aged 10-12 weeks and weighing 25–30 g, were also obtained 
from Harlan Laboratories, Blackthorn, UK. Mice were caged for a minimum of 7 
days before experimentation. Balb/c SCID mice were caged in individually 
ventilated cages and received sterilised food and water. Other mice were allowed free 
access to standard chow and water. The mice were kept in a 12:12-h light-dark cycle. 
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All work involving animals was conducted in accordance with the provisions of the 





The Hsp90 inhibitor AT13387 was kindly provided by Astex Pharmaceuticals [101]. 
17-DMAG was purchased from InvivoGen (San Diego, CA). For in vitro 
experiments, stock solutions were formed in Dimethyl sulfoxide (DMSO) (Sigma-
Aldridge, Dorset, UK) due to a lack of solubility of the compounds in water. 
Aliquots were formed from stock solutions to avoid repeated freeze thawing, and 
were further diluted in culture medium prior to use. Selected doses for in vitro 
experiments ranged from 100 nM to 1000 nM with the lowest effective dose of each 
drug sought in every experiment and controlled for by an appropriate DMSO vehicle 
control. The dosing range for AT13387 and 17-DMAG was established from 
preliminary investigations performed in renal adenocarcinoma cells by Ewen 
Harrison. Pre-treatment with Hsp90 inhibitors was performed in a time window 2-6 h 
prior to ligand stimulation or oxidative stress. For in vivo experiments AT13387 (80 
mg/kg free-base equivalent) was dissolved in (2-Hydroxypropyl)-β-cyclodextrin 
(2HβC) (Sigma-Aldridge, Dorset, UK), which was prepared in distilled water at 
17.5% weight per volume. Mice were treated by intra-peritoneal injection 6-24 h 





TLR4 grade endotoxin-free hyaluronan was purchased from Enzo Life Sciences 
(Exeter, UK), polymyxin B from SERVA (Heidelberg, Germany), 5-
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aminoimidazole-4-carboxyamideribonucleoside (AICAR) from Cell Signaling 
Technology (Boston, MA) and TNFα from Peprotech (London, UK). LPS and 




Transient NF-ҡB transfections were performed using Fugene HD or Fugene HP 
(Roche, Lewes, East Sussex, UK) in experiments assessing NF-ҡB activation in 
HEK293 cells and HEK293-TLR4 cells, as these cells did not have a stably 
transfected NF-ҡB reporter. Transfection efficiency of the NF-ҡB reporter construct 
(GL4.32 [luc2P/NF-κB-RE/Hygro]) was controlled by co-transfecting with a control 
vector (pGL4.73 control vector [hRluc/SV40]) (Promega, Southampton, UK). 
 
2.6 Western blot 
 
Western blotting was performed as previously described [237]. Briefly, whole cells 
extracts were produced and protein concentration determined (BioRad, Hemel 
Hempstead, UK). Proteins were separated by SDS-PAGE (10% or 15% Tris/HCl 
gels) and transferred to nitrocellulose (BioRad, Hemel Hempstead, UK). 
Nitrocellulose membranes were soaked in blocking buffer then primary antibody. 
Primary antibodies were from the IKK isoform antibody kit (Cell Signaling 
Technology, Boston, MA). After washing, the membranes were exposed to a 
horseradish peroxidase-conjugated secondary antibody at a concentration of 1:2000 
to 1:5000. Enhanced chemiluminescence reagent (Amersham, Chalfont St Giles, 
UK) was applied followed by development with autoradiography. Equality of 
loading was confirmed by probing for β-actin (BD Biosciences, San Diego, CA). 
 
 
Chapter 2 - Methods  72 
2.7 Flow Cytometry 
 
Cells were trypsinised, collected and incubated at room temperature with 2% rabbit 
serum. Further incubation was then performed with either PBS/0.5% Bovine Serum 
Albumin (BSA)/0.1% azide (unstained control), mouse IgG1 isotype control 
antibody (Serotec, Oxford, UK) or purified mouse anti-human TLR4 antibody (BD 
Pharmingen, San Diego, CA) for test samples (0.5 mg/ml at 1:50 dilution or 0.5 μg 
per test sample). Cells were washed then incubated with either PBS/0.5% BSA/0.1% 
azide for unstained controls or fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse IgG (Silenus Laboratories, Victoria, Australia) for IgG1 control samples 
and TLR4-test samples. Cells were washed again and results acquired on a BD 




2.8.1 Phosphorylated IҡBα (S32/S36) ELISA 
 
To measure phosphorylated IҡBα in whole cells, a commercially available cell based 
ELISA that used fluorogenic substrates was performed and analysed as per the 
manufacturers instructions (R&D Systems, Abingdon, UK). Normalised relative 
fluorescence units (RFUs) were determined by dividing phosphorylated IҡBα 
fluorescence in each well by the total glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) fluorescence in each well. The normalised RFUs were used to establish 
IҡBα phosphorylation, which is an indicator of NF-ҡB activity. The ELISA was 
performed 10 minutes following ligand stimulation as per the manufacturers 
instructions. This reflects the rapid nature of phosphorylated IҡBα expression.  
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2.8.2 Hsp70 ELISA 
 
Whole cells extracts were produced from tissue lysates and protein concentrations 
were determined (BioRad, Hemel Hempstead, UK). Detection of Hsp70 in tissue 
extracts was then performed using a commercially available ELISA kit according to 
the manufacturer’s instructions (Enzo Life Sciences, Exeter, UK). Sample Hsp70 
(ng/ml) was read from a standard curve and normalised to the total protein content of 




2.9.1 Luciferase assay 
 
Luciferase assays were used to investigate NF-ҡB activity following transient NF-ҡB 
transfections in HEK293 and HEK293-TLR4 cells. At 24 hours after transfection and 
following experimentation, cells were processed for luciferase activity using the 
Dual-Glo luciferase assay system and Turner Biosystems Modulus Microplate 
analyser (Promega, Southampton, UK). Firefly luciferase luminescence activity was 
normalised to that of the co-expressed renilla luciferase to determine the fold 
induction and indicate NF-ҡB activity. Maximal signal intensity was achieved when 
the assay was performed 1 h following ligand stimulation with TNFα and 3 h 
following ligand stimulation with LPS and hyaluronan. 
 
2.9.2 Crystal violet cell viability assay 
 
Cells were split into 6-well plates for experimentation. After experimentation cells 
were twice washed with 37°C Phosphate Buffered Saline (PBS) then incubated with 
 
Chapter 2 - Methods  74 
0.2% crystal violet solution (2% ethanol in distilled water), which is a solution that 
stains DNA, for 10 minutes at room temperature. The plate was then twice washed in 
a large beaker of water. The cell layer was dried upside down on paper towels then 
solubilised with 1% Sodium Dodecyl Sulfate solution. The plate was agitated on an 
orbital shaker for 1 h before results were read on a plate reader at 570 nM 
absorbance. Increasing optical density reflected increased cell density and therefore 
an increased number of viable cells. Results were normalised to cells left in medium 
control for the duration of the experiment, which were considered 100% viable. 
 
2.9.3 SEAP assay 
 
SEAP assays were used to investigate NF-ҡB activity in HEK293-TLR4-NF-ҡB 
cells as these cells were stably transfected with a SEAP reporter under the 
transcriptional control of NF-ҡB. SEAP assays were performed using the SEAPorter 
assay kit (Imgenex, San Diego, USA). The concentration of SEAP secreted into cell 
culture supernatant was calculated from a SEAP standard curve and was used to 
indicate NF-ҡB activation. The assay was performed 24 h after the addition of 
ligands as per the manufacturer’s instructions in order to allow adequate time for 
SEAP to be secreted from cells into the culture medium. 
 
2.10 Human cytokine array panel 
 
Cell culture supernates were mixed with biotinylated detection antibodies. The 
sample/antibody mixture was then incubated with a Human Cytokine Array panel 
(R&D Systems, Abingdon, UK). The panel consisted of a nitrocellulose membrane 
with capture antibodies for 36 human cytokines spotted on its surface in a duplicate 
manner.  Cognate immobilized capture antibodies on the membrane bound any 
cytokine/detection antibody complexes present. Following a wash to remove 
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unbound material, Streptavidin-HRP and chemiluminescent detection reagents were 
added sequentially followed by development using autoradiography. Light produced 
at each spot was used to determine the amount of cytokine bound. 
 
2.11 Renal IRI model 
 
An established model of warm IRI of the left kidney together with a right 
nephrectomy was used [238]. This model was preferred to a bilateral ischemia 
model, as the nephrectomy specimen allowed for confirmation and quantification of 
AT13387 activity via Hsp70 induction in kidney tissue at the time of surgery in each 
individual experimental animal. It also more closely mirrors the clinical scenario of a 
single injured kidney graft in a renal transplant recipient with no other functional 
nephron mass. The model was designed to inflict a moderate to severe acute tubular 
injury with zero animal mortality. Mice were anesthetised with an intra-peritoneal 
injection of Ketamine (75 mg/kg, Vetalar; Pfizer, Kent, UK) and Medetomidine (1 
mg/kg, Domitor, Pfizer). A heated mat maintained body temperature with 
homeostatic control via a rectal temperature probe (Harvard Apparatus, Boston, 
MA). A mid-line laparotomy was performed for access to both kidneys through a 
single incision. The right ureter and renal pedicle were ligated then divided. The right 
kidney was then removed as a control. One half kidney was placed in Methacarn 
(70% methanol, 20% chloroform, 10% acetic acid) with the other half frozen on dry 
ice. The pedicle of the left kidney was dissected and occluded using an atraumatic 
vascular clamp (Micro Serrefine, Fine Science Tools, Linton, UK) for 20 minutes in 
FVB/n mice and 30 or 32 minutes in Balb/c mice and Balb/c SCID mice since the 
tolerance of renal IRI was strain dependent. Following removal of the left pedicle 
clamp, reperfusion was confirmed visually before closure of the abdomen. The 
anaesthetic was reversed with Atipamezole (1 mg/kg, Antisedan, Pfizer), and a 
subcutaneous injection of 0.9% saline (25 ml/kg) and Buprenorphine (0.1 mg/kg) 
was administered. Animals were recovered in an incubator at 29°C until tissue 
collection 24 h later.  
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2.12 Renal transplantation model  
 
An established model of murine renal transplantation was used to perform isograft 
renal transplants from Balb/c donors to syngeneic Balb/c recipient mice [239, 240]. 
To describe the surgical technique briefly, after intraperitoneal administration of the 
same anesthetic regime used in the renal IRI model, the donor kidney was isolated 
and perfused with cooled University of Wisconsin solution (Belzer Bridge to Life, 
Columbia, SC). The donor kidney was stored at 4°C in University of Wisconsin 
solution for 4 h. Based on the findings of a previous publication, as well as in-house 
data, this cold ischemic time was anticipated to cause moderate to severe acute 
tubular necrosis [241]. After unilateral nephrectomy in the recipient, the donor renal 
artery and renal vein were anastomosed to recipient aorta and inferior vena cava, 
respectively, with a mean warm ischemic time of 30 minutes. The donor ureter was 
anastomosed to recipient bladder. The anaesthetic was reversed with Atipamezole (1 
mg/kg, Antisedan, Pfizer), and a subcutaneous injection of 0.9% saline (25 ml/kg) 
and Buprenorphine (0.1 mg/kg) was administered. Animals were recovered in an 
incubator at 29°C until tissue collection 24 h later. All mice had a single intact native 
kidney and the model was not transplant-dependent (i.e. the transplanted kidney was 
not a life-supporting organ [242]).  
 
2.13 Tissue collection  
 
Under terminal general anaesthesia, blood was recovered by intra-cardiac puncture, 
and the serum was stored at -20°C. Kidneys were divided equally in the transverse 
plane. One half kidney was placed in Methacarn with the other half frozen on dry ice. 
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2.14 Lung Digestion and cytometric analysis 
 
Broncho-alveolar lavage (BAL) was performed with 3 x 0.8 ml ice-cold PBS to 
remove alveolar cells. Non-adherent cells were then removed from the lung 
vasculature using 10 ml of PBS flushed through the beating right ventricle after 
cutting the inferior vena cava to allow exsanguination. Lungs were quickly dissected 
free and placed into a bijou containing 2 ml of cold Roswell Park Memorial Institute 
medium (RPMI). After removing the supernatant, lungs were placed in a 1 mg/ml 
DNAse (Sigma, Dorset, UK) and 10 mg/ml collagenase mix (Roche Diagnostics Ltd, 
Welwyn Garden City, UK) before being disrupted with scissors and incubated for 1 h 
at 37°C. Cells were then further released from tissue via vigorous pipetting using a 1 
ml syringe. After a spin at 300g for 15 minutes, red cells were lysed using 
Ammonium-Chloride-Potassium (ACK) lysing buffer (Life Technologies, Paisley, 
UK) for 5 minutes on ice followed by another wash at 300 g with PBS. Cells were 
resuspended in PBS, strained using a 40 µm cell strainer (BD Biosciences, UK) and 
incubated with Fc block (rat anti-mouse CD16/CD32, BD Europe) at 1:100 for 10 
minutes at 4°C prior to a wash. The following antibodies were added; FITC-labelled 
anti-mouse CD11b and Pacific Blue-labelled anti-mouse LY-6G (Biolegend, San 
Diego, CA) for 30 minutes on ice followed by the addition of FACS lysing solution 
(BD Biosciences, Oxford, UK). Samples were spun at 350 g for 5 minutes and 
resuspended in PBS prior to analysis. 
 
2.15 BAL analysis 
 
BAL fluid was weighed and subsequent cell counts were adjusted per microliter of 
BAL fluid collected. Cells were then fixed and stained using a Quick-Diff kit 
(Reagena, UK) following a cytospin, and differential counts were determined. 
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2.16 Immunohistochemistry 
 
Tissue was fixed in methacarn for 24 h before being mounted in paraffin. Sections 
were cut and mounted on SuperFrost slides (Fisher Scientific, Pittsburgh, PA). 
Sections were de-waxed in xylene for 10 minutes and rehydrated through decreasing 
concentrations of alcohol into distilled water. Endogenous peroxidase was blocked 
with 3% H2O2 for 10 minutes followed by washing in distilled water. Antigen 
retrieval was performed by microwaving sections in 10 mM citrate buffer (pH 6.0) 
for 15 minutes. Slides were cooled and transferred to Tris Buffered Saline (TBS). 
Sections were blocked in 10% normal serum of the species the secondary antibody 
was raised in for 20 minutes. Primary antibody in 10% normal serum was then 
applied for 1 h at room temperature or overnight at 4 °C. Primary antibodies were as 
follows: Hsp70 (Enzo Life Sciences, Exeter, UK), CD3 (Dako, Cambridge, UK) and 
Foxp3 (affymetrix eBioscience, Hatfield, UK). After washing in TBS the sections 
were exposed to peroxidase-conjugated secondary antibody for 30 minutes. After 
washing in TBS for 5 minutes, sections were exposed to peroxidase substrate 
solution (3,3-diaminobenzidine tetrahydrochloride, DAB) (DAKO, Glostrup, 
Denmark). Following counterstaining with haematoxylin, sections were dehydrated 
through increasing concentrations of alcohol to xylene, before the cover-slip was 
mounted. Sections were then examined with light-microscopy. Appropriate primary 
antibody-only and secondary antibody-only controls were always performed to 
ensure that non-specific staining was not taking place.  
 
2.17 Scoring of morphological kidney injury 
 
Hematoxylin and eosin-stained sections were evaluated for tubulointerstitial injury. 
A series of non-overlapping fields (x200) were examined by an observer blinded to 
the sample number. A scoring system based on the proportion of tubules with 
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necrotic/detached cells was used (tubular necrosis score: 0, none; 1, <30%; 2, 30 –
70%; 3, >70%) [84]. 
 
2.18 Serum creatinine determination 
 
Plasma samples were prepared from whole blood. Creatinine was determined using 
the creatininase/creatinase specific enzymatic method described by Borner et al. 
(1979) [243], utilising a commercial kit (Alpha Laboratories Ltd,  Eastleigh, UK) 
adapted for use on a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, 
Welwyn Garden City, UK).  
 
2.19 Murine cytokine array panel 
 
Kidney protein lysates (200 μg per sample) were mixed with biotinylated detection 
antibodies. The sample/antibody mixture was then incubated with a mouse cytokine 
array panel (R&D Systems, Abingdon, UK). The panel consisted of a nitrocellulose 
membrane with capture antibodies for 40 murine cytokines spotted on its surface in a 
duplicate manner. Cognate immobilized capture antibodies on the membrane bound 
any cytokine/detection antibody complexes present. Following a wash to remove 
unbound material, Streptavidin-HRP and chemiluminescent detection reagents were 
added sequentially followed by development using autoradiography. Light produced 
at each spot was used to determine the amount of cytokine bound. Mean gray values 
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2.20 Real-time reverse transcriptase–PCR 
 
For the detection of renal TLR4 expression, RNA was extracted from kidneys and 
purified by TRIzol (Invitrogen, Life Technologies, Paisley, UK). RNA concentration 
and quality was determined using a Nanodrop spectrophotometer and Agilent 
Bioanalyzer. Across all samples the mean 260/280 ratio was 2.06 +/- 0.01, and mean 
RNA integrity number was 7.9 +/- 0.6. cDNA was synthesized using a RT2 First 
Strand Kit (Qiagen, Manchester, UK). Real-time PCR was then performed using a 
RT2 qPCR primer assay for mouse TLR4 (Qiagen, Manchester, UK). GAPDH was 
used as the reference gene, and was also quantified using a RT2 qPCR primer assay 
(Qiagen, Manchester UK).  
 
2.21 Statistical analysis 
 
Data are presented as mean and standard error of the mean or in standard boxplots 
with individual results jittered. Statistical comparisons for parametric continuous 
data were made using student’s t-test, one-way analysis of variance (ANOVA) and 
two-way ANOVA without interaction (using the Tukey’s HSD post hoc correction 
for multiple comparisons). Statistical comparisons for non-parametric data were 
made using the Mann-Whitney U test. All comparisons were performed in R v3.0.1 
(R Foundation for Statistical Computing). 
 
2.22 Power calculation 
 
For animal experiments in the renal IRI model, power calculations were performed 
and the number of mice was kept to a minimum required to answer the research 
question. Creatinine was selected as the primary outcome measure since it is 
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objectively measured and less affected by hydration status than blood urea nitrogen. 
Although creatinine levels are affected by muscle mass and thus differ according to 
mouse gender and age, all experiments were performed on male mice of the same 
age. Previous data was used to the estimate effect size for the potential reduction in 
serum creatinine. Based on the reduction in creatinine in animals treated with Hsp90 
inhibitors that underwent contralateral nephrectomy and 30 minutes renal IRI, an 
effect size of 1.70 was calculated [84]. With α set at 0.05 and β set at 0.1 this 
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 Creatinine (µmol/l) 
Test significance level (α) 0.05 
Group 1 mean 97.8 
Group 2 mean 69.5 
Standard deviation 16.6 
Effect size 1.70 
Power (%) 90 
n per group 9 
 
Table 2.1 Power calculation for animal experiments 
Previous data was used to the estimate effect size for the potential reduction in serum creatinine [84]. 
Based on the reduction in creatinine in animals treated with Hsp90 inhibitors that underwent 
contralateral nephrectomy and 30 min renal IRI, an effect size of 1.70 was calculated. This translates 
to a required sample size of 9 animals per treatment group [245]. 
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Chapter 3: AT13387 represses TLR4-mediated 
NF-ҡB activation resulting in reduced pro-




As discussed in Chapter 1, Hsp90 may be needed to stabilise IKK [130] and the use 
of Hsp90 inhibitors could cause dissociation of the IKK complex and prevention of 
NF-ҡB activation [125]. Hsp90 inhibition has previously been used to 
experimentally treat TLR4-mediated autoimmune diseases [86, 87] and reduce 
TNFα-mediated NF-κB activation [131-135]. However, it remains to be proven 
whether TLR4 signalling to NF-ҡB can be similarly targeted by AT13387. This 
chapter will address the hypothesis that AT13387 represses TLR4-mediated NF-ҡB 
activation resulting in reduced pro-inflammatory cytokine release.  
 
3.2 HEK293 cells do not express TLR4 
 
HEK293 cells were selected specifically for these experiments since they are easy to 
grow, transfect efficiently and have previously been reported to lack TLR4 
expression [246, 247]. The absence of TLR4 expression by HEK293 cells was 
confirmed by flow cytometry (Figure 3.1a) [246]. In addition, TLR4 expression was 
unaltered by exposure to oxidative stress with hydrogen peroxide (Figure 3.1b). This 
is in contrast to human renal tubular epithelial cells, which express basal levels of 
TLR4 that are further up-regulated following pro-inflammatory stimulation [248]. 
Successful TLR4 transfection was validated in HEK293-TLR4 and HEK293-TLR4-
NF-ҡB cell lines by flow cytometry (Figure 3.2a,b). HEK293 and HEK293-TLR4 
cells were therefore considered ideal for identifying a suitable TLR4-specific ligand 
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to explore the in vitro hypothesis that AT13387 leads to repression of TLR4-
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Figure 3.1 TLR4 flow cytometry on HEK293 cells  
a) TLR4 expression by HEK293 cells on flow cytometry. Cells were trypsinised and collected at 
50,000 cells per sample. Samples were first incubated at room temperature with 2% rabbit serum for 
20 min. Following this a 30 min room temperature incubation was performed with either 50 μl of 
PBS/0.5% BSA/0.1% azide (unstained control), mouse IgG1 isotype control antibody or purified 
mouse anti-human TLR4 antibody (0.5 mg/ml at 1:50 dilution or 0.5 μg per test sample). The primary 
antibodies were washed off with PBS/0.5% BSA/0.1% azide. The cells were then incubated for a 
further 30 min at room temperature with PBS/0.5% BSA/0.1% azide for unstained controls, and 
FITC-conjugated goat anti-mouse IgG for IgG1 isotype control antibody samples and TLR4 test 
samples. The secondary antibodies were washed off with PBS/0.5% BSA/0.1% azide and results were 
acquired on a BD Accuri C6 flow cytometer. Cells were gated on the basis of forward and side scatter. 
TLR4 expression in HEK293 cells is represented by the red histograms, IgG-FITC negative control 
sample by the pink histograms, PBS-FITC negative control sample by the light blue histograms and 
PBS-PBS negative control sample by the dark blue histograms (n=1). 
 
b) TLR4 expression by HEK293 cells following oxidative stress on flow cytometry. Cells were 
treated with 0.4 mM of Hydrogen Peroxide for 16 h then analysed as per figure 3.1a. The dose of 
hydrogen peroxide was selected from a dose response assay, and was anticipated to cause oxidative 
stress without excessive (<10%) cell death (Figure 4.1). TLR4 expression in HEK293 cells is 
represented by the red histograms, IgG-FITC negative control sample by the pink histograms, PBS-
FITC negative control sample by the light blue histograms and PBS-PBS negative control sample by 
the dark blue histograms (n=1).  
 




Figure 3.2 TLR4 flow cytometry on TLR4 transfected HEK293 cells 
a) TLR4 expression by HEK293-TLR4 cells on flow cytometry. Cells were analysed as per figure 
3.1a. TLR4 expression in HEK293-TLR4 cells is represented by the red histograms, IgG-FITC 
negative control sample by the pink histograms, PBS-FITC negative control sample by the light blue 
histograms and PBS-PBS negative control sample by the dark blue histograms (n=1).  
 
b) TLR4 expression by HEK293-TLR4-NF-ҡB cells on flow cytometry. Cells were analysed as per 
figure 3.1a. TLR4 expression in HEK293-TLR4-NF-ҡB cells is represented by the red histograms, 
IgG-FITC negative control sample by the pink histograms, PBS-FITC negative control sample by the 
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3.3 Endotoxin-free hyaluronan is a sterile TLR4-
specific ligand in HEK293 cells expressing TLR4 
 
Hyaluronan is a DAMP and a proposed endogenous TLR4 ligand that is released in 
increasing amounts during the sterile insult that comprises renal IRI [168]. TLR4 was 
selectively expressed using TLR4-transfected cells (HEK293-TLR4). After ligand 
stimulation NF-ҡB activity was assessed by luciferase assay in comparison to TLR4-
null cells (HEK293). Following hyaluronan stimulation there was increased NF-ҡB 
activity in HEK293-TLR4 cells, but an absence of NF-ҡB up-regulation in HEK293 
cells (HEK293-TLR4 vs. HEK293, p<0.001, t-test) (Figure.3.3). This indicates that 
hyaluronan is a TLR4-specific ligand in HEK293-TLR4 cells. In HEK293-TLR4-
NF-ҡB cells there was also significant NF-ҡB up-regulation following a TLR4-
ligand dose response assay with hyaluronan (Figure 3.4). Furthermore, the level of 
TLR4-mediated NF-ҡB activation assessed by SEAP assay following hyaluronan 
stimulation was not altered by the presence of polymyxin B, a drug that clears 
endotoxin contamination (Figure 3.5). Therefore, hyaluronan was used to model 
sterile TLR4-specific NF-ҡB activation in further experiments.  
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Figure 3.3 Luciferase assay to determine NF-ҡB activity following NF-ҡB transfection and 
hyaluronan stimulation in HEK293 and HEK293-TLR4 cells 
HEK293 and HEK293-TLR4 cells were divided at a cell density of 100,000 cells in 1 ml of growth 
medium per well of a 12-well plate. After 24 h, cells were transfected with 0.5 μg pGL4.32 
[luc2P/NF-κB-RE/Hygro] plasmid DNA (experimental vector) using a ratio of DNA to Fugene HP of 
3:1. A constitutively active control vector (pGL4.73 [hRluc/SV40]) was added at a ratio of 
experimental to control vector of 100:1. 24 h later, cells were treated with hyaluronan at a dose of 25 
μg/ml. After 3 h incubation a luciferase assay was performed to determine firefly activity and renilla 
activity. Fold induction was calculated from the ratio of firefly to renilla and used to reflect NF-κB 
activity. Results are presented as 3 independent experiments in a standard boxplot with individual 
results jittered. The mean fold induction in HEK293 cells was 1.07 +/- 0.09 (standard error of the 
mean), i.e. there was no increase in NF-κB activity following hyaluronan stimulation. ***p<0.001 vs. 
HEK293 & hyaluronan, t-test. 
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Figure 3.4 SEAP assay to determine NF-ҡB activity following a ligand dose response assay using 
hyaluronan stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, medium was changed to medium containing 
hyaluronan at doses ranging from 0 μg/ml to 100 μg/ml. Cells treated with 0 μg/ml of hyaluronan 
were left in basal conditions in normal culture medium. After 24 h incubation a SEAP assay was 
performed to determine NF-ҡB activity. Results are presented from 3 independent experiments in a 
standard boxplot with individual results jittered. *p<0.05 vs. 0 ng/ml hyaluronan and **p<0.01 vs. 0 
ng/ml hyaluronan, ANOVA. 
 
 
Chapter 3 - Results  90 
 
Figure 3.5 SEAP assay to determine NF-ҡB activity following hyaluronan stimulation with and 
without the presence of polymyxin B in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, the medium was changed to medium containing 25 
μg/ml of hyaluronan either with or without 50 μg/ml of polymyxin B. After 24 h incubation a SEAP 
assay was performed to determine NF-ҡB activity. Results are presented from 4 independent 
experiments in a standard boxplot with individual results jittered. Outlier data are highlighted by a dot 
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3.4 AT13387 and 17-DMAG pre-treatment leads to 
repression of TLR4-mediated NF-ҡB activation 
 
Hyaluronan was used to test whether pre-treatment with AT13387 and 17-DMAG 
could lead to a significant reduction in NF-ҡB activity when mediated by a sterile 
and highly TLR4-specific stimulus. In HEK293-TLR4-NF-ҡB cells, pre-treatment 
with AT13387 and 17-DMAG significantly reduced hyaluronan-mediated NF-ҡB 
activity assessed by SEAP assay (AT13387 1000 nM vs. DMSO vehicle, p<0.001, 
17-DMAG 1000 nM vs. DMSO vehicle, p<0.001, AT13387 500 nM vs. DMSO 
vehicle, p<0.001, ANOVA) (Figure 3.6). In fact, pre-treatment with AT13387 
reduced NF-ҡB activity assessed by SEAP assay following hyaluronan stimulation to 
a level equivalent of cells in basal conditions in normal culture medium (Figure 3.5). 
In addition, AT13387 was significantly more effective at reducing hyaluronan-
mediated NF-ҡB activity assessed by SEAP assay than 17-DMAG (AT13387 1000 
nM vs. 17-DMAG 1000 nM, p<0.01, ANOVA) including at a lower dose (AT13387 
500 nM vs. 17-DMAG 1000 nM, p<0.05, ANOVA). 17-DMAG was ineffective at 
reducing NF-ҡB activity at these lower doses. AT13387 therefore had inhibitory 
efficacy at lower doses than 17-DMAG.  
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Figure 3.6 NF-ҡB activity determined by SEAP assay following pre-treatment with AT13387 or 
17-DMAG and hyaluronan stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, cells were pre-treated with AT13387, 17-DMAG, 
DMSO vehicle or medium control for 6 h. Hyaluronan was added at a dose of 25 μg/ml for 24 h and a 
SEAP assay was performed to determine NF-ҡB activity. Results are presented from 4 independent 
experiments in a standard boxplot with individual results jittered. *p<0.05 vs. 17-DMAG, **p<0.01 
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3.5 Pre-treatment with AT13387 and 17-DMAG leads 
to loss of the IKK complex 
 
IKK is composed of two protein kinase subunits IKKα and IKKβ as well as the 
regulatory subunit NEMO [127]. IKK activation leads to the dissociation of NF-ҡB 
from IҡB and its subsequent activation. Hsp90 inhibition, using pre-treatment with 
AT13387 and 17-DMAG led to breakdown of the IKK complex on Western blot 
following hyaluronan stimulation in HEK293-TLR4-NF-ҡB cells (Figure 3.7).  
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Figure 3.7 IKKα, IKKβ and NEMO levels on Western blotting following AT13387 or 17-DMAG 
pre-treatment and hyaluronan stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 500,000 cells in 2 ml of growth medium 
per well of a 6-well plate. 24 h later, cells were then pre-treated with AT13387, 17-DMAG, DMSO 
vehicle or medium control for 12 h. With the exception of cells pre-treated with medium control, 
hyaluronan was added for 4 h. Whole-cell lysates were then prepared and analysed by Western 
blotting using antibodies to IKKα, IKKβ and NEMO, with β-actin being indicated as a loading control 
(n=1). Three different β-actin levels are presented because three separate Western blots were 
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3.6 IKKα is degraded by autophagy following 
treatment with AT13387 and 17-DMAG  
 
Hsp90 inhibition has previously been shown to result in a proteasome-independent 
and autophagy-mediated degradation of IKK, which can be prevented by the 
autophagy inhibitor AICAR [249]. In further experiments, pre-incubation with, and 
the presence of, AICAR prevented IKKα degradation on Western blot by Hsp90 
inhibition in HEK293-TLR4-NF-ҡB cells (Figure 3.8). AICAR also prevented IKKα 
degradation on Western blot by Hsp90 inhibition in HEK293-TLR4-NF-ҡB cells 
following hyaluronan stimulation (Figure 3.9). However, in contrast to the previous 
study [249], AICAR did not appear to affect the level of IKKβ or NEMO detected on 
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Figure 3.8 IKKα, IKKβ and NEMO levels on Western blotting following AT13387 or 17-DMAG 
treatment with and without pre-incubation/presence of AICAR in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 500,000 cells in 2 ml of growth medium 
per well of a 6-well plate. 24 h later, cells were treated with AT13387 or 17-DMAG for 12 h or were 
pre-incubated with AICAR for 1 h then treated with AT13387 or 17-DMAG in the presence of 
AICAR for 12 h. Whole-cell lysates were prepared and analysed by Western blotting using antibodies 
to IKKα, IKKβ and NEMO, with β-actin being indicated as a loading control (n=1). Three different β-
actin levels are presented because three separate Western blots were performed on the same samples 









Chapter 3 - Results  97 
 
Figure 3.9 IKKα, IKKβ and NEMO levels on Western blotting following AT13387 or 17-DMAG 
pre-treatment with and without pre-incubation/presence of AICAR and hyaluronan stimulation 
in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided and treated as per figure 3.8. Hyaluronan was then added 
for 4 h. Whole-cell lysates were prepared and analysed by Western blotting using antibodies to IKKα, 
IKKβ and NEMO, with β-actin being indicated as a loading control (n=1). Three different β-actin 
levels are presented because three separate Western blots were performed on the same samples to 
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3.7 AICAR partially restores NF-ҡB activity in 
AT13387 and 17-DMAG pre-treated cells following 
hyaluronan stimulation 
 
On SEAP assay, pre-incubation and presence of AICAR significantly reduced 17-
DMAG but not AT13387-mediated NF-ҡB repression in HEK293-TLR4-NF-ҡB 
cells stimulated with hyaluronan (17-DMAG 1000 nM & AICAR 1 mM vs. 17-
DMAG 1000 nM, p<0.05, AT13387 1000 nM & AICAR 1 mM vs. AT13387 1000 
nM, p=0.26, t-test). In these experiments, AT13387 and 17-DMAG were 
administered at a high dose (1000 nM). There was again marked NF-ҡB down-
regulation and in contrast to earlier results both drugs appeared equally effective at 
this dose (AT13387 1000 nM vs. DMSO vehicle, p<0.001, 17-DMAG 1000 nM vs. 
DMSO vehicle, p<0.001, ANOVA). AICAR alone also led to partial de-activation of 
TLR4-mediated NF-ҡB activity by hyaluronan (AICAR 1 mM vs. DMSO 1000 nM, 
p=0.06, t-test) (Figure 3.10).  
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Figure 3.10 SEAP assay to determine NF-ҡB activity following pre-treatment with AT13387 or 
17-DMAG with and without pre-incubation/presence of AICAR and hyaluronan stimulation in 
HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, cells were pre-incubated with AICAR for 1 h or were 
left alone. AICAR pre-incubated cells were either pre-treated with AT13387 or 17-DMAG in the 
presence of AICAR or AICAR alone for 2 h. The non-AICAR incubated cells were then pre-treated 
with AT13387, 17-DMAG, DMSO vehicle or medium control for 2 h. After which hyaluronan was 
added at a dose of 25 μg/ml. Following 24 h incubation a SEAP assay was performed to determine 
NF-ҡB activity. Results are presented from 3 independent experiments in a standard boxplot with 
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3.8 AT13387 and 17-DMAG pre-treatment reduces 
TLR4-mediated pro-inflammatory cytokine release 
 
The in vitro model that was developed simulated the sterile inflammatory 
environment of renal IRI, but it was unclear what the cytokine response would be 
like following stimulation with hyaluronan in HEK293 cells. Therefore a cytokine 
array panel was performed in order to evaluate the expression of a broad range of 
cytokines. AT13387 and 17-DMAG pre-treatment led to a reduction in the release of 
cytokines as assessed by cytokine array panel following hyaluronan stimulation. 
Most notably, there was marked reduction in the expression of the pro-inflammatory 
chemokine GROα (Figure 3.11). As this was a single array, quantitative analysis was 
not performed, and all other differentially expressed cytokines must be cautiously 
interpreted.  
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Figure 3.11 Cytokine expression following AT13387 or 17-DMAG pre-treatment and 
hyaluronan stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 500,000 cells in 2 ml of growth medium 
per well of a 6-well plate. 24 h later, cells were pre-treated with AT13387, 17-DMAG, DMSO vehicle 
or medium control for 6 h. With the exception of medium control pre-treated cells, which were left in 
basal conditions, hyaluronan was added at a dose of 25 μg/ml. After 24 h incubation a cytokine array 
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3.9 Pre-treatment with AT13387 and 17-DMAG 
reduces non-TLR4-specific activation 
 
It has previously been shown in vitro, in various cell lines, that Hsp90 inhibition may 
reduce non-TLR4-specific NF-κB activation mediated by TNFα [131-135]. These 
results were confirmed in HEK293 cells, where NF-ҡB activity assessed by 
luciferase assay increased with TNFα stimulation (Figure 3.12), and pre-treatment 
with AT13387 and 17-DMAG led to a significant reduction in TNFα-mediated NF-
ҡB activity (AT13387 100 nM vs. DMSO vehicle, p<0.001, 17-DMAG 1000 nM vs. 
DMSO vehicle, p<0.05, ANOVA) (Figure.3.13). The results were further validated 
in HEK293-TLR4-NF-ҡB cells where pre-treatment with AT13387 and 17-DMAG 
led to both reduced TNFα-mediated IҡBα phosphorylation on ELISA (AT13387 
1000 nM vs. DMSO vehicle, p<0.01, 17-DMAG 1000 nM vs. DMSO vehicle, 
p<0.001, ANOVA) (Figure 3.14) and NF-ҡB activation assessed by SEAP assay 
(AT13387 1000 nM vs. DMSO vehicle, p<0.001, 17-DMAG 1000 nM vs. DMSO 
vehicle, p<0.001, ANOVA) (Figure 3.15).  
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Figure 3.12 Luciferase assay to determine NF-ҡB activity following NF-ҡB transfection and a 
ligand dose response assay using TNFα stimulation in HEK293 cells 
HEK293 cells were divided at a cell density of 100,000 cells in 1 ml of growth medium per well of a 
12-well plate. After 24 h, cells were transfected with 0.5 μg pGL4.32 [luc2P/NF-κB-RE/Hygro] 
plasmid DNA (experimental vector) using a ratio of DNA to Fugene HD of 5:1. A constitutively 
active control vector (pGL4.73 [hRluc/SV40]) was added at a ratio of experimental to control vector 
of 100:1. 24 h later, TNFα was added at doses ranging from 0 ng/ml to 10 ng/ml (as per the 
manufacturer’s instructions) for 1 h. A luciferase assay was then performed to determine firefly 
activity and renilla activity. Fold induction was calculated from the ratio of firefly to renilla and used 
to reflect NF-κB activity. Results are presented from 3 independent experiments in a standard boxplot 
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Figure 3.13 Luciferase assay to determine NF-ҡB activity following NF-ҡB transfection, pre-
treatment with AT13387 or 17-DMAG and TNFα stimulation in HEK293 cells 
HEK293 cells were divided and transfected as per figure 3.12. 24 h later, cells were pre-treated with 
AT13387, 17-DMAG, DMSO vehicle or medium control for 3h. TNFα was then added at a dose of 
0.1 ng/ml for 1 h. This dose was selected from figure 3.12 as a potentially modifiable level of NF-κB 
activity. A luciferase assay was then performed to determine firefly activity and renilla activity. Fold 
induction was calculated from the ratio of firefly to renilla and used to reflect NF-κB activity. Results 
are presented from 3 independent experiments in a standard boxplot with individual results jittered. 
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Figure 3.14 ELISA to determine phosphorylated IҡBα levels following pre-treatment with 
AT13387 or 17-DMAG and TNFα stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, cells were pre-treated with AT13387, 17-DMAG, 
DMSO vehicle or medium control for 6 h. TNFα was then added at a dose of 1 ng/ml for 10 min and a 
phosphorylated IҡBα ELISA was performed. The dose of TNFα was increased in this experiment to 
maximise the possibility of detecting an increase in phosphorylated IҡBα. Normalised RFUs (relative 
fluorescence units) were determined by dividing phosphorylated IҡBα fluorescence in each well by 
the total GAPDH fluorescence in each well. The normalised RFUs were used to establish IҡBα 
phosphorylation, which is an indicator of NF-ҡB activity. The ELISA was performed 10 minutes 
following ligand stimulation as per the manufacturers instructions. This reflects the rapid nature of 
phosphorylated IҡBα expression. Results are presented from 3 independent experiments in a standard 
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Figure 3.15 SEAP assay to determine NF-ҡB activity following pre-treatment with AT13387 or 
17-DMAG and TNFα stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, cells were pre-treated with AT13387, 17-DMAG, 
DMSO vehicle or medium control for 4 h. TNFα was then added at a dose of 1 ng/ml for 16 h and a 
SEAP assay was performed to determine NF-ҡB activity. The dose of TNFα was selected on the basis 
of the previous experiment (Figure 3.14). Results are presented from 4 independent experiments in a 
standard boxplot with individual results jittered. Outlier data are highlighted by a dot with a diamond 
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3.10 Pre-treatment with AT13387 and 17-DMAG 
reduces non-sterile NF-ҡB activation 
 
It has previously been shown that Hsp90 inhibition can reduce non-sterile LPS-
mediated NF-ҡB activity in human monocytic cell lines [73, 250, 251]. These results 
were confirmed in HEK293-TLR4-NF-ҡB cells, where NF-ҡB activity assessed by 
SEAP assay increased with LPS stimulation (Figure 3.16), and pre-treatment with 
AT13387 and 17-DMAG led to a significant reduction in LPS-mediated NF-ҡB 
activity (AT13387 1000 nM vs. DMSO vehicle, p<0.001, 17-DMAG 1000 nM vs. 
DMSO vehicle, p<0.001, AT13387 100 nM vs. DMSO vehicle, p<0.05, ANOVA) 
(Figure 3.17). Moreover, pre-treatment with AT13387 reduced NF-ҡB activity 
assessed by SEAP assay following LPS stimulation to a level equivalent of cells in 
basal conditions in normal culture medium (Figure 3.16). In further experiments, 
breakdown of IKK on Western blot was noted following Hsp90 inhibition and LPS 
stimulation (Figure 3.18). In addition, a reduction in the release of cytokines was 
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Figure 3.16 SEAP assay to determine NF-ҡB activity following a ligand dose response assay 
using LPS stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, the medium was changed to medium containing LPS at 
doses ranging from 0 ng/ml to 1000 ng/ml. Cells treated with 0 ng/ml of LPS were left in basal 
conditions in normal culture medium. After 24 h incubation a SEAP assay was performed to 
determine NF-ҡB activity. Results are presented from 3 independent experiments in a standard 
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Figure 3.17 SEAP assay to determine NF-ҡB activity following pre-treatment with AT13387 or 
17-DMAG and LPS stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 10,000 cells in 100 μl of growth 
medium per well of a 96-well plate. 24 h later, cells were pre-treated with AT13387, 17-DMAG, 
DMSO vehicle or medium control for 6 h. LPS was then added at a dose of 100 ng/ml for 24 h and a 
SEAP assay was performed to determine NF-ҡB activity. Results are presented from 4 independent 
experiments in a standard boxplot with individual results jittered. Outlier data are highlighted by a dot 
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Figure 3.18 IKKα, IKKβ and NEMO levels on Western blotting following AT13387 or 17-
DMAG pre-treatment and LPS stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 500,000 cells in 2 ml of growth medium 
per well of a 6-well plate. 24 h later, cells were then pre-treated with AT13387, 17-DMAG, DMSO 
vehicle or medium control for 12 h. With the exception of cells pre-treated with medium control, LPS 
was added for 4 h. Whole-cell lysates were then prepared and analysed by Western blotting using 
antibodies to IKKα, IKKβ and NEMO, with β-actin being indicated as a loading control (n=1). Three 
different β-actin levels are presented because three separate Western blots were performed on the 
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Figure 3.19 Cytokine expression following AT13387 or 17-DMAG pre-treatment and LPS 
stimulation in HEK293-TLR4-NF-ҡB cells 
HEK293-TLR4-NF-ҡB cells were divided at a cell density of 500,000 cells in 2 ml of growth medium 
per well of a 6-well plate. 24 h later, cells were pre-treated with AT13387, 17-DMAG, DMSO vehicle 
or medium control for 6 h. With the exception of medium control pre-treated cells, which were left in 
basal conditions, LPS was added at a dose of 100 ng/ml. After 24 h incubation a cytokine array panel 
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3.11 Summary 
 
In this chapter it has been shown that AT13387 represses TLR4-mediated NF-ҡB 
activation, which may be an important pro-inflammatory signalling pathway 
involved in renal IRI. The mechanism of this repression appears to be through a loss 
of the IKK complex. The further experiments performed with TNFα and LPS suggest 
that in addition to repressing sterile TLR4-mediated NF-ҡB activation; Hsp90 
inhibition also reduces NF-ҡB activity from both non-TLR4-specific and non-sterile 






The fact that the experiments in this chapter were conducted in only one 
immortalized cell type is the major weakness of the data presented. Immortalized 
HK2 cells (human cells with the proximal renal tubule the presumed cell type of 
origin) would have been a potentially useful adjunct to HEK293 cells [252]. The 
caveat being that the use of HK2 cells, which express basal levels of TLR4, may 
have been problematic in terms of excluding off target effects (i.e. non-TLR4 effects) 
of ligands [248]. Furthermore, the fact HK2 cells are also immortalized implies they 
have undergone genetic and phenotypic alterations that make them different from the 
cells from which they were derived [253]. The question then becomes whether HK2 
cells would accurately model typical kidney cells. Primary renal cells would 
therefore be an attractive alternative but there are disadvantages to using primary 
cells, such as modest cell yields and reduced cell viability [254]. There could also 
have be difficulty with repeated passages, and transfection [255].  
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3.12.2 Variability 
 
In this chapter there were differing levels of SEAP and fold induction between 
assays, even in control samples, which reflects inter-experimental variability and 
calls into question the reproducibility of these results. Since intra-experimental 
results appeared consistent with few outlying data points, and the overall pattern of 
results were similar, cell passage number at the time of experimentation or 
imbalances in cell number between experiments could explain this variation. The 
latter could be secondary to the small volumes of cell suspensions used in 96-well 
plates. Indeed greater consistency of results was achieved in the cell viability assays 
reported in the next chapter when larger 6-well plates were utilised. This made it 
easier to control the consistency of cell concentration across wells.  
 
A further inconsistency was noted in the potency of high dose 17-DMAG at reducing 
hyaluronan-mediated NF-ҡB activation. As such, the variability in the 17-DMAG 
results could represent a batch effect due to use of different stock solutions of 17-
DMAG. As AT13387 100 nM and 17-DMAG 500 nM actually increased NF-ҡB 
activation on SEAP assay, it could also be suggested that the dose of these drugs is 
critical to their effect. This is more likely to be a real effect, and there could be 
complex interactions of different molecules resulting in pro-inflammatory effects of 
Hsp90 inhibitors under certain conditions (e.g. at low doses), but anti-inflammatory 
in others (e.g. at high doses). A final consideration of this chapter is that the Western 
blots using AICAR lacked a medium control and a vehicle control. All samples 
received Hsp90 inhibitors therefore it is not possible to be certain that Hsp90 
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3.12.3 Reproducibility  
 
In the experiments reported in this chapter, HEK293 cells were not used as an in 
vitro model of typical kidney cells. They were selected specifically for these 
experiments since they are widely available, deliver reproducible results, transfect 
efficiently and have previously been reported to lack TLR4 expression [246, 247]. 
This previously reported phenotype was confirmed on flow cytometry. The main 
limitations of the flow cytometry data are that the results are only displayed for one 
experiment. This is similar to the Western blots and cytokine arrays performed later 
in the chapter. Single experiments do not take into account the potential for variation 
and do not confirm the reproducibility of the experiments. Despite this concern, the 
results of Western blots and cytokine arrays were replicated with LPS later in the 
chapter.  
 
A doubling of fluorescence signal on flow cytometry for TLR4 was noted after 
oxidative stress with hydrogen peroxide, in comparison to control conditions. This is 
probably due to variation (as opposed to up-regulation of TLR4) since there was no 
increase in TLR4 expression above the three negative control samples in either 
experiment. An additional limitation of this experiment was the lack of verification 
of the efficacy of hydrogen peroxide. In the next chapter a reduction in cell viability 
with hydrogen peroxide is demonstrated though. The experiments in the next chapter 
should also alleviate concerns that DMSO may be exerting toxicity in the 
experiments performed in this chapter, since there is no reduction in cell viability 
with DMSO [256]. This is in comparison to cells left in normal culture medium (i.e. 
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Chapter 4: AT13387 enables cellular survival 




In Chapter 3, it was shown that AT13387 repressed a pro-inflammatory signalling 
pathway that may be important in mediating kidney damage following renal IRI. 
Oxidative stress also leads to cell death and contributes to kidney injury following 
renal IRI [257, 258]. Hsp90 inhibition with 17-DMAG has previously been used to 
protect cells from oxidative stress and increase cell viability [84, 90]. However, it 
remains to be proven whether AT13387 is equally capable of protecting cells from 
oxidative stress. This chapter will address the hypothesis that AT13387 enables 
cellular survival following oxidative stress.  
 
4.2 Oxidative stress reduces cell viability 
 
Hydrogen peroxide is applied to in vitro models to investigate the oxidative stress 
responses of cells. When administered to cells at a high concentration (≥ 1 mM), 
hydrogen peroxide causes necrotic cell death [259]. The cytotoxic potency of 
hydrogen peroxide is dependent on the concentration of hydrogen peroxide used, the 
ability of the cells to eliminate hydrogen peroxide and the cell concentration [259]. 
Therefore to achieve greater consistency of results; initial hydrogen peroxide 
concentration finding experiments were performed in HEK293-TLR4 cells. The cells 
were split into 6-well plates for experimentation to make it easier to control the 
consistency of cell concentration across wells. In these initial experiments, 
incubation with hydrogen peroxide led to a dose-dependent decrease in cell viability 
in HEK293-TLR4 cells on crystal violet assay (Figure 4.1).  
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Figure 4.1 Cell viability determined by crystal violet assay following oxidative stress with 
hydrogen peroxide in HEK293-TLR4 cells 
HEK293-TLR4 cells were divided at a cell density of 500,000 cells in 2ml of growth medium per well 
of a 6-well plate. 24 h later, medium was changed and contained hydrogen peroxide at doses ranging 
from 0 mM to 1 mM. After 15 h incubation a crystal violet assay was performed to determine cell 
viability. Results are presented from 3 independent experiments in a standard boxplot with individual 
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4.3 Hsp90 inhibition increases cell viability following 
oxidative stress 
 
In a previous study, pre-treatment of renal adenocarcinoma cells with 17-DMAG 
protected cell viability in an in vitro model of oxidative stress involving hydrogen 
peroxide [84]. It was found on crystal violet assay in HEK293-TLR4 cells that 
following pre-treatment with AT13387 and 17-DMAG there was a significant 
increase in cell viability after incubation with hydrogen peroxide (AT13387 100 nM 
vs. DMSO vehicle, p<0.001, 17-DMAG 100 nM vs. DMSO vehicle, p<0.01, 
ANOVA). In addition, AT13387 was significantly more effective at increasing cell 
viability than 17-DMAG (AT13387 100 nM vs. 17-DMAG 100 nM, p<0.05, 
ANOVA) (Figure 4.2).  
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Figure 4.2 Crystal violet assay to determine cell viability following pre-treatment with AT13387 
or 17-DMAG and oxidative stress with hydrogen peroxide in HEK293-TLR4 cells 
HEK293-TLR4 cells were divided at a cell density of 500,000 cells in 2 ml of growth medium per 
well of a 6-well plate. 24 h later, cells were pre-treated with AT13387, 17-DMAG, DMSO vehicle or 
medium control for 3 h. The medium was then changed and contained hydrogen peroxide at 1 mM or 
medium control (DMSO 100 nM only and medium control only). Cells left in medium control for the 
duration of the experiment were considered 100% viable. After 15 h incubation a crystal violet assay 
was performed to determine cell viability, which was normalised to the 100% viable cells. Results are 
presented from 6 independent experiments in a standard boxplot with individual results jittered. 
Outlier data are highlighted by a dot with a diamond in the midline. *p<0.05 vs. 17-DMAG, **p<0.01 
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4.4 Summary 
 
In this chapter, AT13387 enabled cellular survival in an in vitro model involving a 
cellular insult with hydrogen peroxide. The results in this chapter therefore suggest 
that in common with other Hsp90 inhibitors, AT13387 may enable cellular survival 
following oxidative stress and at equivalent doses could actually be more effective 
than 17-DMAG in this respect.  
 




In this chapter, a crystal violet assay was selected for the measurement of cell 
viability. The strength of the assay was that it was cheap, had been established in the 
laboratory and provided consistent results [260]. The major disadvantage was that as 
a traditional end-point assay it only provided one static result. As such the crystal 
violet assay did not provide any real-time indication of the kinetic responses of the 
cells. A real-time assay would have provided more information about the biological 
status of the cells in terms of cell growth, senescence, morphological changes and 
apoptosis. An example of a more advanced assay that would provide this data is the. 
xCELLigence System (ACEA Biosciences, San Diego, CA).  
 
The experiments in this chapter were again performed in only one immortalized cell 
line; HEK293-TLR4 cells, and involved one type of cell insult. The major weakness 
of in vitro assays of this nature is that they oversimplify the complexity of IRI and 
evaluate isolated mechanisms of injury [17]. Indeed, oxidative stress is only one 
aspect of IRI, and there are various other cell culture models of renal IRI that could 
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supplement the results in this chapter, such as chemical insults and hypoxic injury 
using hypoxia or anaerobic chambers. Other common criticisms of in vitro assays 
include the use of non-representative cell lines (e.g. cancer cells and non-human 
cells), and the inability to assess the impact of systemic factors (e.g. cellular 
infiltration). Developing methods of differentiating human kidney cells from stem 
cells, adopting co-culture models to evaluate cellular interactions and assessing the 




The effect of hydrogen peroxide is known to depend not only on the concentration of 
hydrogen peroxide used, but also the cell concentration [259]. For the experiments in 
this chapter, the cells were split into 6-well plates for experimentation to make it 
easier to control the consistency of cell concentration across wells. As a result the 




In the medium control samples there was a consistent level of cell death following 
the addition of 1 mM of hydrogen peroxide between the two experiments performed 
in this chapter. Therefore the results are considered consistent and reproducible in the 
cell line that was selected. It would be of interest to assess the reproducibility of the 
results in other assays, and in different cell lines.  
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Chapter 5: AT13387 leads to induction of renal 




In Chapter 4, it was shown in an in vitro model that Hsp90 inhibition with AT13387 
enabled cellular survival following oxidative stress. However, other potential cellular 
and molecular mechanisms of protection from renal IRI offered by Hsp90 inhibitors 
remain to be fully delineated. Defining these is essential for their further 
development and translation to patients. As discussed in Chapter 1, Hsp90 inhibitors 
block the ATP-binding site of Hsp90, which releases HSF1 from a repressive multi-
chaperone complex involving Hsp90, allowing it to translocate to the cell nucleus 
and up-regulate Hsp70 [121]. Hsp70 induction is strongly associated with protection 
from renal IRI [118]. In previous studies, Balb/c mice and Balb/c SCID mice have 
been shown to increase renal Hsp70 expression following Hsp90 inhibition with 17-
DMAG [84, 263]. This chapter will address the hypothesis that AT13387 leads to 
induction of renal Hsp70 in mice, including FVB/n mice.  
 
5.2 AT13387 increases Hsp70 expression in the 
kidney of FVB/n mice 
 
AT13387 increased renal Hsp70 levels on ELISA in FVB/n mice 6 h following 
treatment (AT13387 vs. 2HβC vehicle, p<0.005, t-test) (Figure 5.1) and at 24 h renal 
Hsp70 levels remained significantly elevated (AT13387 vs. 2HβC vehicle, p<0.001, 
t-test) (Figure 5.2). Immunohistochemistry showed that in comparison to vehicle 
treatment, Hsp70 induction following AT13387 treatment was strongest in the outer 
stripe of the outer medulla of the kidney and was noted predominantly within renal 
tubular cells (Figure 5.3 and Figure 5.4).  
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Figure 5.1 Renal Hsp70 expression following AT13387 or vehicle treatment on ELISA in FVB/n 
mice 
FVB/n mice were treated with AT13387 or 2HPβC vehicle (n=3 per group) 6 h prior to kidney 
harvest. Whole-organ lysates were prepared and analysed by an ELISA for Hsp70. Results are 
presented in a standard boxplot with individual results jittered. **p<0.005 vs. 2HβC vehicle, t-test. 
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Figure 5.2 Renal Hsp70 expression following AT13387 or vehicle pre-treatment in the control 
kidney on ELISA in FVB/n mice 
Mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy and 20 min of left renal pedicle clamping. Following 
removal the right (control) kidney was frozen. Whole-organ lysates were later prepared and analysed 
by an ELISA for Hsp70. Data are displayed for n=8 (instead of 9) in the vehicle group due to a failure 
processing one control kidney for analysis. Results are presented in a standard boxplot with individual 
results jittered. Outlier data are highlighted by a dot with a diamond in the midline. ***p<0.001 vs. 
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Figure 5.3 Renal Hsp70 expression following vehicle treatment in the outer stripe of the outer 
medulla of the kidney on immunohistochemistry in FVB/n mice 
FVB/n mice were treated with 2HPβC vehicle (n=3) 6 h prior to kidney harvest. Sections were later 
prepared and stained with an antibody to Hsp70. A representative section of the outer stripe of the 
outer medulla of the kidney at x 100 magnification is shown. There is minimal positive brown staining 
for Hsp70. 
 
Figure 5.4 Renal Hsp70 expression following AT13387 treatment in the outer stripe of the outer 
medulla of the kidney on immunohistochemistry in FVB/n mice 
FVB/n mice were treated with AT13387 (n=3) 6 h prior to kidney harvest. Sections were later 
prepared and stained with an antibody to Hsp70. A representative section of the outer stripe of the 
outer medulla of the kidney at x 100 magnification is shown. There is positive brown staining for 
Hsp70 evident in the renal tubular cells. 
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5.3 AT13387 increases Hsp70 expression in the 
kidney of Balb/c and Balb/c SCID mice 
 
In comparison to pre-treatment with vehicle, equivalent levels of renal Hsp70 
induction on ELISA were observed in Balb/c and Balb/c SCID mice 24 h following 
pre-treatment with AT13387 (AT13387 vs. 2HβC vehicle, p<0.001, t-test) (Figure 
5.5).  
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Figure 5.5 Renal Hsp70 expression following AT13387 or vehicle pre-treatment in the control 
kidney on ELISA in Balb/c and Balb/c SCID mice 
Mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy and 30 min of left renal pedicle clamping. Following 
removal the right (control) kidney was frozen. Whole-organ lysates were later prepared and analysed 
by an ELISA for Hsp70. Results are presented in a standard boxplot with individual results jittered. 
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5.4 Summary 
 
The results in this chapter show that similar to treatment with 17-DMAG, AT13387 
treatment leads to an increase in renal Hsp70 expression in Balb/c and Balb/c SCID 
mice [84, 263]. AT13387 also leads to the induction of renal Hsp70 in FVB/n mice, 






Assessing for the induction or inhibition of a molecule of interest, is particularly 
important when using drugs prophylactically prior to the onset of IRI, since it 
ensures adequate dosing and administration of the protective agent [238] The 
strengths of the data presented in this chapter are that there was uniform up-
regulation of Hsp70 in each experiment, and also across different strains of mice. 
The results of the ELISA were consistent between experiments, and were also 
validated using immunohistochemistry. Hsp70 is the most commonly used biomarker 
of Hsp90 inhibition so this data suggests a consistent effect of AT13387 after 24 h of 
administration [264]. The weaknesses of this data are the limited sample size (n=3) 
used in the experiment that assessed Hsp70 levels 6 h after AT13387 treatment. This 
experiment was performed to give some preliminary data regarding the onset of 
Hsp90 inhibition with AT13387. A fuller time course experiment could provide 
additional data on the kinetics of Hsp90 inhibition with AT13387, but was 
considered beyond the scope of this chapter, as the intention was to treat mice 24 h 
before renal IRI.  
 
 
Chapter 5 - Results  128 
5.5.2 Variability 
 
The results presented in this chapter were consistent. A large factor in this 
consistency was the simplicity of the experiments. The ELISAs were performed on 
uninjured control kidneys following either organ harvest of nephrectomy. Despite 
this, certain mice did appear to have greater up-regulation of Hsp70 than others. 
Indeed, one outlier was noted in the FVB/n group treated with AT13387, but this was 




There are no significant issues with the reproducibility of the data presented in this 
chapter. Indeed, the up-regulation of Hsp70 in Balb/c SCID mice is further replicated 
in Chapter 8.  
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Chapter 6: AT13387 pre-treatment results in 
functional and morphological protection from 




In Chapter 3, Hsp90 inhibition repressed pro-inflammatory signalling pathways that 
may be important in renal IRI. Then in Chapter 4, Hsp90 inhibition protected cells 
from oxidative stress, which is a known consequence of renal IRI [257]. As 
previously described in Chapter 1, reducing IRI is vital to achieving better outcomes 
in renal transplantation. It has previously been demonstrated that functional and 
morphological protection from renal IRI in mice follows pre-treatment with the 
Hsp90 inhibitors geldanamycin and the geldanamycin-analogues 17-AAG and 17-
DMAG [84]. 17-DMAG is the most effective of these agents at reducing renal IRI, 
and being water-soluble it is easier to administer both intravenously and orally [83, 
84]. However, patients poorly tolerate all these older Hsp90 inhibitors. AT13387 has 
a low toxicity profile in phase II human studies in oncology and should be better 
tolerated by patients [99, 100]. This chapter will investigate whether there is 
protection from renal IRI in mice following AT13387 pre-treatment. This chapter 
therefore addresses the hypothesis that AT13387 pre-treatment results in functional 
and morphological kidney protection from renal IRI. Injured kidneys are also 
assessed to evaluate if AT13387 pre-treatment reduces renal TLR4 expression and 
NF-ҡB activation following renal IRI 
 
6.2 Establishing a renal IRI model in FVB/n mice 
 
In Chapter 5, it was shown that AT13387 induces renal Hsp70 expression across 
different strains of mice including those on an FVB/n background. FVB/n mice were 
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available from in-house colonies for use in this thesis. In a previous study utilising 
the model of IRI described in this thesis, a renal pedicle clamp time of 30 minutes 
was used to inflict moderate to severe acute tubular injury in Balb/c mice [84]. 
However, in a further study using the same model in FVB/n mice, a clamp time of 20 
minutes was utilised, thus suggesting a strain-dependent difference in the tolerance 
of these mice to renal IRI [265]. Given these potential differences in ischemic 
tolerance, an initial model-establishing experiment, testing clamp times of 20 
minutes and 25 minutes was performed in FVB/n mice. The former was found to be 
sufficient to induce renal IRI, as determined by a rise in serum creatinine, 
comparable to that observed in these previous publications (Figure 6.1) [84, 265].  
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Figure 6.1 Serum creatinine 24 h following renal IRI in FVB/n mice 
FVB/n mice were anaesthetised and underwent right nephrectomy and 20 or 25 min of left renal 
pedicle clamping (n=3-4 per group). Control mice (n=4) did not undergo renal pedicle clamping (i.e. 
clamp time 0 minutes). Following 24 h of recovery, blood was obtained by intra-cardiac puncture and 
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6.3 AT13387 pre-treatment reduces functional and 
morphological kidney injury following renal IRI in 
FVB/n mice 
 
On serum analysis, in comparison to vehicle, AT13387 pre-treatment in FVB/n mice 
significantly reduced creatinine 24 h following renal IRI (AT13387 vs. 2HβC 
vehicle, p<0.05, t-test) (Figure 6.2). AT13387 pre-treatment in FVB/n mice also 
reduced tubular necrosis score (AT13387 vs. 2HβC vehicle, p<0.05, Mann-Whitney 
U test) (Figure 6.3) on histological assessment 24 h following renal IRI (Figure 6.4 
and Figure 6.5). 
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Figure 6.2 Serum creatinine following AT13387 or vehicle pre-treatment and 24 h following 
renal IRI in FVB/n mice 
FVB/n mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy and 20 min of left renal pedicle clamping. Following 
24 h of recovery, blood was obtained by intra-cardiac puncture and serum creatinine was determined. 
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Figure 6.3 Tubular necrosis score following AT13387 or vehicle pre-treatment and 24 h 
following renal IRI in FVB/n mice 
FVB/n mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy and 20 min of left renal pedicle clamping. Following 
24 h of recovery, the left kidney was harvested and placed in methacarn. Sections were later prepared 
and stained with haematoxylin and eosin. A blinded observer then determined the tubular necrosis 
score. Results are presented as mean and standard error of the mean. *p<0.05 vs. 2HβC vehicle, 
Mann-Whitney U test. 
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Figure 6.4 Morphological kidney injury following pre-treatment with vehicle and 24 h following 
renal IRI in FVB/n mice 
FVB/n mice were pre-treated with 2HβC vehicle (n=9). 24 h later, mice were anaesthetised and 
underwent right nephrectomy and 20 min of left renal pedicle clamping. Following 24 h of recovery, 
the left kidney was harvested and placed in methacarn. Sections were later prepared and stained with 
haematoxylin and eosin. A representative section of kidney cortex at x 200 magnification is shown. 
There are detached necrotic cells evident.  
 
Figure 6.5 Morphological kidney injury following pre-treatment with AT13387 and 24 h 
following renal IRI in FVB/n mice 
FVB/n mice were pre-treated with AT13387 (n=9). 24 h later, mice were anaesthetised and underwent 
right nephrectomy and 20 min of left renal pedicle clamping. Following 24 h of recovery, the left 
kidney was harvested and placed in methacarn. Sections were later prepared and stained with 
haematoxylin and eosin. A representative section of kidney cortex at x 200 magnification is shown. 
Only minimal tubular dilatation is observed.  
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6.4 AT13387 pre-treatment reduces the expression of 
TLR4 and inflammatory chemokines in the kidney 
following renal IRI 
 
On PCR analysis, in comparison to vehicle, AT13387 pre-treatment in FVB/n mice 
significantly reduced renal TLR4 expression 24 h following renal IRI (AT13387 vs. 
Vehicle, p<0.01, Mann-Whitney U test) (Figure 6.6). On cytokine array panel, in 
comparison to vehicle, AT13387 pre-treatment in FVB/n mice also reduced renal 
expression of chemokine (C-X-C motif) ligand 1 (CXCL1) and chemokine (C-X-C 
motif) ligand 2 (CXCL2) 24 h following renal IRI (AT13387 vs. 2HβC vehicle, 
p<0.05, t-test) (Figure 6.7). There were no other significant differences in cytokine or 
chemokine expression.  
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Figure 6.6 Renal TLR4 expression following AT13387 or vehicle pre-treatment and 24 h 
following renal IRI in FVB/n mice 
FVB/n mice were pre-treated with AT13387 or 2HβC vehicle (n=6 per group) and underwent renal 
IRI as per figure 6.2. The left kidney was harvested and stored in RNAlater for 24 h before being 
frozen. RNA was later extracted and converted to cDNA. PCR was then performed to determine 
TLR4 expression. TLR4 expression was normalised to GAPDH expression. Results are presented in a 
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Figure 6.7 Renal cytokine expression following AT13387 or vehicle pre-treatment and 24 h 
following renal IRI in FVB/n mice 
FVB/n mice were pre-treated with AT13387 or 2HβC vehicle (n=4 per group) and underwent renal 
IRI as per figure 6.2. Following 24 h of recovery, the left kidney was harvested and snap frozen. 
Protein lysates were later prepared and an array panel was used to determine cytokine expression. The 
grid describes the cytokines assessed (right panel). A representative array is shown (upper left panel). 
Mean gray values were quantified using Image J and were used to reflect CXCL1 and CXCL2 
expression. Results are presented in a standard boxplot with individual results jittered (lower left 
panel). *p<0.05 vs. 2HβC vehicle, t-test. 
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6.5 Summary 
 
In this chapter, pre-treatment with AT13387 was found to significantly reduce serum 
creatinine and tubular necrosis following renal IRI. This chapter has therefore 
confirmed that similar to previous reports of the protective effect of Hsp90 inhibition 
in renal IRI [84, 85], AT13387 pre-treatment in mice results in functional and 
morphological protection of the kidney. CXCL1 and CXCL2 are NF-ҡB target 
genes, and the expression of these pro-inflammatory chemokines is NF-ҡB 
dependent [266, 267]. The expression of CXCL1 and CXCL2 in the kidney was 
reduced following renal IRI in mice pre-treated with AT13387. There was also a 
significant reduction in renal TLR4 expression.  
 




Murine models of IRI typically involve a warm ischemic period of variable duration 
induced by temporary clamping of the blood supply to the kidneys [238]. Adjusting 
the clamp time appropriately titrates the level of injury so that acute tubular necrosis 
occurs in the kidney but without animal suffering or mortality. Establishing a suitable 
clamp time is a challenge and can be dependent on the mouse strain [268]. Therefore 
an initial injury titration experiment was performed at the outset of the work 
involving FVB/n mice. This was across a limited sample size but was sufficient to 
determine a suitable clamp time to cause an acute rise in serum creatinine but 
without animal mortality. This was imperative since experiments that utilise survival 
as an endpoint introduce various confounding factors, such as hyperkalemia [17].  
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In these experiments, a unilateral kidney ischemia and contra-lateral nephrectomy 
model was preferred to a bilateral ischemia model, as the nephrectomy specimen 
allowed for confirmation and quantification of AT13387 activity via Hsp70 
induction in kidney tissue at the time of surgery in each individual experimental 
animal. A single injured kidney is also closer to the clinical scenario of an injured 
kidney graft in a renal transplant recipient with no other functional nephron mass. 
While it is appreciated that a similar experiment can be performed in a bilateral 
ischemia model, using sham mice to confirm adequate dosing, this does not fully 
exclude inadequate dosing (e.g. from a misplaced injection) in the experimental 
animals that are being used to determine the primary outcome measure. Another 
concern is that in the bilateral ischemia model there is a small but inevitable time lag 
period between clamping the kidney on the contra-lateral side. An absence of sham-
operated mice in the experiments in this chapter is a potential weakness, but can be 
justified by the fact this is an established model, and these sham experiments have 
previously been performed [84, 238]. In terms of tubular necrosis score, this is a 
more subjective outcome measure than serum creatinine, which is objectively 
determined. The use of only one blinded observer was a further weakness, and 
ideally at least two observers should be used (one of which is a renal pathologist). 
Although, given the simplicity of the tubular necrosis score adopted, it is felt unlikely 




Serum creatinine, 24 h after surgery, was assessed and while there was a significant 
reduction in mice treated with AT13387, there were mice in the AT13387 group that 
appeared more protected than others. This is not explained by surgery being 
performed on different days, or on different types of mice, as all were from same 
colony. It is essential to reduce variability in the IRI model by minimising blood loss 
and controlling temperature carefully, and this spread of data may have been the 
result of technical issues during the earlier part of the experimental learning curve 
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[269]. There is also a plateau in the level of injury with increasing clamp times, 
which leads to a more consistent level of injury when the severity is increased. 
Therefore it is equally possible that the level of injury induced by 20 minutes of 
clamping was not on the plateau, and was at a highly modifiable level in terms of 
serum creatinine reduction. Performing bilateral clamping could potentially have 
reduced variability, as it is a simpler model to perform. Furthermore, it would be 
interesting to assess additional markers of kidney function, such as glomerular 
filtration rate to see whether there is similar variation. Other markers of kidney 
injury, such as kidney injury molecule-1, and senescence (e.g. p16 and p21) could 




In the next chapter the protective effect of AT13387 is replicated in Balb/c mice. 
However, the assessment of injury at only one time point 24 h after surgery means 
that there is a possibility that AT13387 may be simply delaying the onset of kidney 
injury. This issue could be addressed in further experiments with a longer recovery 
period. The potential for ‘real-time’ measurement of glomerular filtration rate in 
animals using intravascular optical technology could be another exciting future 
opportunity in this context, as it would provide immediate and on-going information 
about renal function after surgery [272, 273].  
 
TLR4 expression in kidneys injured by IRI was assessed by real-time PCR. A 
significant reduction in TLR4 expression was identified following AT13387 pre-
treatment. The NF-κB activation status of kidneys injured by IRI in each group was 
also assessed in further experiments by cytokine array. The arrays showed a 
significant reduction in the expression of the NF-κB-dependent chemokines CXCL1 
and CXCL2 following AT13387 pre-treatment [266, 267]. This suggests an anti-
inflammatory effect of AT13387, and the data is complementary to the in vitro 
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results reported in Chapter 3. However, at just 24 hours following renal IRI, it is 
likely that protective effect of AT13387 may have involved programmed cell death 
rather than inflammation [43]. As such, the causality of the reduction in TLR4 and 
NF-κB expression in the protective effect of AT13387 cannot be assumed from this 
data. Indeed, the possibility remains that reduced TLR4 and NF-κB expression are 
simply additional “read outs” of less damage to the kidney. Nevertheless, it has 
previously been identified that following renal IRI, there is increased expression of 
CXCL1 and CXCL2. In addition, treatment with neutralizing antibodies to both 
CXCL1 and CXCL2 significantly improves kidney function within 48 hours of renal 
IRI [274]. Therefore another area of research worth pursuing is the further 
development of Hsp90 inhibition with AT13387 to establish the relevance in vivo of 
repressing TLR4-mediated NF-ҡB activation in renal IRI. This could potentially be 
achieved through the use of TLR4-/- mice, and is discussed further in Chapter 10. 
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Chapter 7: The protection afforded from renal 




In Chapter 5, it was shown that AT13387 induced Hsp70 expression in the kidney of 
mice. It has previously been observed that renal Hsp70 induction is associated with 
protection from kidney injury as a result of renal IRI [118]. In keeping with this 
observation, in Chapter 6, AT13387 pre-treatment resulted in functional and 
morphological kidney protection from renal IRI. It has recently been reported in the 
context of heat preconditioning that the protective effect of Hsp70 up-regulation in 
renal IRI is lymphocyte-dependent [224]. Consequently, it is predicted that an Hsp70 
inducing candidate drug such as AT13387, could similarly reduce renal IRI by 
modulating lymphocyte behaviour. This chapter addresses the hypothesis that the 
protection afforded from renal IRI by AT13387 is lymphocyte-dependent.  
 
7.2 AT13387 reduces renal IRI in Balb/c mice but not 
Balb/c SCID mice 
 
Balb/c SCID mice lack adaptive immunity due to a deficiency of mature B and T 
lymphocyte cells in the peripheral blood and lymphoid organs [275]. Balb/c and 
Balb/c SCID mice were therefore used to assess the influence of lymphocytes on the 
effect of AT13387 pre-treatment on kidney injury following renal IRI. Compared to 
pre-treatment with vehicle, AT13387 pre-treatment in Balb/c mice significantly 
reduced serum creatinine 24 h following renal IRI (AT13387 vs. 2HβC vehicle, 
p<0.05, t-test) (Figure 7.1). AT13387 pre-treatment in Balb/c mice also reduced 
tubular necrosis score (AT13387 vs. 2HβC vehicle, p<0.05, Mann-Whitney U test) 
(Figure 7.2) on histological assessment 24 h following renal IRI (Figure 7.3 and 
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Figure 7.4). However, pre-treatment with AT13387 in Balb/c SCID mice, did not 
significantly alter serum creatinine in comparison to vehicle pre-treatment 24 h 
following renal IRI (AT13387 vs. 2HβC vehicle, p=0.18, t-test) (Figure 7.1). 
AT13387 pre-treatment in Balb/c SCID mice also did not reduce tubular necrosis 
score on histological assessment 24 h following renal IRI (AT13387 vs. 2HβC 
vehicle, p=0.10, Mann-Whitney U test). At 24 h following renal IRI, vehicle treated 
Balb/c mice had significantly lower serum creatinine levels than vehicle treated 
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Figure 7.1 Serum creatinine following AT13387 or vehicle pre-treatment and 24 h following 
renal IRI in Balb/c and Balb/c SCID mice 
Balb/c and Balb/c SCID mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h 
later, mice were anaesthetised and underwent right nephrectomy and 30 min of left renal pedicle 
clamping. Following 24 h of recovery, blood was obtained by intra-cardiac puncture and serum 
creatinine was determined. Data are displayed for n=8 (instead of 9) in the Balb/c vehicle group 
because of one intra-operative clamp failure, and n=8 (instead of 9) in the Balb/c SCID AT13387 
group because of one inadequate serum sample. Results are presented in a standard boxplot with 
individual results jittered. Outlier data are highlighted by a dot with a diamond in the midline. ^p<0.05 
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Figure 7.2 Tubular necrosis score following AT13387 or vehicle pre-treatment and 24 h 
following renal IRI in Balb/c mice 
Balb/c mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy and 30 min of left renal pedicle clamping. Following 
24 h of recovery, the left kidney was harvested and placed in methacarn. Sections were later prepared 
and stained with haematoxylin and eosin. A blinded observer then determined the tubular necrosis 
score. Data are reported for n=8 (instead of 9) in the vehicle group because of one intra-operative 
clamp failure. Results are presented as mean and standard error of the mean. *p<0.05 vs. 2HβC 
vehicle, Mann-Whitney U test. 
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Figure 7.3 Morphological kidney injury following pre-treatment with vehicle and 24 h following 
renal IRI in Balb/c mice 
Balb/c mice were pre-treated with 2HβC vehicle (n=9). 24 h later, mice were anaesthetised and 
underwent right nephrectomy and 30 min of left renal pedicle clamping. Following 24 h of recovery, 
the left kidney was harvested and placed in methacarn. Sections were later prepared and stained with 
haematoxylin and eosin. A representative section of kidney cortex at x 200 magnification is shown. 
There are areas of tubular necrosis and significant tubular cell damage. 
 
Figure 7.4 Morphological kidney injury following pre-treatment with AT13387 and 24 h 
following renal IRI in Balb/c mice 
Balb/c mice were pre-treated with AT13387 (n=9). 24 h later, mice were anaesthetised and underwent 
right nephrectomy and 30 min of left renal pedicle clamping. Following 24 h of recovery, the left 
kidney was harvested and placed in methacarn. Sections were later prepared and stained with 
haematoxylin and eosin. A representative section of kidney cortex at x 200 magnification is shown. 
There is evidence of tubular dilatation and loss of epithelial brush borders but less necrosis than in the 
vehicle treated mice. 
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7.3 Tregs in the spleen following AT13387 treatment 
 
In the study by Kim et al. (2014), which was discussed in Chapter 1, heat 
preconditioning increased the number of splenic Tregs [224]. In the experiments 
performed here, Tregs were identified on immunohistochemistry in the spleen in 
both vehicle and AT13387 treated Balb/c mice (Figure 7.5 and Figure 7.6) but there 
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Figure 7.5 Foxp3 expression on immunohistochemistry in the spleen of Balb/c mice following 
vehicle treatment 
Balb/c mice were treated with 2HPβC vehicle (n=3). 24 h later, mice were anaesthetised, and the 
spleen was harvested and placed in methacarn. Sections were later prepared and stained with an 
antibody to Foxp3. A representative section of the spleen at x 400 magnification is shown. Positive 




Figure 7.6 Foxp3 expression on immunohistochemistry in the spleen of Balb/c mice following 
AT13387 treatment 
Balb/c mice were treated with AT13387 (n=4). 24 h later, mice were anaesthetised, and the spleen was 
harvested and placed in methacarn. Sections were later prepared and stained with an antibody to 
Foxp3. A representative section of the spleen at x 400 magnification is shown. Positive brown staining 
Tregs are evident. 
 




Figure 7.7 Splenic Foxp3 expression on immunohistochemistry following AT13387 or vehicle 
treatment in Balb/c mice  
Balb/c mice were treated with AT13387 or 2HPβC vehicle (n=3-4 per group). 24 h later, mice were 
anaesthetised, and the spleen was harvested and placed in methacarn. Sections were later prepared and 
stained with an antibody to Foxp3. The average amount of Foxp3+ cells across five non-overlapping 
random high-powered fields per slide was counted by a blinded observer. Results are presented as 
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7.4 T-lymphocytes in the kidney following renal IRI 
 
In the study by Kim et al. (2014), increased numbers of Tregs were also detected by 
flow cytometry in enzyme-dissociated kidneys following renal IRI compared with 
sham kidneys, indicating localisation of Tregs to the injured kidney. However, 
following IRI in these experiments, there were no Tregs identified within the injured 
kidney in either group at 24 h following renal IRI on immunohistochemistry. Since it 
has been shown elsewhere that NF-ҡB plays a key role in T cell activation, and T 
cell-specific NF-ҡB inhibition provides protection against renal IRI, injured kidneys 
were also assessed for T-lymphocytes [276]. T-lymphocytes were identified on 
immunohistochemistry in the injured kidney in both vehicle and AT13387 pre-
treated Balb/c mice (Figure 7.8 and Figure 7.9). Again there was no significant 
difference in the number of cells identified between experimental groups (Figure 
7.10).  
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Figure 7.8 Renal CD3 expression on immunohistochemistry following vehicle pre-treatment and 
24 h following renal IRI in Balb/c mice 
Balb/c mice were pre-treated with 2HPβC vehicle (n=9). 24 h later, mice were anaesthetised and 
underwent right nephrectomy and 30 min of left renal pedicle clamping. Following 24 h of recovery, 
the left kidney was harvested and placed in methacarn. Sections were later prepared and stained with 
an antibody to CD3. A representative section of the cortex of the kidney at x 400 magnification is 
shown. Positive brown staining T-lymphocytes are evident. 
 
Figure 7.9 Renal CD3 expression on immunohistochemistry, following AT13387 pre-treatment 
and 24 h following renal IRI in Balb/c mice 
Balb/c mice were pre-treated with AT13387 (n=9). 24 h later, mice were anaesthetised and underwent 
right nephrectomy and 30 min of left renal pedicle clamping. Following 24 h of recovery, the left 
kidney was harvested and placed in methacarn. Sections were later prepared and stained with an 
antibody to CD3. A representative section of the cortex of the kidney at x 400 magnification is shown. 
Positive brown staining T-lymphocytes are evident. 
 




Figure 7.10 Renal CD3 expression on immunohistochemistry following AT13387 or vehicle pre-
treatment and 24 h following renal IRI in Balb/c mice  
Balb/c mice were pre-treated with AT13387 or 2HPβC vehicle (n=9 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy and 30 min of left renal pedicle clamping. Following 
24 h of recovery, the left kidney was harvested and placed in methacarn. Sections were later prepared 
and stained with an antibody to CD3. A blinded observer selected three random samples per group, 
and the average amount of CD3+ cells across five non-overlapping random high-powered fields per 
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7.5 Summary         
  
In this chapter, AT13387 protected kidney function and morphology from renal IRI 
in Balb/c mice but not Balb/c SCID mice. These two groups of mice are strain 
matched so the only difference between them should be a lack of an adaptive 
immune response in the SCID mice. The results of the experiments in this chapter 
therefore suggest that the protective effect of AT13387 involves the adaptive 
immune system. This would indicate that the protective effect of AT13387 is at least 
partially lymphocyte-dependent. However, from the immunohistochemical staining 
performed, it is currently unclear whether there is Treg or T-lymphocyte 
involvement, as previously hypothesised on the basis of previous work in this area 
using heat preconditioning [224].  
 




In the experiments in this chapter Balb/c SCID suffered more severe kidney 
dysfunction following renal IRI than wild-type Balb/c mice. Following renal IRI the 
absence of B and T cells has previously been shown to lead to both renal protection 
[213], and a similar kidney injury to wild type controls [214, 215]. These previous 
experiments were performed in RAG-1-/- mice as opposed to SCID mice, and also 
utilised a bilateral ischemia model [213-215]. It is possible that the SCID mice 
tolerate the unilateral IRI model poorly and suffer worse injury. Further experiments 
ideally without treatment or vehicle should be performed to clarify this difference 
between Balb/c and Balb/c SCID in terms of tolerance of renal IRI.  
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While the immunohistochemistry performed did not identify any differences in T-
cell or Treg numbers, this was only preliminary data that was performed on a 
relatively small number of wild-type mice. The data should therefore be cautiously 
interpreted, and the sample size of these experiments should be increased. In 
addition, flow cytometry of blood, spleen and kidneys of wild-type mice should be 
performed to further elucidate differences in lymphocyte responses following 
AT13387 treatment. Compared to immunohistochemistry, flow cytometry could also 
provide more quantitative information on the cell numbers, as well as being more 
sensitive at detecting cells expressed in relatively low numbers (e.g. Tregs in the 
kidney) [224]. However, it wouldn’t provide detailed information regarding the 




Less in-group variability was noted for serum creatinine in the renal IRI experiment 
performed in this chapter, compared to the experiment performed with FVB/n mice 
in Chapter 6. This may reflect the fact the experiments were performed after the 
initial experimental learning curve, with less blood loss and better control of 
temperature [269]. As previously mentioned there is also a plateau in the level of 
injury with increasing clamp times, which leads to a more consistent level of injury. 
Therefore it is equally possible that the level of injury induced by 30 minutes of renal 
pedicle clamping, as performed in this chapter, compared to 20 minutes in the last 
chapter, was on the plateau and therefore less variable. The higher serum creatinine 
and tubular necrosis scores in this chapter, compared to Chapter 6, would support 
this theory. Despite this, there did seem again to be some mice that responded more 
to AT13387 than others in the Balb/c group. This cannot be explained by 
performance of surgery on different days, or on different types of mice, as all were 
from same provider. As previously mentioned, it would be interesting to assess for 
variation in other markers of kidney function and injury, such as glomerular filtration 
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rate and kidney injury molecule-1, [270]. Of similar interest would be the levels of 




In this chapter, the overall pattern of results of the protective effect of AT13387 in 
Balb/c mice was similar to that seen in the FVB/n mice in Chapter 6. The pattern of 
the results of the SCID mouse experiment is also replicated in the next chapter, but a 
longer clamp time (32 minutes) is used in the model. This reflects good 
reproducibility of experimental data within the thesis. However, the lack of a 
protective phenotype in SCID mice is at odds with a previous abstract publication by 
Ferenbach et al. (2012) [277]. The possible reasons for this discrepancy are 
discussed further in Chapter 10.   
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Chapter 8: AT13387 reduces lung injury 




Secondary lung injury is a known consequence of renal IRI [278]. In Chapter 6 and 
7, it was demonstrated that AT13387 pre-treatment leads to functional and 
morphological protection from renal IRI in FVB/n and Balb/c mice. There could be 
further systemic benefit of AT13387 treatment by inducing Hsp70 in the lungs of 
mice in order to reduce secondary lung injury. The kidney protective effect of 
AT13387 was previously shown in Chapter 7 to be at least partially lymphocyte-
dependent, as AT13387 failed to reduce kidney injury following renal IRI in Balb/c 
SCID mice. It was therefore considered possible to provide the same level of kidney 
injury from renal IRI to induce secondary lung injury despite AT13387 pre-treatment 
by using Balb/c SCID mice in a further renal IRI experiment. The experiments in this 
chapter were performed in conjunction with Duncan Humphries (performed BAL, 
lung digestion and cytometric analysis) and Ewen Harrison (performed the 
experiments in Figure 8.1 and Figure 8.2). 
 
8.2 Renal IRI causes secondary lung injury 
 
This paragraph contains data that will be reported in Duncan Humphries’ thesis. 
Compared to intervention naive control Balb/c mice, there was no increase in lung 
injury, in terms of interstitial neutrophil accumulation on flow cytometry of digested 
lungs or on BAL analysis in Balb/c mice undergoing sham laparotomy or 
nephrectomy only. In addition, compared to control, sham and nephrectomy only 
groups, on BAL analysis, cell counts were similar in both Balb/c and Balb/c SCID 
mice undergoing renal IRI. However, in comparison to control mice, 24 h following 
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renal IRI in both Balb/c and Balb/c SCID mice, there was a significant increase in 
interstitial neutrophil accumulation on flow cytometry of digested lungs (Balb/c vs. 
control, p<0.05, Balb/c SCID vs. control, p<0.01, t-test), as well as an increase in 
pulmonary haemorrhage on BAL analysis (Balb/c vs. control, p<0.05, Balb/c SCID 
vs. control, p<0.05, t-test). These findings confirm that renal IRI, using the model 
described in this thesis, causes secondary lung injury in Balb/c and Balb/c SCID 
mice.  
 
8.3 AT13387 increases Hsp70 expression in the lung 
 
AT13387 treatment resulted in a significant dose dependent increase in Hsp70 within 
the lungs on ELISA 6 h following treatment (AT13387 vs. 2HβC vehicle, p<0.05, 
ANOVA) (Figure 8.1). Levels of Hsp70 remained elevated in the lungs 24 h 
following AT13387 treatment (AT13387 vs. 2HβC vehicle, p<0.05, t-test) (Figure 
8.2). 
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Figure 8.1 Hsp70 expression in the lung 6 h following AT13387 or vehicle treatment on ELISA 
in Balb/c mice 
Balb/c mice were treated with AT13387 (20-80 mg/kg) or 2HPβC vehicle 6 h prior to organ harvest 
(n=2-3 per group). Whole-organ lysates were prepared and analysed by an ELISA for Hsp70. Results 
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Figure 8.2 Hsp70 expression in the lung up to 24 h following AT13387 or vehicle treatment on 
ELISA in Balb/c mice 
Balb/c mice were pre-treated with AT13387 or 2HPβC vehicle at 4, 6, 8, 16 and 24 h prior to organ 
harvest (n=2-3 per group). Whole-organ lysates were prepared and analysed by an ELISA for Hsp70. 
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8.4 Establishing the model for assessing lung injury 
following pre-treatment with AT13387 and renal 
IRI  
 
An experimental model was then established using Balb/c SCID mice to assess 
whether AT13387 could reduce secondary lung injury following renal IRI. The renal 
pedicle clamp time for this experiment was extended to 32 minutes to maximise renal 
IRI and thus secondary lung injury. In comparison to pre-treatment with vehicle, 
significant renal Hsp70 induction on ELISA was again observed in Balb/c SCID 
mice 24 h following pre-treatment with AT13387 (AT13387 vs. 2HβC vehicle, 
p<0.001, t-test) (Figure 8.3). Compared to vehicle pre-treatment, pre-treatment with 
AT13387 again did not significantly alter levels of serum creatinine 24 h following 
renal IRI in Balb/c SCID mice (AT13387 vs. 2HβC vehicle, p=0.47, t-test) (Figure 
8.4). In addition, compared to vehicle pre-treatment, on BAL analysis, cell counts 
were similar with AT13387 pre-treatment 24 h following renal IRI in Balb/c SCID 
mice (Figure 8.5). 
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Figure 8.3 Renal Hsp70 expression following AT13387 or vehicle pre-treatment in the control 
kidney on ELISA in Balb/c SCID mice 
Mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy and 32 min of left renal pedicle clamping. Following 
removal the right (control) kidney was frozen. Whole-organ lysates were later prepared and analysed 
by an ELISA for Hsp70. Results are presented in a standard boxplot with individual results jittered. 
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Figure 8.4 Serum creatinine following AT13387 or vehicle pre-treatment and 24 h following 
renal IRI in Balb/c SCID mice 
Balb/c SCID mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice 
were anaesthetised and underwent right nephrectomy and 32 min of left renal pedicle clamping. 
Following 24 h of recovery, blood was obtained by intra-cardiac puncture and serum creatinine was 
determined. Data are displayed for n=8 (instead of 9) in the AT13387 group because of one post-
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Figure 8.5 BAL cell count following AT13387 or vehicle pre-treatment and 24 h following renal 
IRI in Balb/c SCID mice 
Balb/c SCID mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice 
were anaesthetised and underwent right nephrectomy and 32 min of left renal pedicle clamping. 
Following 24 h of recovery, BAL was performed and the fluid underwent cytometric analysis. Data 
are displayed for n=8 (instead of 9) in the vehicle group and n=6 (instead of 9) in the AT13387 group, 
because in addition to one post-operative mortality in the AT13387 group; three mice had a low cell 
yield from the BAL and a total nucleated cell count below the limit of detection. Results are presented 
in a standard boxplot with individual results jittered. Outlier data are highlighted by a dot with a 
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8.5 AT13387 reduces lung injury secondary to renal 
IRI 
 
Compared to pre-treatment with vehicle, there was protection from secondary lung 
injury caused by renal IRI in Balb/c SCID mice pre-treated with AT13387. This was 
evidenced by a significant reduction in interstitial neutrophil accumulation on flow 
cytometry of digested lungs (AT13387 vs. 2HβC vehicle, p<0.001, t-test) (Figure 
8.6), as well as a reduction in pulmonary haemorrhage on BAL analysis (AT13387 
vs. 2HβC vehicle, p<0.05, t-test) (Figure 8.6, Figure 8.7, Figure 8.8, Figure 8.9 and 
Figure 8.10).  
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Figure 8.6 Interstitial neutrophils in the lungs following AT13387 or vehicle pre-treatment and 
24 h following renal IRI in Balb/c SCID mice 
Balb/c SCID mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice 
were anaesthetised and underwent right nephrectomy and 32 min of left renal pedicle clamping. 
Following 24 h of recovery, lungs were harvested, digested and underwent cytometric analysis. Data 
are displayed for n=8 (instead of 9) in the AT13387 group because of one post-operative mortality. 
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Figure 8.7 BAL cell differential following AT13387 or vehicle pre-treatment and 24 h following 
renal IRI in Balb/c SCID mice 
Balb/c SCID mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice 
were anaesthetised and underwent right nephrectomy and 32 min of left renal pedicle clamping. 
Following 24 h of recovery, BAL was performed and the fluid underwent cytometric analysis. Data 
are displayed for n=8 (instead of 9) is in the vehicle group and n=7 (instead of 9) in the AT13387 
group, because in addition to one post-operative mortality in the AT13387 group; two mice had a low 
cell yield from the BAL and a cell differential below the limit of detection. In one sample with too low 
a yield for BAL cell count (Figure 8.5); it was still possible to perform a BAL cell differential. Results 
are presented in a standard boxplot with individual results jittered. Outlier data are highlighted by a 
dot with a diamond in the midline. *p<0.05 vs. 2HβC vehicle, t-test. RBCs=red blood cells. 
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Figure 8.8 BAL cytospin following vehicle pre-treatment and 24 h following renal IRI in Balb/c 
SCID mice 
Balb/c SCID mice were pre-treated with 2HβC vehicle (n=9). 24 h later, mice were anaesthetised and 
underwent right nephrectomy and 32 min of left renal pedicle clamping. Following 24 h of recovery, 
BAL was performed. A representative cytospin at x 400 magnification is shown. Macrophages are 
evident amongst numerous red blood cells.  
 
 
Figure 8.9 BAL cytospin following AT13387 pre-treatment and 24 h following renal IRI in 
Balb/c SCID mice 
Balb/c SCID mice were pre-treated with AT13387 (n=9). 24 h later, mice were anaesthetised and 
underwent right nephrectomy and 32 min of left renal pedicle clamping. Following 24 h of recovery, 
BAL was performed. A representative cytospin at x 400 magnification is shown. Macrophages are 
evident but there are minimal red blood cells. 
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Figure 8.10 BAL following AT13387 or vehicle pre-treatment and 24 h following renal IRI in 
Balb/c SCID mice 
Balb/c SCID mice were pre-treated with AT13387 or 2HβC vehicle (n=9 per group). 24 h later, mice 
were anaesthetised and underwent right nephrectomy and 32 min of left renal pedicle clamping. 
Following 24 h of recovery, BAL was performed. A photograph of primary and secondary lavages in 
separate eppendorf tubes is shown for each group (n=4-5 per group shown in photograph). There is 
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8.6 Summary 
 
In this chapter, it was shown that AT13387 induces Hsp70 expression in the lungs of 
mice. Following pre-treatment with AT13387 there was also a reduction in 
pulmonary haemorrhage and neutrophil accumulation in the lungs of mice following 
renal IRI. This was despite equivalent levels of kidney injury, which was made 
possible by the use of SCID mice. The results of these experiments suggest that 
AT13387 may have protective properties in the lungs, perhaps involving Hsp70 
induction, which reduce secondary lung injury following renal IRI.  
 




It was decided to utilise SCID mice in this chapter, as it was hypothesised from 
previous experiments in Chapter 7 that there would be similar levels of kidney injury 
in vehicle and AT13387-treated SCID mice after renal IRI. This in theory would 
mean that the stimulus for secondary lung injury would be similar between the 
groups. As per this hypothesis, pre-treatment with AT13387 again did not reduce 
kidney injury following renal IRI in SCID mice. This could be viewed as strength of 
the data; since an experiment involving only wild-type mice would have introduced 
the possibility that changes in secondary lung injury were the result of less damage to 
the kidney after AT13387 pre-treatment. However, it is also a weakness, as there are 
no corroborating data from wild-type mice. In the following chapter, lung injury is 
assessed in wild-type mice following renal IRI caused by kidney transplantation, but 
this is across a smaller number of animals. The effect of AT13387 on secondary lung 
injury in wild-type mice should therefore be formally determined in the renal IRI 
model as well.  
 
Chapter 8 - Results  171 
8.7.2 Variability  
 
In this chapter lung injury was assessed by interstitial neutrophil accumulation on 
flow cytometry of digested lungs, and pulmonary haemorrhage on BAL analysis. 
Pulmonary haemorrhage was determined by the percentage of red blood cells in the 
cytospin of the BAL. The cell count of the BAL was similar but not identical 
between the groups therefore it was decided to quantify the amount of red blood cells 
as a percentage of the total cytospin in each BAL, rather than cell number. As the 
percentage of red blood cells increased, the percentage of the other cells present (i.e. 
macrophages, as neutrophils did not cross over from the interstitial space to the 
alveolar space) decreased as a result. This does not reflect a change in macrophage 
number per se. In terms of flow cytometry of digested lungs to detect interstitial 
neutrophils, non-adherent cells were removed from the lung vasculature and 





The results of the SCID mouse experiment, in terms of renal Hsp70 induction by 
AT13387, and a lack of functional kidney protection by AT13387 after renal IRI, has 
been replicated from Chapter 5 and Chapter 7 respectively. Moreover, across both 
experimental groups, there was a significant increase in interstitial neutrophil 
accumulation on flow cytometry of digested lungs, as well as an increase in 
pulmonary haemorrhage on BAL analysis in SCID mice undergoing renal IRI. This 
was a consistent effect from the initial work performed by Duncan Humphries, which 
confirmed that secondary lung injury occurred in the renal IRI model with both 
Balb/c and Balb/c SCID mice (section 8.2). This reflects good reproducibility of 
data. In the following chapter lung injury is again reduced by AT13387, but this is 
across a small number of wild-type mice following renal transplantation. The 
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reproducibility of the lung data in SCID mice following renal IRI with AT13387 pre-
treatment is therefore currently unclear, and should be confirmed.  
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Chapter 9: Recipient treatment with AT13387 




In Chapter 7 and 8, the kidney protective effect of AT13387 was shown to be at least 
partially lymphocyte-dependent. This could mean that the protective effect of 
AT13387 is systemic and immunomodulatory in nature. As such, it may be feasible 
to pre-treat recipient mice in order to modify the recipient’s immune response to 
reperfusion. This could reduce the detrimental effects of IRI in the transplanted 
kidney. However, in Chapter 6 and 7, the renoprotective effect of AT13387 was 
demonstrated following pre-treatment in a renal IRI model. It is therefore uncertain 
whether there is any therapeutic potential for using AT13387 in a recipient prior to 
transplantation or whether treatment needs localised to the kidney prior to the onset 
of injury. This chapter addresses the hypothesis that recipient treatment with 
AT13387 reduces renal IRI in transplantation. The experiments in this chapter were 
performed in conjunction with George Tse (performed renal transplantations) and 
Duncan Humphries (performed BAL, lung digestion and cytometric analysis). 
 
9.2 Recipient treatment with AT13387 is feasible in a 
renal transplant model  
 
An isograft renal transplantation model involving 4 h of cold ischemia prior to 
transplantation was used. Compared to pre-treatment of recipient Balb/c mice with 
vehicle, AT13387 pre-treatment of recipient Balb/c mice resulted in no chenge in 
tubular necrosis score (AT13387 vs. 2HβC vehicle, p=0.71, Mann-Whitney U test) 
(Figure 9.1) on histological assessment of the transplanted kidney 24 h following 
renal transplantation (Figure 9.2 and Figure 9.3). 
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Figure 9.1 Tubular necrosis score in the transplanted kidney following AT13387 or vehicle pre-
treatment of recipient Balb/c mice and 24 h following renal transplantation 
Mice were pre-treated with AT13387 or 2HβC vehicle (n=3-4 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy. This was followed by isograft renal transplantation 
with a donor kidney that had been harvested from a treatment naive donor mouse and cold stored at 
4°C for 4 h. All mice had a single intact native left kidney and the model was not transplant-
dependent. Following 24 h of recovery, the transplanted kidney was harvested and placed in 
methacarn. Sections were later prepared and stained with haematoxylin and eosin. A blinded observer 
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Figure 9.2 Morphological kidney injury in the transplanted kidney following pre-treatment of 
recipient Balb/c mice with vehicle and 24 h following renal transplantation 
Mice were pre-treated with 2HβC vehicle (n=3). 24 h later, mice were anaesthetised and underwent 
right nephrectomy. This was followed by isograft renal transplantation with a donor kidney that had 
been harvested from a treatment naive donor mouse and cold stored at 4°C for 4 h. All mice had a 
single intact native left kidney and the model was not transplant-dependent. Following 24 h of 
recovery, the transplanted kidney was harvested and placed in methacarn. Sections were later prepared 
and stained with haematoxylin and eosin. A representative section of kidney cortex at x 200 
magnification is shown. There are areas of tubular necrosis and significant tubular cell damage. 
 
Figure 9.3 Morphological kidney injury in the transplanted kidney following pre-treatment of 
recipient Balb/c mice with AT13387 and 24 h following renal transplantation 
Mice were pre-treated with AT13387 (n=4). 24 h later, mice were anaesthetised and underwent right 
nephrectomy. This was followed by isograft renal transplantation as per Figure 9.2. A representative 
section of kidney cortex at x 200 magnification is shown. There are areas of tubular necrosis and 
significant tubular cell damage.  
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9.3 AT13387 reduces secondary lung injury in renal 
transplantation 
 
Compared to intervention naive control Balb/c mice, in both vehicle and AT13387 
pre-treated recipient Balb/c mice, cell counts on BAL analysis were similar 24 h 
following renal transplantation (Figure 9.4).  
 
However, compared to controls, in both vehicle and AT13387 pre-treated recipient 
Balb/c mice, 24 h following renal transplantation there was evidence of secondary 
lung injury. This was demonstrated by a significant increase in pulmonary 
haemorrhage on BAL analysis (renal transplantation vs. control, <0.05, t-test) 
(Figure 9.5) and interstitial neutrophil accumulation on flow cytometry of digested 
lungs (renal transplantation vs. control, <0.05, t-test) (Figure 9.6). This indicates that 
significant secondary lung injury occurred following renal transplantation in this 
model. 
 
Compared to pre-treatment of recipient Balb/c mice with vehicle, there was 
protection from secondary lung injury induced by renal transplantation in recipient 
Balb/c mice pre-treated with AT13387. This was evidenced by a significant 
reduction in pulmonary haemorrhage on BAL analysis (AT13387 vs. 2HβC vehicle, 
p<0.05, t-test) (Figure 9.5). However, compared to vehicle, on flow cytometry of 
digested lungs, there was no reduction in interstitial neutrophil accumulation induced 
by renal transplantation in Balb/c recipient mice pre-treated with AT13387 (Figure 
9.6).   
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Figure 9.4 BAL cell count following AT13387 or vehicle pre-treatment and 24 h following renal 
transplantation in Balb/c mice. 
Balb/c mice were pre-treated with AT13387 or 2HβC vehicle (n=3-4 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy. This was followed by isograft renal transplantation 
with a donor kidney that had been harvested from a treatment naive donor mouse and cold stored at 
4°C for 4 h. All mice had a single intact native left kidney and the model was not transplant-
dependent. Following 24 h of recovery, BAL was performed and the fluid underwent cytometric 
analysis. The negative controls were treatment naive mice that did not undergo renal transplantation or 
any other intervention (n=3). Data are displayed for n=2 (instead of 3) in the vehicle group because 
one animal did not have a BAL performed. Results are presented in a standard boxplot with individual 
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Figure 9.5 BAL cell differential following AT13387 or vehicle pre-treatment and 24 h following 
renal transplantation in Balb/c mice 
Balb/c mice were pre-treated with AT13387 or 2HβC vehicle (n=3-4 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy. This was followed by isograft renal transplantation 
with a donor kidney that had been harvested from a treatment naive donor mouse and cold stored at 
4°C for 4 h. All mice had a single intact native left kidney and the model was not transplant-
dependent. Following 24 h of recovery, BAL was performed and the fluid underwent cytometric 
analysis. The negative controls were treatment naive mice that did not undergo renal transplantation or 
any other intervention (n=3). Data are displayed for n=2 (instead of 3) in the vehicle group because 
one animal did not have a BAL performed. Results are presented in a standard boxplot with individual 
results jittered. Outlier data are highlighted by a dot with diamond in the midline. *p<0.05 vs. 2HβC 
vehicle, ^p<0.05 vs. control and ^^p<0.01 vs. control, t-test. RBCs=red blood cells. 
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Figure 9.6 Interstitial neutrophils in the lungs following AT13387 or vehicle pre-treatment and 
24 h following renal transplantation in Balb/c mice 
Balb/c mice were pre-treated with AT13387 or 2HβC vehicle (n=3-4 per group). 24 h later, mice were 
anaesthetised and underwent right nephrectomy. This was followed by isograft renal transplantation 
with a donor kidney that had been harvested from a treatment naive donor mouse and cold stored at 
4°C for 4 h. All mice had a single intact native left kidney and the model was not transplant-
dependent. Following 24 h of recovery, lungs were harvested, digested and underwent cytometric 
analysis. The negative controls were treatment naive mice that did not undergo renal transplantation or 
any other intervention (n=3). Data are displayed for n=2 (instead of 3) in the vehicle group because 
one animal did not have lungs harvested. Results are presented in a standard boxplot with individual 
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9.4 Summary 
 
The experiments in this chapter demonstrate that recipient treatment with AT13387 
in a renal transplant model is feasible but not associated with significant protection of 
kidney morphology across a limited sample size. There does appear to be protection 
from secondary lung injury in this model following pre-treatment of the recipient 
mice with AT13387. Again a limited sample size may have negated the full benefit 
or lack of benefit from this aspect of AT13387 recipient therapy. These issues are 
discussed further below, and in Chapter 10.  
 




The results in this chapter provide preliminary data about the efficacy of recipient 
treatment with AT13387 in a renal transplantation model utilising a cold ischemic 
time of 4 h. In a previous publication that utilised a murine renal transplantation 
model of IRI, approximately 75% of tubules in the corticomedullary junction showed 
tubular epithelial necrosis after 4 h of cold ischemia [241]. On the basis of this 
previous publication and previous in-house data, this cold ischemic time was 
therefore selected for these experiments as well. The major weakness of this 
experiment is the low sample size, which could have resulted in the experiment being 
underpowered to detect differences between the groups. Indeed, such small numbers 
of animals preclude any meaningful interpretation of the data. Despite this, the 
experiment is an important step towards translational relevance, and the sample size 
of this experiment should be increased to build on this preliminary data. 
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A non-transplant dependent model, which leaves the recipient mouse with a native 
kidney in situ, was selected to aid survival [242]. However, this reduces the utility of 
certain biochemical markers of kidney injury, such as creatinine, as the native kidney 
takes on the responsibility of clearing creatinine for the injured kidney graft. 
Assessment of histological injury markers in the kidney graft remained feasible in 
the context of this non-transplant dependent model, but it is a more subjectively 
determined outcome measure. Given that only one blinded observer performed 




In this chapter there was variation in tubular necrosis score within the groups. This is 
understandable given the technical demands of the procedure. Translating treatments 
from IRI models to small animal transplant studies is one of the most challenging 
steps in the process of drug development in transplantation. Even when technical 
expertise is available there can be issues with variability and survival at the injury 
levels required to produce acute tubular necrosis in the kidney graft. One option to 
reduce variability is to leave the native kidney in situ long enough to give the graft 
time to recover (e.g. 5 days), but this requires a second procedure for the 




An interesting finding of this chapter was that lung injury was present following 
renal transplantation. This is agreeable with the data presented from the renal IRI 
model in the previous chapter, and suggests that secondary lung injury is consistent 
consequence of renal IRI. Across a limited sample size, AT13387 also reduced lung 
injury in terms of reduced pulmonary haemorrhage on BAL. This is similar to the 
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reduction in lung injury observed in Balb/c SCID mice in Chapter 8. As per the 
analysis performed of lung injury in Chapter 8, apparent differences in macrophages 
on BAL between the groups were a reflection of a reduction in red blood cells (i.e. 
pulmonary haemorrhage), as opposed to a true difference in macrophage number. 
This is because the result was again expressed as a percentage of the total cytospin. 
These findings should also be confirmed across a greater sample size.  
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In this final chapter, the significance of the findings of this thesis will be discussed in 
the order they were presented, starting with in vitro data before moving on to 
consider the later in vivo results. Then the strengths and weaknesses of the data will 
be further evaluated, and the future directions of each area of research will be 
outlined. The results of the experiments performed will also be put in the context of 
current published evidence on this topic of investigation. The meetings where the 
data from this thesis have been presented are later described on page 229 and the 
peer review publications resulting from this work are listed on page 230. 
 
10.2 In vitro data 
 
10.2.1 Chapter 3 
 
In mechanistic work in Chapter 3, a carefully designed in vitro model was developed 
to simulate the sterile inflammatory environment of renal IRI. It was found that 
Hsp90 inhibition with AT13387 and 17-DMAG resulted in breakdown of IKKα, 
IKKβ and NEMO, which are the three subunits of the IKK complex. This reduced 
highly specific TLR4-mediated NF-ҡB activation by hyaluronan to the level of 
untreated cells left in basal conditions in normal culture medium. Moreover, it led to 
a reduction in the release of pro-inflammatory cytokines.  
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These findings suggest a potent anti-inflammatory effect from AT13387. However, 
the relevance of reduced inflammatory signalling and cytokine expression in 
HEK293 cells, which were primarily selected for their ease of use in evaluating 
TLR4 signalling rather than similarities to human renal epithelial cells, is uncertain. 
Also, since the cytokine array and Western blot data is displayed for only one 
experiment; it is difficult to know how reproducible these results are. Albeit, similar 
results were later observed in Chapter 3 following LPS stimulation.  
 
In experimental renal IRI, transgenic mice that are missing TLR4 [168, 170, 172, 
176], or that have been treated with TLR4-blocking agents demonstrate a markedly 
protected phenotype [173]. Donor TLR4 status is also of critical importance in 
human transplantation [178]. Furthermore, NF-ҡB de-activation with small 
interfering RNAs targeting either IKKβ or NF-ҡB transcription factor RelB, or in 
vivo transfection with NF-ҡB decoy oligodeoxynucleotides have previously been 
shown to protect the kidney from IRI [279-281]. Therefore, despite a lack of data to 
suggest a definitive pathway of protection, the potential of AT13387 to interrupt 
TLR4-mediated NF-ҡB signalling is still highly attractive from a translational 
perspective since it offers a pharmacological strategy to temporarily de-activate NF-
ҡB. This in contrast to ablation of the IKK complex, which reduces NF-ҡB mediated 
inflammation but also prevents subsequent NF-ҡB mediated protection from 
apoptosis [137].  
 
In Chapter 3 of this thesis it has also been confirmed, as previously described 
elsewhere in the literature, that TNFα-mediated NF-ҡB activity can be reduced by 
Hsp90 inhibition [131, 132, 134, 135]. Furthermore, in keeping with other studies in 
human cell lines, it was confirmed that LPS-mediated NF-ҡB activity could be 
decreased by Hsp90 inhibition [73, 250, 251]. These combined results suggest that 
the repressive effect of Hsp90 inhibition on NF-ҡB activity is not only TLR4-
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specific or mediated by sterile DAMPs. Hsp90 may therefore be an integral part of 
NF-ҡB activation, primarily at a junction downstream from TLR4.  
 
Although numerous pathways can lead to NF-κB activation, IKK is a common point 
of convergence [128], and activation of NF-κB occurs nearly universally via IKK-
mediated degradation of IκB [129]. Indeed, it has previously been shown in HeLa 
cells that geldanamycin can prevent the formation of a proposed hetero-complex 
involving IKK and Cdc37/Hsp90, reducing the size of the complex and preventing 
activation of NF-κB [133]. It has also been observed in alveolar epithelial cells that 
treatment with geldanamycin induces dissociation of Hsp90 from the IKK complex, 
rendering the complex detergent insoluble and the NF-ҡB system impassive to 
cytokine stimulation [136]. 
 
It therefore seems likely that Hsp90 inhibitors repress TLR4-mediated NF-κB 
activity primarily through IKK. The breakdown of all the major subunits of IKK by 
AT13387 and 17-DMAG following hyaluronan or LPS stimulation in this study 
would support this hypothesis. The hypothesis is also endorsed by partial regain of 
NF-ҡB activity following pre-treatment and incubation with AICAR, which is a 
compound that prevents IKKα degradation by AT13387 and 17-DMAG through 
inhibition of autophagy [249].  
 
AICAR is an activator of 5' AMP-activated protein kinase (AMPK) but it inhibits 
autophagy by an AMPK independent mechanism through prevention of class III PI3-
kinase binding to beclin-1 [282]. AICAR alone led to partial repression of TLR4-
mediated NF-ҡB activation by hyaluronan, which may have resulted from its ability 
to stimulate 5' AMPK. This could explain the inability of AICAR to completely 
reverse NF-ҡB repression due to Hsp90 inhibition despite its capacity to prevent 
IKKα degradation. In addition, although a significant regain of NF-ҡB activity was 
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observed in 17-DMAG pre-treated cells, it did not have as pronounced an effect in 
AT13387 pre-treated cells, which could be explained by the increased potency of 
AT13387. 
 
In keeping with this observation an additional finding of Chapter 3 was that 
AT13387 appeared more consistently effective at rendering NF-ҡB unresponsive to 
cytokine stimulation than 17-DMAG. It was initially noted at 1000 nM doses that 
AT13387 was more effective at reducing hyaluronan-mediated NF-ҡB activity, but 
in subsequent experiments both drugs seemed equivalent at this higher dose. As 
such, the variability in the 17-DMAG 1000 nM results could represent a batch effect 
secondary to using different stock solutions of 17-DMAG. Despite this, AT13387 
was conclusively more potent in most other experiments at reducing NF-ҡB activity 
at lower doses than 17-DMAG, for example, following TNFα, LPS and hyaluronan 
stimulation. In further in vitro experiments AT13387 was also significantly more 
effective at improving cell survival following oxidative stress than 17-DMAG. 
Although AT13387 does not appear to act through different mechanisms from 17-
DMAG, it is a smaller molecule Hsp90 inhibitor and therefore may be more 
efficacious in this respect. A final consideration is that AT13387 100 nM and 17-
DMAG 500 nM actually increased NF-ҡB activation on SEAP assay following 
hyaluronan stimulation. The dose of these drugs could therefore be critical to their 
effect. Indeed, there could be complex interaction of different molecules resulting in 
pro-inflammatory effects of Hsp90 inhibitors with lower doses, but anti-
inflammatory effects at a higher dose. 
 
10.2.1.1 Future directions 
 
The data gathered in this chapter would be made more robust by replicating the 
experiments that were performed on only one occasion e.g. the cytokine arrays and 
Western blots. The results of the experiments performed should also be confirmed in 
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other cell lines. Particularly since HEK293 cells were primarily selected for their 
ease of use in evaluating TLR4 signalling rather than similarities to human renal 
epithelial cells. This could include other established cell lines (e.g. HK2 cells) or 
primary renal cells. Detailed analysis of the dose effect of AT13387 and 17-DMAG 
would also be of interest.  
 
Another area of research worth pursuing is the further development of Hsp90 
inhibition with AT13387 to establish the relevance in vivo of repressing TLR4-
mediated NF-ҡB activation in renal IRI. It was difficult to establish after the in vivo 
experiments described in this thesis, whether potential reductions in TLR4 and NF-
ҡB expression in injured kidneys by AT13387 were the cause of protection or simply 
“read outs” of less damage to the kidney. As such, enquiries have been made about 
acquiring TLR4 -/- mice for this line of investigation.  
 
The use of TLR4 -/- mice could provide a better answer to the question of whether 
repression of TLR4-mediated NF-ҡB activation is a key to the protection in renal IRI 
by AT13387. Due to inherent protection from renal IRI observed in TLR4-/- mice, it 
could be challenging to demonstrate any potential drug or loss of drug effect, and 
careful titration of the level of injury would be needed [168, 170, 172, 176]. In 
addition, if there were a loss of protection from renal IRI by AT13387 in TLR4 -/- 
mice, it is unclear at this stage what the “add back” experiment to show regain of 
protection by the drug would be. This may mean that pursuing a conditional TLR4 
knockout model would be a better option. 
 
10.2.2 Chapter 4  
 
The potential lack of similarity between HEK293s and human renal tubular epithelial 
cells, also calls into question the relevance in Chapter 4 of demonstrating in vitro 
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protection from oxidative stress with Hsp90 inhibition in these cells. The 
significance of this limitation is lessened considerably by the convincing and 
reproducible level of in vivo protection demonstrated by AT13387 from renal IRI in 
later chapters.  
 
In experiments that have not been reported in this thesis, there were further 
difficulties demonstrating the mechanisms of protection from oxidative stress offered 
by Hsp90 inhibition. In particular, it was not possible to link cytoprotection to either 
enhanced Hsp70 expression or a reduction in inflammatory signalling in HEK293 
cells. This was firstly due to a high background expression of Hsp70 in these cells 
under basal conditions. This made it difficult to significantly modify Hsp70 
expression following Hsp90 inhibition, but might also signify that the protection 
demonstrated in this model was not Hsp70-mediated.  
 
Secondly, an anticipated reduction in the numbers of viable cells in assays following 
oxidative stress, which is a cytotoxic insult, made it problematic to demonstrate any 
differences in NF-ҡB signalling between experimental conditions. For example, 
despite starting experiments with equal cell numbers, following oxidative stress, 
there were a greater number of viable cells after Hsp90 inhibition. It is anticipated 
that these Hsp90 inhibitor treated cells would probably secrete lower levels of SEAP, 
which was used to indicate NF-ҡB activity. However, a smaller number of viable 
cells after vehicle treatment could conversely secrete high levels of SEAP, which 
could have led to a balancing out of SEAP levels between experimental groups. The 
same problem was encountered when assessing NF-ҡB activity following oxidative 
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10.2.2.1 Future directions 
 
The results of the experiments performed in Chapter 4 should also be confirmed in 
other cell lines, and potentially other models of cellular injury (e.g. chemical insults 
and hypoxia). It would be useful to adopt a more advanced assay of cell viability 
(e.g. xCELLigence System) to acquire real-time data on cell viability, rather than a 
single static result at the end of the experiment. Moreover, it would be interesting to 
establish if TLR4-mediated NF-ҡB activation actually leads to cell death. This was 
not formally assessed in this thesis, but no obvious differences in cell number were 
identified when performing the cell signalling experiments in Chapter 3. Although it 
should be noted that these experiments were conducted over a relatively short time 
frame of 24 h, and perhaps if the experiments were extended there would have been a 
reduction noted in cell viability.  
 
10.3 In vivo data 
 
10.3.1 Chapter 5 
 
As described in Chapter 1, previous studies have shown that pharmacological 
inhibition of Hsp90 is protective from experimental renal IRI in mice [84, 85]. 
However, a drug designed to reduce IRI in renal transplantation has an absolute 
requirement for low toxicity. Therefore, one of the main challenges going forward is 
to develop low toxicity drugs that can be safely utilised in human renal 
transplantation. AT13387 is a novel small molecule Hsp90 inhibitor with a low 
toxicity profile in phase II human studies in oncology and therefore excellent 
translational potential in this context [99, 100]. In Chapter 5 of this thesis, AT13387 
led to a marked induction of Hsp70 expression in the kidneys of mice.  
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This up-regulation of Hsp70 was consistent across various strains of mice including 
FVB/n, Balb/c and Balb/c SCID mice. As AT13387 was being used as a pre-
treatment to prevent renal IRI, these experiments were an important step prior to 
assessing the efficacy of this agent in reducing renal IRI [238]. The results of the 
ELISA were also validated using immunohistochemistry, which clarified that Hsp70 
induction was within renal tubular cells, and maximal in the outer stripe of the outer 
medulla of the kidney  
 
10.3.1.1 Future directions 
 
The weaknesses of this data were that Hsp70 induction was only assessed at two time 
points (6 h and 24 h). The experiment performed at 6 h also had a limited sample size 
(n=3), and therefore caution must be exercised in interpreting the data. A more 
complete time course experiment, using more animals at each time point, could 
provide additional data on the kinetics of AT13387. Hsp70 is the most commonly 
used biomarker of Hsp90 inhibition but it would be useful to explore other indicators 
of Hsp90 inhibition, particularly if experiments using Hsp70-/- mice are to be 
considered in future [264].  
 
10.3.2 Chapter 6 
 
In Chapter 6, AT13387 pre-treatment resulted in functional and morphological 
kidney protection following renal IRI in FVB/n mice. Cytokine arrays were used to 
evaluate CXCL1 and CXCL2 expression, and therefore the NF-κB activation status 
of the kidneys injured by IRI in AT13387 treated mice, compared to vehicle treated 
mice [266, 267]. Similar to the human cytokine array panels used in Chapter 3, the 
arrays also assessed 38 other chemokines and cytokines, many of which are markers 
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of inflammation. In contrast, the arrays in this chapter were performed on 4 kidney 
lysates per group, in order to allow for quantitative analysis.  
 
CXCL1 and CXCL2 expression was significantly reduced in the kidney following 
renal IRI in mice pre-treated with AT13387. CXCL1 is the equivalent of GROα, 
which had reduced expression following AT13387 pre-treatment in the arrays 
performed in Chapter 3. The significant reduction in the renal expression of CXCL1 
and CXCL2 with AT13387 pre-treatment suggests a reduction in NF-κB-mediated 
inflammatory signalling within the kidney. This is also suggested by a significant 
reduction in TLR4 expression on real time PCR analysis of injured kidneys 
following AT13387 pre-treatment.  
 
10.3.2.1 Future directions 
 
In Chapter 6 there was notable variation in serum creatinine levels, particularly in the 
AT13387 group, with the unilateral IRI model. By adopting a simpler bilateral 
ischemia model the variability could be reduced. This wouldn’t give information on 
the induction of Hsp70 in each experimental animal but as Hsp70 is so consistently 
up-regulated with the 80 mg/kg dose of AT13387, perhaps this isn’t a major issue. In 
the unilateral IRI model, it would be interesting to assess other markers of kidney 
function, such as glomerular filtration rate, and other markers of kidney injury (e.g. 
kidney injury molecule-1) or cellular senescence (e.g. p16 or p21) [270, 271]. 
Furthermore, at just 24 hours following renal IRI, it is likely that protective effect of 
AT13387 may have involved programmed cell death, so markers of apoptosis (e.g. 
caspase activation) could also be assessed [159]. Moreover, since injury was assessed 
at only one time point (24 h after surgery), additional experiments could be 
performed using a longer recovery period. This could address whether AT13387 is 
simply delaying the onset of kidney injury, or preventing it from occurring. The 
unilateral IRI model could also be extended beyond the initial 7 days it takes for 
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acute tissue injury to resolve. This would assess the impact of AT13387 pre-
treatment on eventual kidney regeneration following renal IRI [238].  
 
10.3.3 Chapter 7 
 
In Chapter 7, AT13387 pre-treatment resulted in functional and morphological 
kidney protection following renal IRI in Balb/c mice. Using Balb/c SCID mice, it 
was demonstrated that the kidney protection from renal IRI afforded by AT13387 is 
at least partially lymphocyte-dependent. This is similar to the lymphocyte-dependent 
nature of the protection from renal IRI that is garnered by Hsp70 induction using 
heat preconditioning [224]. In contrast to previous heat preconditioning studies by 
Kim et al. (2014), there was no evidence found on immunohistochemistry to suggest 
that the protective effect of AT13387 is either T-cell or more specifically Treg 
dependent [224]. This data was preliminary, and performed across small numbers of 
animals; it should therefore be cautiously interpreted. Further work, with increased 
sample sizes, and potentially involving flow cytometry of blood, spleen and kidneys, 
needs to be performed to understand what the key subset of lymphocytes or the 
adaptive immune response involved may be.  
 
There are also additional caveats to the work demonstrating the potentially 
lymphocyte-dependent nature of the protection from renal IRI exhibited with 
AT13387. For instance, while the majority of SCID mice lack functional 
lymphocytes, in a process termed “leakiness” 2-23% appear to develop a limited 
number of B and T cells [283]. This usually occurs in older SCID mice (> 3 months 
old) than were used in the experiments described in this thesis (6-8 weeks) but could 
still represent a limitation of the findings [283].  
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In addition, in further experiments performed in Edinburgh, it has been reported in an 
abstract publication by the Ferenbach et al. (2012), that compared to Balb/c mice, 
Balb/c SCID mice have a protective phenotype in renal IRI [277]. This was not 
observed in either renal IRI experiment performed using SCID mice in Chapter 7 or 
8 of this thesis. This variation echoes other inconsistencies in this area that have 
previously been reported, with renal IRI studies using RAG-1-/- mice (lacking B and 
T cells) showing both renal protection [213], and a similar kidney injury to wild type 
controls [214, 215].  
 
In a publication by Day et al. (2006), the only study in which RAG-1-/- mice 
displayed a protective phenotype from renal IRI, the authors address these 
inconsistent outcomes, and discuss the variations between published studies that 
could potentially have contributed. These variations include the method of pedicle 
clamping, use of heparin and anesthetic agents, and degree of injury [213]. In a study 
by Park et al. (2002), the background strains of the RAG-1-/- mice were C57BL/6, 
and mixed C57BL/6 and B6129. The mice received heparin 1 h prior to surgery and 
were anesthetized with inhalational isoflurane. The authors used 27.5 min of bilateral 
renal artery only clamping, and allowed for 30 h of recovery from IRI [215]. Burne-
Taney et al. (2005) used RAG-1-/- mice with a background strain of C57BL/6, which 
underwent 30 min of bilateral renal pedicle clamping, and also RAG-1-/- mice on a 
BALB/c background that underwent 35 min of bilateral clamping. The mice were 
anesthetized with intra-peritoneal sodium pentobarbital, and were recovered for 72 h 
[214]. Day et al. (2006) used RAG-1-/- mice on a C57BL/6 background. Mice were 
anesthetized with intra-peritoneal ketamine and xylazine, and intra-muscular 
acepromazine. They then clamped the renal pedicles bilaterally for 32 min, and 
allowed for 24 h of recovery [213]. While all these publications using RAG-1 -/- 
mice adopted bilateral IRI models, Ferenbach et al. (2012) used the same unilateral 
model described in this thesis. A possible reason for the conflicting results presented 
in this thesis, is that a 20 min clamp time was used by Ferenbach et al. (2012), rather 
than the 30 min and 32 min clamp times used in Chapter 7, and Chapter 8, 
respectively [277].  
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There are further discrepancies in this thesis that call into question the link between 
increased Hsp70 expression and lymphocyte dependency of the protection from renal 
IRI offered by AT13387. For instance, it is unclear why in Chapter 5 of this thesis, 
on immunohistochemistry, Hsp70 induction following AT13387 treatment in the 
kidney was observed mainly in renal tubular cells rather than in interstitial 
lymphocyte type cells. It is also uncertain why in Chapter 4, in vitro protection from 
oxidative stress was demonstrable with AT13387 despite the obvious absence of 
lymphocytes in the cell system used. These inconsistencies may just reflect a 
multimodal mechanism of protection offered by AT13387, which was anticipated at 
the outset of this thesis and does not necessarily disprove the importance of 
lymphocytes in the protective effect of this agent.  
 
10.3.3.1 Future directions 
 
It should be highlighted that the experiments in Chapter 7, involving Balb/c and 
Balb/c SCID mice groups, were not designed to address the specific question of 
whether SCID mice are inherently protected from renal IRI. As such, mice from each 
group (Balb/c and Balb/c SCID) were separately randomised based on type of 
treatment (AT13387 vs. vehicle). In fact, Balb/c mice underwent their operations 
first, in order to demonstrate kidney protection from renal IRI following pre-
treatment with AT13387. At a later date Balb/c SCID were acquired and then 
experimented on to specifically assess the importance of lymphocytes in the 
protective effect of AT13387. A true comparison between Balb/c and Balb/c SCID 
mice would require proper randomisation specifically for this purpose with 
experiments performed in each group on the same days. This would ensure that 
experimental conditions (e.g. room temperature) were identical and would provide a 
more robust answer to the question of whether SCID mice have an innate protection 
from renal IRI. Although a rectal temperature probe was used to minimise variation 
in temperature in the experiments reported in this thesis, even 1–2 degree changes in 
temperature can markedly alter the degree of injury and its long-term consequences 
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[17]. Therefore it makes sense to have surgery performed in each group of mice on 
the same day if possible. These additional experiments should be performed using 
both 20 min and 30 min clamp times, and bilateral and unilateral models of renal IRI. 
Consideration should also be given to using different background strains of SCID 
mice.   
 
As previously mentioned, more experiments should be performed to help understand 
what subset of lymphocytes or the adaptive immune response involved in the effect 
of AT13387 may be. Flow cytomtery of blood, spleens and kidneys of mice treated 
by AT13387 could supplement expansion of the initial immunohistochemistry to a 
larger group of animals. In addition, more targeted depletion of lymphocyte subsets 
(e.g. by anti-CD25 antibodies) could also be performed. 
 
It is possible that “add back” experiments involving adoptive transfer of Tregs to 
SCID mice prior to renal IRI could be considered to assess whether the protective 
effect of AT13387 is restored in the presence of Tregs. This could establish that 
Tregs are a critical cell type involved in the protective effect of AT13387 and would 
further complement the findings of Kim et al. (2014) [224]. However, in similar 
experiments recently performed in Edinburgh by Devey et al. (2012), it was 
unexpectedly found that adoptive transfer of Tregs failed to protect mice from liver 
IRI [284]. This was explained by an inability to transfer sufficient Tregs to 
ameliorate injury and suggests difficulties with this approach even in the hands of 
scientists dedicated to lymphocyte research [284].  
 
Before performing challenging adoptive transfer studies there are also other issues to 
consider. There is the potential involvement of other cell types, such as macrophages, 
to contemplate. Indeed, one option would be to carry out monocyte/macrophage 
depletion experiments first to assess the influence of these cells on the protective 
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effect of AT13387. These experiments could be performed using an in-house colony 
of CD11b-DTR mice, which express the human diphtheria toxin receptor under the 
control of the CD11b promoter. Treatment with diphtheria toxin in these mice 
induces conditional renal and circulating monocyte/macrophage depletion [42, 240, 
265]. Importantly, and in contrast to clodronate, this monocyte/macrophage depletion 
strategy itself should not lead to any protection from renal IRI, eliminating the need 
for injury titration [265]. 
 
10.3.4 Chapter 8 
 
Treating transplant donors raises issues regarding the potential for a detrimental 
impact on other donor organs by systemic treatments. This possibility must be 
excluded in the context of donor pre-treatment and multi-organ donation, but may 
not be an issue if organs share pathways of protection [285]. There are therefore 
organ-specific issues that need resolved before AT13387, can be implemented in 
transplantation, as there is the possibility that AT13387 may be beneficial to one 
organ but not to others. Hsp90 inhibition with geldanamycin has previously been 
shown to induce Hsp70 levels in the lung and reduce secondary lung injury resulting 
from haemorrhagic shock [138]. In Chapter 8 of this thesis, AT13387 was 
additionally shown to induce Hsp70 up-regulation in the lungs of mice, which 
appeared to provide protection from secondary lung injury caused by both renal IRI 
in Chapter 8 and then renal transplantation in Chapter 9.  
 
10.3.4.1 Future directions 
 
The experiments in Chapter 8 are again limited since they were performed in SCID 
mice and did not involve wild-type mice. In the Chapter 9, lung injury was assessed 
in wild type mice following renal IRI caused by renal transplantation, but only in a 
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small number of renal transplants (n=2 in the vehicle group). The results of both 
experiments should therefore be verified in wild type mice and across a larger sample 
of animals. However, the results still highlight that Hsp90 inhibitors may be 
protective to both kidneys and lungs, which could represent a particular advantage of 
Hsp90 inhibitors over other agents. Acute lung injury severe enough to require 
mechanical ventilation occurs in 2.7% of renal transplantations from extended 
criteria donors, and results in a 5-fold increase in 1-year mortality. Therefore the lung 
protective properties of AT13387 could be of clinical relevance in renal 
transplantation [286]. Nevertheless, it is likely that this avenue of research would be 
better pursued in different models where the clinical need is greater, such as sepsis 
induced lung injury or sepsis induced lung injury combined with a head injury 
(“double hit” model [287]). Due to limitations on the material transfer agreement 
with Astex for use of AT13387, collaborations are on going with Duncan Humphries 
to investigate generic Hsp90 inhibitors, including 17-DMAG, in this context.   
 
10.3.5 Chapter 9 
 
IRI in the context of transplantation deserves special consideration. During the initial 
warm ischemic period of organ recovery, hypoxia depletes adenosine triphosphate 
stores, generates reactive oxygen species and leads to failure of cellular ion 
exchange. Cold storage during organ transportation reduces metabolic activity and 
slows cell death, but adds to ischemic tissue damage on reperfusion. Following 
reperfusion, tissue injury is extensive and the innate immune system is aggressively 
activated. Inflammatory cells infiltrate the graft and release various cytokines, pro-
coagulant factors and further free radicals. Microvascular dysfunction and 
endothelial binding of leucocytes causes capillary obstruction and exacerbates 
ischemic damage. Rapid cell death ensues with the release of DAMPs that trigger a 
profound adaptive immune response. Over the following days repair and 
regeneration processes occur on a background of resolving inflammation [28, 288]. 
The IRI model used in previous chapters assessed only a warm ischemic insult, while 
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the transplant-associated IRI model in Chapter 9 incorporated an additional period of 
cold ischemia. This experiment is therefore an important step towards translational 
relevance.  
 
Due to the potential systemic and immunomodulatory nature of the protective effect 
of AT13387, it was hypothesised that it may be feasible to pre-treat recipient mice 
with the aim of reducing IRI in a transplanted kidney. This hypothesis was driven by 
a desire to broaden the range of these therapies to a wider group of patients including 
renal transplant recipients. In Chapter 9, in the experiment designed to address this 
hypothesis, no difference in tubular necrosis scores was observed following recipient 
pre-treatment with AT13387 and isograft renal transplantation. Transplants were 
performed with a kidney graft that had been harvested from a treatment naive mouse 
and subjected to cold ischemia for a period of 4 h to cause moderate to severe IRI.  
 
Due to the low numbers of animals used, it is not possible to meaningfully interpret 
this result. In addition, the utility of serum creatinine, which was the primary 
outcome measure for all the previous IRI experiments, was reduced by the fact that 
the model was not transplant-dependent (i.e. the transplanted kidney was not a life-
supporting organ [242]). The presence of a single intact native kidney capable of 
creatinine clearance meant serum creatinine was not a valid outcome measure in this 
experiment. In renal IRI experiments, preservation of kidney function is arguably a 
more objective indicator of renal protection than kidney morphology and although 
the two methods tend to correlate, it is probably more relevant to human disease 
[289, 290]. 
 
The murine transplantation model was designed to primarily assess for features of 
acute and chronic rejection on histology in the transplanted kidney and the presence 
of a native kidney in the model ensures a higher survival rate [239, 240, 242]. The 
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peri-operative mortality rate in the experiments in Chapter 9 across both groups was 
already high at 56% (9/16). As these deaths occurred within 24 h, they were probably 
due to technical problems, rather than the prolonged cold ischemic time required to 
induce moderate to severe IRI, which is normally not necessary in the model. 
Removing both recipient native kidneys prior to transplantation of a severely injured 
kidney would have been higher risk. Therefore an alternative would be to leave the 
native kidney in situ long enough to give the graft time to recover e.g. 5 days [242]. 
 
10.3.5.1 Future directions 
 
The possibility of modulating immune responses to kidney reperfusion by renal 
transplant recipients is very attractive. Since therapies that mediate protection from 
renal IRI entirely through renal parenchymal cells, renal tubular cells or resident 
leucocytes may necessitate earlier localisation of the treatment to the kidney. This 
could require donor pre-treatment and hence there will be ethical and logistical 
barriers to clinical implementation. These barriers include lack of legislation and 
difficulty establishing consent from both donor and recipient. Therefore treatment of 
transplant recipients using AT13387 has exciting translational potential and is 
worthy of further exploration.  
 
The variability inherent in the technically challenging murine transplantation model 
means that despite observing a moderate effect size for reduction in tubular necrosis 
score by AT13387 (cohen’s d= 0.45), a larger sample would be required to pursue 
this experiment further. As previously mentioned, altering the model so that the 
native kidney is left in situ long enough to give the graft time to recover, is another 
option to consider [242] In addition, it would be useful to evaluate further 
experimental groups, such as donor pre-treated mice, as well as treatment of both 
donor and recipient with AT13387. 
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Following a recent successful funding application, this treatment strategy will be also 
be explored in a larger animal porcine transplantation model, which is currently 
being developed in Edinburgh. A project licence is currently under review and the 
plan is for AT13387 to be initially tested in an auto-transplantation model. The larger 
body size of the pig will allow for surgical procedures that are more technically 
feasible including transplant dependent models, and will facilitate the collection of 
peripheral blood for determination of serum creatinine on a repeated basis [291]. The 
input of veterinary anaesthetists and use of invasive monitoring will additionally lead 
to less haemodynamic instability during prolonged transplantation procedures, which 
may be a problem leading to variation and peri-operative death in the murine 
transplantation model.  
 
10.4 Published evidence  
 
Over the past 25 years various agents have been tested in RCTs to assess whether 
renal transplant related IRI could be reduced. In a double-blinded RCT by 
Schneeberger et al. (1989), recipients of deceased donor kidneys were randomised to 
receive superoxide dismutase (n=81), a free radical scavenger, or placebo (n=96) 
infused intravenously prior to reperfusion. There was no difference in early graft 
function between the groups to suggest that superoxide dismutase prevented the early 
impact of IRI on the kidney graft [29]. The lack of protection provided by this agent 
was confirmed in a further RCT by Pollak et al. (1993) of 116 patients [30]. 
However, on four-year follow up of the patients included in the study by 
Schneeberger et al. (1989), graft survival was found to be better in those patients 
who received superoxide dismutase secondary to a lower incidence of rejection [31].  
 
At the beginning of the 1990s, an open label study by Rabl et al. (1993) randomised 
recipients of deceased donor kidneys to receive omnibionta (n=16), an anti-oxidant 
therapy intravenously prior to reperfusion, or control (n=14). Creatinine levels were 
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significantly lower in the omnibionta treatment group but only up to day 6 post-
operatively [32]. Noel et al. (1997) then performed a double blind RCT of 
intravenous pentoxifylline, an anti-inflammatory agent, at induction of anaesthesia 
and for 48 hours post-operatively in 140 patients receiving kidney transplants from 
deceased donors. Pentoxifylline had no demonstrable effect on ischemic graft injury 
when compared to placebo [33]. Haug et al. (1993) performed an initial phase I trial 
of 18 patients who received deceased donor kidneys at high risk for DGF and 
showed that use of an anti-ICAM-1 murine monoclonal antibody, enlimomab, 
reduced DGF [34]. However, it was later found in a multicentre RCT of 262 patients 
receiving deceased donor kidneys by Salmela et al. (1999) that an intravenous 
injection of enlimomab 3 hours before transplantation, followed by a single dose for 
the next 5 days did not reduce DGF when compared to placebo [35].  
 
In the last decade, Hladunewich et al. (2003) randomised 43 adult recipients of DBD 
donor kidneys with reduced creatinine clearance 2 h post-transplant to treatment with 
insulin-like growth factor, within 5 hours after transplant and twice a day for 6 days 
following transplant, but observed no difference in graft function compared to 
placebo [36]. In a study by Fontana et al. (2005), 26 recipients of deceased donor 
kidneys were treated with either dopamine or fenoldopam (dopamine-1 receptor 
agonist) for 48 hours post-transplant, but there were no significant differences in 
graft function between the groups [37]. In a multicentre open label study with 
blinded evaluation of endpoints only, Martinez et al. (2010) randomised 104 
recipients of deceased donor kidneys at increased risk of DGF to high doses of 
epoetin beta before surgery and at 12 hours, 7 days and 14 days post transplantation, 
but found that the frequency of DGF was similar to control [38]. Finally, a Cochrane 
review has evaluated 13 RCTs with 724 patients, comparing calcium channel 
blockers via various routes of administration in the peri-transplantation period with 
controls. The review concluded that calcium channel blockers may reduce the 
incidence of DGF post-transplantation, but that the results should be treated with 
caution due to the heterogeneity of the trials [39]. 
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More recently, diannexin, a recombinant form of the endogenous human annexin V 
protein, was tested in a double blind, placebo-controlled Phase II/III RCT of renal 
transplant recipients. However, during the second part of the clinical trial participant 
recruitment was suspended (clinical trials.gov identifier: NCT01442337) with further 
analysis of pre-clinical toxicology data noted as the reason [40]. Further clinical trials 
are ongoing with various other novel agents [41]. OPN-305 (Opsona Therapeutics 
Ltd), a Toll-like receptor-specific monoclonal antibody, is currently under 
investigation in a multicenter RCT of adult deceased donor renal transplant recipients 
receiving kidneys at high risk for DGF [40]. Eculizumab, a humanized monoclonal 
antibody directed against the C5 component of the complement cascade 
(ClinicalTrials.gov Identifier: NCT01756508, NCT01403389), QPI-1002 (also 
known as I5NP, Quark Pharmaceuticals), a synthetic siRNA (ClinicalTrials.gov 
Identifier: NCT00802347) and mirococept, a complement inhibitor (International 
Standard Randomised Controlled Trial Number: 49958194) are also under 




With the increasing use of DCD kidneys for renal transplantation the need to develop 
pharmacological agents to reduce the impact of IRI has never been greater. 
Producing pharmacological strategies for reducing IRI is highly challenging at every 
stage of development from initial experiments using cell culture models, to small 
animal studies, then large animal investigations and eventually clinical trials. There 
will clearly be various challenges that will occur when attempting to translate 
AT13387 from these initial pre-clinical studies to a future clinical trial, and these are 
worth considering when providing context to the findings of this thesis.  
 
For the majority of treatments of IRI tested thus far, the benefits in terms of early 
outcomes in relation to better early graft function and prevention of DGF have not 
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been apparent [41]. The question then becomes, why are promising therapies in pre-
clinical studies not translating to significant clinical benefit in human trials? The past 
decade in particular has seen rapid progress in understanding of the pathophysiology 
of IRI and still there remains a need to gain yet further mechanistic insight into the 
vast array of molecular events that occur during IRI [22]. As a consequence, perhaps 
the most efficacious treatments have not been subject to RCTs in humans yet.  
 
There is also a striking disconnect between experimental animal studies that are 
typically conducted in young, healthy animals with no comorbidities and the renal 
transplant population in the UK and abroad. For instance, the median age of a patient 
requiring a renal transplant in England is 45 years of age and on average 16% have 
diabetes, 5% have pulmonary disease and 3% have had a myocardial infarction 
[292].  
 
Furthermore, in many animal studies the agent is administered to the donor prior to 
the ischemic period (pre-conditioning); in humans, discussions regarding the ethics 
of this are going, but precedents exist in DBD transplantation. Indeed, the optimum 
management of DBD donors already encompasses the provision of a range of drugs 
and infusions to preserve organs in a suitable condition for transplantation. In 
contrast, pre-treatments in the DCD donor to either precondition organs or optimise 
the donor, may influence the process leading to death and this is rightly considered 
unacceptable [231]. Current legislation forbids pre-mortem intervention in DCD 
donors, and with this limitation in place, pharmacological pre-treatment is not 
currently possible [14]. Despite this, in the setting of DCD organ recovery, 
normothermic regional perfusion and normothermic ex-vivo perfusion are two 
emerging techniques that could circumvent these barriers and allow earlier treatment 
of either the donor or kidney graft with pharmacological agents. There is also the 
issue of the increasing use of multiple drugs in renal transplantation, with recipients 
potentially exposed to a number of pharmacological agents that might interact with 
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the protective pathways under manipulation by test agents [293]. Finally, an absence 
of long-term follow up in these trials could mean that any long-term impact of 
therapies have been undetected. 
 
It is clear that the clinical trials that have been conducted over the past 25 years have 
included relatively small number of patients. This may not allow robust statistical 
analysis of the efficacy of the agents that have been tested thus far [294]. For 
instance, one may wish to consider the number of participants that would need to be 
recruited in order to test whether a pharmacological agent has the efficacy to reduce 
the current 49% incidence of DGF in DCD kidney transplantation to an incidence 
more typically observed after DBD kidney transplantation (presently 24% in the UK) 
[15]. In this example, to have a 90% (β = 0.1) chance of detecting significance at the 
5% level (α = 0.05), an RCT would have to recruit 146 patients receiving a DCD 
kidney transplant (73 per arm of trial). This may not initially sound difficult to 
achieve, but across 24 transplant centres performing DCD kidney transplants during 
2013/14 in UK, the median number of DCD kidney transplants performed per centre 
was only 31 (range 3 - 98) [10].  
 
An obvious solution to this problem is the organisation of larger multicenter RCTs of 
the most promising agents. However, there are challenges to be overcome with 
multicenter trials in the context of transplantation. Clinical protocols may differ 
vastly between units with regards to donor or recipient criteria, kidney discard rates, 
ex-vivo management of organs and use of preservation fluids. These differences may 
have to be accepted and a more pragmatic attitude to “real-world” comparisons 
adopted. Nevertheless, intrinsic variability between units will inevitably lead to the 
need for even larger sample sizes and increased drug effects. When controlling for 
differences in donor factors, paired kidney allocation studies designs may reduce 
variability but these studies are difficult to execute [17].  
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Another issue in the appropriate sizing and powering of trials is the choice of 
endpoints. In terms of defining DGF, the need for dialysis is subjective with a 
variation in threshold for dialysis evident across centers [295]. Some patients may be 
dialysed mainly for hyperkalaemia rather than uraemia so DGF defined on use of 
dialysis is not exact. The use of biomarkers of graft injury is also problematic. For 
example, despite being widely used, serum creatinine is considered a relatively poor 
biomarker of kidney injury since numerous factors may regulate its generation, 
volume of distribution and excretion [296]. Although urine output is clinically useful 
and absence can indicate DGF, urinary biomarkers are limited by graft anuria as well 
as persistent native kidney diuresis [297]. Clear definitions of graft function are 
therefore required and should be supplemented with circulating biomarkers of graft 
injury, such as aspartate transaminase, heart-type fatty acid–binding protein and 
neutrophil gelatinase–associated lipocalin [297].  
 
AT13387 is a promising agent, and mechanistic insight into the protective mode of 
action in renal IRI has been acquired in this thesis. However, there is still clearly 
much to learn about this drug, and many barriers to overcome before it can be tested 
in human patients in the setting of renal transplantation. Despite this, there is patient 
safety data already available for AT13387. It is therefore possible that if the data 
presented in this thesis can be taken be forward, then AT13387 could be more 
rapidly translated into a RCT in recipients of deceased donor kidneys. This is in 
comparison to other agents that are at a similar pre-clinical stage of development but 
lack toxicology data. Indeed, the assessment of drugs that are already in clinical use 
is an area of future opportunity in renal IRI. A recent example is heme arginate, 
which is already used in patients to treat porphyria. The fact there is patient safety 
data already available for heme arginate, has meant that only a few years after it was 
shown to reduce renal IRI in aged mice, it has already been translated into a RCT in 




Chapter 10 - Discussion   206 
10.6 Summary 
 
In conclusion, this thesis aimed to establish mechanisms of protection offered by 
Hsp90 inhibitors in renal IRI and investigate a less toxic analogue that has the 
potential to be safely translated into human studies. These aims have been achieved 
as the data presented has demonstrated potential mechanisms of protection offered by 
these drugs and highlighted a new agent in AT13387 that is capable of reducing both 
functional and morphological kidney injury following renal IRI. These are novel 
findings that increase the current understanding of IRI. They also highlight AT13387 
as a potentially exciting new therapy for reducing renal IRI and secondary lung 
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